Molecular investigations of iduronate-2-sulfatase mutants. by Lau, Kin Chong. & Chinese University of Hong Kong Graduate School. Division of Chemical Pathology.
Molecular Investigations of 
Iduronate-2-sulfatase Mutants 
LAU Kin Chong 
A Thesis Submitted in Partial Fulfillment 
of the Requirements for the Degree of 
Master of Philosophy 
in 
Chemical Pathology 
© The Chinese University of Hong Kong 
August 2006 
The Chinese University of Hong Kong holds the copyright of this thesis. Any 
person(s) intending to use a part or whole of the materials in the thesis in a proposed 
publication must seek copyright release from the Dean of the Graduate School. 









Abstract of thesis entitled: 
Molecular investigations of iduronate-2-sulfatase mutants 
Submitted by Lau Kin-Chong 
for the Degree of Master of Philosophy in Chemical Pathology 
at The Chinese University of Hong Kong in June 2006 
In Hong Kong, we have four rare subtypes of Mucopolysaccharidoses (MPS). 
Only Mucopolysaccharidosis type II (MPS II) is the subtype that is X-linked. 
Deficiency of iduronate-2-sulfatase (IDS) leads to intralysosomal accumulation of 
undegraded glycosaminoglycans (GAG) and causes the phenotypes. Clinically, a 
broad spectrum of phenotypes is observed among the MPS II patients. This 
heterogeneity is partially contributed by the different mutations of the IDS gene. 
Molecular investigations of a specific disease-causing mutation can lead to a better 
understanding of the pathological mechanism of this disease. 
In this study, direct sequencing techniques were used to identify the mutations 
in four Hong Kong Chinese MPS II patients. Three different mutations were found in 
exon 8 of the IDS gene. Two of them are novel which include a nonsense mutation at 
i 
codon 369 (S369X) and a missense mutation at codon 339 (L339P). The known 
mutation was a nonsense mutation at codon 389 (Q389X). Three female carriers 
were detected and prenatal diagnosis was performed in one family. The fetus was 
finally confirmed to be normal. 
To study possible genotype-phenotype correlation, in-situ mutagenesis studies 
at the codon 339 were carried out by cell-based in vitro expression. Transient 
expression of L339P and L339R in COS-7 cells revealed that both mutants had 
similar mRNA expression level as the wild-type. However, the enzymatic activities 
were found to be significantly reduced (less than 2.5 %). Additionally, structural 
analysis suggested that Leu339 residue is close to substrate binding site of the 
enzyme. In this study, wild-type IDS was also expressed using five different cell-free 
in vitro expression systems. Using cell-free in vitro expression systems, IDS 
precursors were successfully synthesized either based on prokaryotic or eukaryotic 
translation machinery. Results of cell-free in vitro expression and functional study of 
mutant IDS with modified N-terminal suggested that synthesis of catalytic active 
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Chapter 1 Introduction 
1.1 Mucopolysaccharidosis type II as a lysosomal storage disease 
Mucopolysaccharidoses (MPS) is a group of inborn errors of metabolism with 
defects in degradation of glycosaminoglycans (GAG) or mucopolysaccarides, in 
lysosomes. Up to date, there are 11 known enzyme deficiencies that give rise to 7 
distinct MPS. Mucopolysaccharidosis type II (MPS II)，MIM entry: #309900，is 
caused by the deficiency of the lysosomal enzyme iduronate-2-sulfatase (IDS) 
which initiates the stepwise degradation of GAG [Neufeld EF and Muenzer J, 
2001]. The genetic defects lying in the IDS gene result in lysosomal accumulation 
of GAG This disorder was first described by Charles Hunter in 1917 and has the 
eponym Hunter syndrome. In majority of lysosomal storage diseases (LSDs) 
including most MPS subtypes are autosomal recessive. MPS II is one of the 
exceptions that inherited in an X-linked manner [Neufeld EF and Muenzer J, 2001]. 
Most of the patients are males however there are a few cases of well-documented 
MPS II female patients [Winchester B et al., 1992; Sukegawa K et al., 1998; Cudry 
S et al.’ 2000]. For those female patients of mild form, the mutant allele is most 
likely to occur as heterozygote. Their clinical manifestations are the results of 
skewed X-chromosome inactivation which prevents the expression of the normal 
allele. 
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1.1.1 Prevalence of MPS II 
All types of MPS are rare genetic diseases. MPS II is the most prevalent 
subtype among MPS worldwide [Neufeld EF and Muenzer J, 2001; Kato T et al., 
2002]. Patients were identified in the western populations as well as in the Asian 
populations such as Japanese [Sukegawa K et al., 1995; Isogai K et al., 1998; Kato 
T et al, 2005], Korean [Kim CH et al.’ 2003], and Taiwanese [Chang JH et al” 
2005]. The average estimated incidence of MPS II is about 1 in 110,000 live 
newborn males [Tomanin R et al, 2002]. In Northern Ireland, there is 1 in 72,000 
male live births inherited MPS II [Nelson J. 1997]. And there is 1 in 165,000 male 
live births affected in Western Australia [Nelson J et al.’ 2003]. 
In Hong Kong, we have different types of LSDs. According to the Joint 
Metabolic Clinic under Prince of Wales Hospital (data published in 2004), LSDs are 
relatively more common than the other metabolic disorders (Table 1.1). There are 
totally 20 patients affected by various types of LSDs, of which only 3 patients are 
inherited MPS II. We also have three other MPS subtypes, i.e. type I, type III and 
type VI (Table 1.2). In Hong Kong, MPS III is relatively more common than the 
other subtypes. Besides the MPS, the following LSDs are also found in Hong Kong, 
i.e., mucolipidosis type II and Niemann-Pick C. 
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Table 1.1 Inborn error of metabolism in Hong Kong 
Inborn errors of metabolism No. of patients 
Lysosomal storage diseases (LSDs) 20 
Disorders of fatty acid oxidation 10 
Peroxisomal disorders 10 
Mitochondrial disorders 9 
Disorders of carbohydrate metabolism 8 
Organic acidurias 8 
Disorders of transport & mineral metabolism 6 
Urea cycle disorders 2 
Table 1.1 There are various types of metabolic disorders in Hong Kong. The data 
was published by the Joint Metabolic Clinic under Prince of Wales Hospital in 
August 2004. 
Table 1.2 Lysosomal storage diseases (LSDs) in Hong Kong 
Lysosomal storage diseases No. of patients 
(Total = 20) 
Mucopolysaccharidosis Type III 5 
Mucopolysaccharidosis Type I 3 
Mucopolysaccharidosis Type II 3 
Mucopolysaccharidosis Type VI 3 
Mucolipidosis Type II 3 
Niemann Pick Type C 3 
Table 1.2 There are mainly three different types of LSDs in Hong Kong. The data 




1.1.2 Pathophysiology of MPS II 
The deficiency of the housekeeping enzyme IDS causes lysosomal 
accumulation of undegraded GAG affecting various tissues and organs such as heart 
valves, liver, lung and kidney [Neufeld EF and Muenzer J, 2001; Muenzer J et al” 
2002; Tomanin R et al., 2002]. For instance, vacuolization of lymph nodes and 
synoviocytes in the limbs account for swollen joints and hinder the joints movement 
[Muenzer J et al., 2002]. Depending on the dynamic balance between the level of 
storage products and residual enzyme activity, the patients will develop various 
chronic and progressive patterns of clinical severity [Tomanin R et al., 2002; 
Parkinson EJ et al., 2004]. Indeed, the clinical heterogeneity is the results of 
different mutations at the IDS gene affecting enzyme expression level, protein 
stability, or catalytic function [Wilson PJ et al., 1990; Hopwood JJ et al., 1993; 
Tomatsu S et al., 2004]. 
1.1.3 Clinical features of MPS II 
MPS II patients are usually normal at birth. When GAG begins to accumulate 
abnormally, various organs become dysfunction and symptoms develop [Tomanin R 
et al., 2002]. As demonstrated in a knockout mouse model of MPS II，swollen joints 
were visualized from 4 weeks of age. And the vacuolization was widely spread at 60 
weeks [Muenzer J et al.’ 2002]. In human, GAG deposits in the testes and leads to 
sterile male patients. And the patients develop cardiovascular disorders because of 
GAG deposition in the intima. Besides, deposits of GAG in the central nervous 
system may lead to mental retardation. Other clinical phenotypes include 
hepatosplenomegaly, dysostosis with dwarfism, deafness, coarse fades and massive 
excretion of heparan sulfate in urine. In general, the manifestations of MPS II are 
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less severe than MPS I and MPS II does not affect the cornea [Neufeld EF and 
Muenzer J, 2001]. 
MPS II patients have a broad spectrum of clinical phenotypes [Neufeld EF and 
Muenzer J, 2001]. The classification of clinical severity depends on the features 
including age of onset, survival period, skeletal changes, developmental delay and 
the presence of progressive mental retardation [Neufeld EF and Muenzer J, 2001]. 
Mainly, MPS II can be classified into a mild form and a severe neuronopathic form. 
The mild form involves slow deterioration and fairly normal intelligence while the 
severe form is early onset and mentally retarded. Some of the patients are regard as 
intermediate between the two extremes [Neufeld EF and Muenzer J, 2001]. 
The patients who are mildly affected usually preserve normal intelligence with 
no mental deterioration. They have obvious somatic changes of joint stiffness and 
short status. The symptoms are late onset with reduced rate of progressing. The 
patients can survive into the fourth or fifth decade of life [Young ID et al., 1982; 
Neufeld EF and Muenzer J, 2001]. In contrast, the severe form has global 
retardations leading to cardiovascular disorders, respiratory diseases, 
hepatosplenomegaly and mental retardation. The patients have short stature with 
stiff joints and skeletal deformities which seriously disturbing their behaviour. Also, 
the patients have coarse facial features that can be easily recognized since 2- to 
4-year-old. Due to the progressive deterioration of many organs and early onset, 
patients suffering from the debilitating diseases lead to an early demise before the 
age of fifteen years [Young ID et al., 1982; Neufeld EF and Muenzer J, 2001]. 
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1.1.4 Clinical management of MPS II 
1.1.4.1 Diagnostic methods for MPS II 
GAG deposits in the kidney leading to massive excretion of GAG in urine and 
forms the basis for a routine biochemical diagnostic test for MPS. Analysis of 
urinary lysosomal membrane-associated protein (LAMP-1) may also serve as a 
marker for MPS. Further quantification of the specific mucopolysaccharides in the 
urine samples can confirm the diagnosis of most MPS subtypes. However, MPS I 
and MPS II share the same biochemical markers, heparan sulfate and dermatan 
sulfate. Therefore, residual enzyme activity should be tested in order to differentiate 
the two subtypes. MPS I patients have a-L-iduronidase (IDUA) deficiency while 
MPS II patients show IDS deficiency. 
IDS deficiency can be determined in a variety of cells and body fluids. The 
activity assay can be simply performed using patients' serum or plasma samples. 
Cultured fibroblasts, developed lymphoblastoid cells, peripheral blood leukocytes 
and hair roots can also be obtained from the patients for enzyme assays [Li P, 
Bellows AB and Thompson JN, 1999]. Actually, residual enzyme activity itself does 
not provide comprehensive information for MPS II diagnosis. Usually, a low level of 
active enzyme is enough for maintenance of normal phenotypes in most LSDs but 
the minimum amount of IDS is unknown [Thomas GH，1994]. Additionally, the IDS 
protein level and its residual activity show little or no direct correlation with the 
clinical severity of MPS II [Parkinson EJ et al., 2004; Kato T et al, 2005]. Enzyme 
assays are also not feasible for carrier detection because the activities of carriers 
overlap with normal range [Lyon MF, 1961; Cudry S et al., 2000]. 
RT-PCR sequencing for IDS cDNA or direct PGR sequencing for IDS genomic 
DNA is more feasible to characterize the molecular lesions in MPS II patients 
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[Isogai K et al., 1998; Li P, Bellows AB and Thompson JN, 1999]. DNA sequencing 
of the IDS gene serves as an excellent tool for direct diagnosis of MPS II because it 
provides definitive results and is automated. Additionlly, it is reliable for carrier 
detection and prenatal diagnosis. Direct sequencing for the coding sequences and the 
exon-intron boundaries of the IDS gene helps to identify small mutations like single 
nucleotide changes, deletions or insertions. For detecting gross structural alterations, 
we can use southern blot analysis. Other approaches like direct restriction enzyme 
digestion, single-strand conformation polymorphism (SSCP) analysis, heteroduplex 
analysis with mutation detection enhancement (MDE) gel electrophoresis are also 
useful for mutational analysis [Isogai K et al., 1998]. 
1.1.4.2 Treatments for MPS II 
Bone marrow transplantation (BMT), enzyme replacement therapy (ERT), 
substrate deprivation therapy and enzyme enhancement therapy are some of the 
symptomatic therapies for most LSDs. The allogeneic BMT has been described for 
treating several MPS subtypes including type 11，type IV and type VI with evidences 
of metabolic correction in various tissues and organs [Warkentin PI et al” 1986; 
Coppa GV et al, 1995]. However, only MPS II patients with mild form can be 
considered for this procedure [Coppa GV et al., 1995]. The application of BMT is 
also limited by the lack of histocompatible donors, its complications such as 
graft-versus-host disease, and the significant mortality rate up to 20 - 50 % 
[Warkentin PI et al., 1986]. 
New therapeutic measures of MPS II are under active developments. 
Approaches like ERT can ameliorate the signs and symptoms of some LSDs. The 
first enzyme available for ERT was Alglucerase in treating the Gaucher disease 
[Whittington R and Goa KL, 1992]. Nowadays, we have two more enzyme products 
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developed. They were approved in European and American markets for treating 
Fabry disease and MPS I since the early 2000s. Currently, there are ongoing trials 
for glycogen storage disease II/ Pompe disease, MPS II and MPS VI [Muenzer J et 
al” 2002]. ERT for MPS II started the Phase I/II clinical trial since 2002. It showed 
pronounced effects of GAG reduction in the heart, lung, liver, kidney, spleen, skin 
and skeletal muscle of the animal models [Muenzer J et al., 2002]. However, 
purified enzyme may be quite expensive for the patients [Tomanin R et al., 2002]. 
Gene therapy is another potential treatment for MPS II patients started the 
Phase I/II clinical trial since early 2000s [Braun SE et al, 1993; Whitley CB et al., 
1996; Stroncek DF et al, 1999]. Mainly, amphotropic retroviral and adenoviral 
containing wild-type human IDS coding sequence are considered for transduction 
due to their engineered non-immunogenic microcapsules. Recent study suggested 
that MT-based vectors also have great potential strategy of gene therapy utilizing 
human CD34+ stem cell as targets. [Hong YT et al, 2003] And the recombinant IDS 
enzyme synthesized in over-expressing cell clones such as macrophagic cells would 
be therapeutic for GAG clearance in the central nervous system [Braun SE et al., 
1993; Krivit W et al., 1995; Tomanin R et al., 2002]. 
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1.2 Idiironate-2-Su丨fatase protein (IDS) 
1.2.1 Role in GAG degradation 
IDS (EC 3.1.6.13) is a house keeping lysosomal enzyme. Expression of IDS is 
found in all types of cells except mature red blood cells. The enzyme is classified as 
sulfuric ester hydrolase acting on the sulfated monosaccharide residue. It belongs to 
a sulfatases family containing at least nine members that hydrolyze sulfate esters in 
human cells. IDS protein has high degree of homology with the other mammalian 
sulfatases but each of them displays absolute substrate specificity [Wilson PJ et al., 
1990]. Human IDS is responsible for hydrolysis of the C2-sulfate ester bond from 
non-reducing-terminal L-iduronic acid residues in the heparan sulfate and dermatan 
sulfate [Neufeld EF and Muenzer J, 2001]. It is the first enzyme catalyzes the 
breakdown of the storage GAG compounds. The sequential degradation pathway is 
shown in Figure 1.1. Besides sulfatases, there are glycosidases and nonhydrolytic 
transferase involved in the pathway. 
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Figure 1.1 Glycosaminoglycan degradation pathways 
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Figure 1.1 The stepwise degradation of heparin sulfates and dermatan sulfatase. 
The carbohydrate chains of GAG are sequentially removed by a series of lysosomal 
enzymes. IDS is encoded as EC 3.1.6.13 which initiate the reaction. The entire first 
step of degradation is completed by another enzyme, IDUA (EC 3.2.1.76). 
Deficiency of IDS or IDUA results in large amount of herparan sulfase and dermatan 
sulfase excreted in the urine. 
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1.2.2 Post-translational modifications 
There are eight lysosomal sulfatases including IDS and three non-lysosomal 
sulfatases in the human cells. Some of them may be evolutionarily related to a 
common ancestral gene and show similar amino acid sequences (Appendix 1 and 2)， 
structures and catalytic mechanisms [Wilson PJ et al., 1990]. Like many mammalian 
sulfatases, IDS polypeptide is synthesized as a larger precursor which is composed 
of 550 amino acids. Then, it undergoes several secondary modifications during the 
transport from endoplasmic reticulum (ER) to lysosomes (Figure 1.2). Although IDS 
is known to have no disulphide bonds, there are other post-translational processings 
include formylglycine (FGly) formation, glycosylation, phosphorylation of 
oligosaccharide chains, signal peptides cleavage, an N-terminal proteolytic step 
downstream of residue 33, and a C-terminal proteolytic step upstream of residue 456 
[Wilson PJ et a!., 1990; Froissart R et al., 1995]. Furthermore, there is an internal 
cleavage to form additional mature IDS of 45-44 kDa [Millat G et al., 1997a]. 
1.2.2.1 Formylglycine formation 
For catalytic activity, all prokaryotic and eukaryotic sulfatases require a 
common form of post-translational modification at the active site that converts 
cysteine into 2-amino-3-oxopropionic acid residue (Ca-formylglycine) [Schmidt B 
el al” 1995]. The pentapeptide C-X-P-S-R (IDS residues 84 - 88) is highly 
conserved in all human sulfatases for catalytic activity (Appendix 1). Therefore, 
functional IDS requires FGly conversion at Cys84 residue [Schmidt B et al.’ 1995; 
Millat G et al., 1997a]. ER-residential FGly generating enzyme (FGE) is responsible 
for such conversion either as co-translational or early post-translational modification 
prior to folding of the newly synthesized polypeptides [Baenziger JU, 2003; 
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Preusser-Kunze A et al, 2005]. FGE is encoded by the sulfatase modifying factor 1 
(SUMF 1) gene located on human chromosome 3p26. The gene has orthologs in all 
eukaryotes and most prokaryotes except E.coli, S. cerevisiae and C. elegans 
[Landgrebe J et al, 2003]. There should be alternative FGly formation mechanisms 
for their sulfatases. 
1.2.2.2 Glycosylation 
IDS polypeptide has 8 potential N-linked glycosylation sites (Asn-X-Ser/Thr) 
at residues Asn31，AsnllS, Asnl44，Asn246, Asn280, Asn325, Asn513 and Asn537 
[Wilson PJ et al., 1990]. Glycosylation takes place in the endoplasmic reticulum and 
the oligosaccharide chains are then phosphorylated. The first potential site (Asn31 
residue) is lost during N-terminal proteolysis. The molecular weight of the 
C-terminal 18 kDa polypeptides suggested that the two N-glycosylation sites at 
Asn513 and Asn537 residues are used. However, the total number of glycosylated 
sites in the mature forms remains unknown [Wilson PJ et al., 1990; Froissart R et al” 
1995; Millat G et al, 1997b]. Previous study revealed that none of the potential sites 
is essential for lysosomal targeting [Tikkanen R et al., 1995; Millat G et al, 1997a]. 
It is believed that high level of complex-type oligosaccharide chains on circulating 
IDS has functions to promote protein stability and mask its immune reactivity 
[Parkinson-Lawrence E et al” 2005]. 
1.2.2.3 Proteolysis 
IDS is synthesized initially as 76 kDa precursor and glycosylated to 90 kDa 
precursor. They are converted through a 62 kDa intermediate into the mature 
polypeptides of 55 and 45 kDa [Millat G et al” 1997a]. For N-terminal processing, 
propeptide of eight amino acids (residues 26 - 33) is removed immediately following 
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the signal peptides cleavage (residues 1 - 25) shortly after transferred into lysosomes 
[von Heijne G, 1986]. For the first C-terminal proteolytic cleavage (C-proteolysis 1)， 
removal of 18 kDa polypeptide produces the 62 kDa intermediate form [Froissart R 
et al., 1995]. Previous study sequenced the 18 kDa polypeptide and found that it 
contains the 95 amino acids at the C-terminal end of IDS precursor [Wilson PJ et al, 
1990]. For the second C-terminal proteolytic cleavage (C-proteolysis 2)，a 7-8 kDa 
polypeptide is released and produces the other mature form of IDS with 45-44 kDa 
[Millat G et al, 1997a]. 




Phosphorylation Deglycosyiation Deglycosylatlon C-Proteolysia 2 
76 kOa • 90 kDa ^ 62 kDa • 55 kDa — • 4 5 - 4 4 kDa 
(60) (60) (46) (46) (39-38) 




Figure 1.2 IDS processing in COS-7 cells is identical as in human fibroblast. 
[Millat G et al” 1997b] Precursor IDS processing to mature forms involve FGly 
formation, glycosylation, N-terminal proteolytic cleavages and C-terminal 
proteolytic cleavages. Molecular masses of deglycosylated polypeptides are 
indicated in parentheses (kDa). 
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1.2.3 Iduronate-2-sulfatase gene (IDS) 
The IDS cDNA containing the complete coding sequence was first isolated in 
1990 [Wilson PJ et al., 1990]. The genomic organization and nucleotides sequence 
of IDS gene were then reported in 1993 [Flomen RH et al., 1993; Wilson PJ et al” 
1993]. The gene has 1650 base pairs (bp) open reading frame and is mapped to 
Xq27.3-q28 boundary of the long arm of the X-chromosome spanning 
approximately 24 kb [Wilson PJ et al., 1990; Flomen RH et al., 1993; Wilson PJ et 
al., 1993; Timms KM et al., 1995]. The potential promoter for IDS gene lacks a 
TATA box but like many other housekeeping genes, it contains a GC box consensus 
sequence that span from 400 bp upstream to 150 bp downstream of the initiation 
codon ATG. The cDNA sequences are numbered in accordance with the A of the 
ATG initiation codon shown as “+1” (Appendix 3). 
There are two transcription variants synthesized from the same IDS locus 
(Figure 1.3). Including the untranslated region, one of the variant (GenBank 
accession number: NM一000202) is a 2.3 kb transcript containing 9 exons [Wilson PJ 
et al., 1990]. The alternative form (GenBank accession number: NM_006123) is a 
1.4 kb transcript containing only exon 1 to exon 7 with a distinct C-terminal end 
[Malmgren H et al.’ 1995]. Both exons 8 and 9 are absent in this alternative variant 
and the 207 amino acids at the C-terminal end of variant 1 are replaced by 7 amino 
acids (F-L-M-R-T-N-T). Besides, there is an /Z)5'-like pseudogene located about 20 
kb distal from the telomeric end of the active IDS gene [Timms KM et al., 1995]. 
This pseudogene comprises the copies of IDS exons 2, 3 and intron 7 which have 
homologous regions with the active gene. 
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Figure 1.3 Genomic structure of IDS gene 
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Figure 1.3 Exon/ intron organization of the human IDS gene. There are two 
transcription variants. In this study, the mutations were located at exon 8 and which 
does not contain in the transcription variant 2. Thus, the IDS cDNA was cloned from 
transcription variant 1，i.e. NM_000202. 
1.2.3.1 Properties of IDS mutations 
Over 300 mutations underlying MPS II were identified worldwide indicating a 
high degree of allelic heterogeneity at IDS locus [Stenson PD et al., 2003; Human 
Gene Mutation Database]. The wide spectrum of genetic alterations including 
deletions, insertions, point mutations, splice site mutations, frameshift and 
homologous recombination imply for the pathogenesis and the observed clinical 
heterogeneity. Approximately 89 % of mutations are small lesions affecting 1 to 20 
bp (Table 1.3). Of which, about 70.4 % are point mutations predicting amino acids 
replacement (missense), premature termination of translation (nonsense) and 
aberrant splicing. 13 % of patients have homologous intrachromosomal 
recombination with IDS pseudogene [Bondeson ML et al.’ 1995]. A 
loop-cleavage-repair model suggested that homologous regions exchange between 
IDS intron 7 and sequences close to exon 3 of pseudogene [Bondeson ML et al., 
1995; Birot A M et al., 1999]. Patients carrying structural rearrangements or gross 
alterations result in clinically severe MPS II. 
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Table 1.3 Allelic heterogeneity at IDS locus 
Mutation type Total no. of mutations Percentage (%) 
Nucleotide substitutions 171 53.61 
(missense/ nonsense) 
Nucleotide substitutions 29 9.09 
(splicing) 
Small deletions 58 18.18 
Small insertions 23 7.21 
Small indels 3 0.94 
Gross deletions 26 8.15 
Gross insertions & duplications 1 0.31 
Complex rearrangements 8 2.51 
(including inversions) 
Total 319 100 
Table 1.3 Over 300 different mutations underlying IDS gene result in 
mucopolysaccharidosis type II. Mostly, the patients inherited point mutations 
predicting amino acid replacement and premature termination of translation. Only 11 




1.2.3.2 Methylation patterns are correlated with transitional mutations 
The point mutations are nonrandomly distributed over the exons and relatively 
more frequent in exons 3, 5，8 and 9 of IDS gene (Figure 1.4 & Table 1.4) 
[Rathmann M et al., 1996]. They are likely to correlate with methylation patterns of 
CpG sites in the exons [Tomatsu S et al., 2004]. And almost all recurrent transitional 
mutations are associated with CpG sites. For instance, codons Ala85, Arg88, Ser333, 
Arg443 and Arg468 with CpG dinucleotide hypomethylated, are the mutational 
hotspots [Isogai K et al., 1998; Li P, Bellows AB and Thompson JN, 1999]. Over 35 
% point mutations found in CpG sites and nearly 80 % are derived from C � T or 
G>A transitional events by in situ methylation-deamination process [Cooper DN and 
Krawczak M, 1993; Rathmann M et al., 1996; Li P, Bellows AB and Thompson JN, 
1999; Tomatsu S et al” 2004]. 
For mammalian housekeeping genes, CpG islands are normally located in the 
5' region and mostly unmethylated. And the general patterns of methylation 
throughout the IDS active allele (Xa) are very similar between normal females and 
normal males without any difference between the sexes [Tomatsu S et al., 2004]. 
However, the IDS inactive allele (Xi) has methylation patterns quite different from 
Xa because of its nature of X-chromosomal inactivation among the females. All the 
CpG sites on Xi are characteristically hypermethylated and highly mutable [Gartler 
SM and Riggs AD, 1983; Park JG and Chapman VM，1994]. The asymmetrical 
methylation patterns of both IDS alleles in the female carriers may lead to 
symptomatic MPS II when non-random inactivation of X-chromosome occurs 
[Cudry S et al., 2000]. Nevertheless, de novo mutations tend to occur frequently in 
male meioses [Rathmann M et al, 1996; Froissart R et al., 1998]. 
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Figure 1.4 Mutation map of IDS gene 
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Figure 1.4 The mutation map was obtained from the Human Gene Mutation 
Database. There are 171 point mutations reported on IDS gene responsible for MPS 
II. Exons 3，5, 8 and 9 are the hot spots of missense mutation. Nearly 25 % of point 
mutations were located in exon 9. Previously unreported mutations are indicated as 
star on the map, i.e. p.S369X and p.L339R 
Table 1.4 Non-random distribution of point mutations on IDS gene 
Exon number 1 2 3 4 5 6 7 8 9 
Frequency (total = 171) 4 12 38 6 24 13 11 21 42 
Table 1.4 The data of mutation frequency was obtained from the Human Gene 
Mutation Database. In this study, two novel mutations were identified at exon 8 but 
they were not included in the table. 
18 
Introduction I ^ B 
1.2.3.3 Genotype-phenotype correlations between IDS gene and MPS II 
Several studies showed presence of genotype-phenotype correlations between 
IDS gene mutations and MPS II by structural analysis, or more comprehensively by 
in vitro expression [Rathmami M et al., 1996; Millat G et al., 1997a; Villani GRD et 
al., 2000; Bonuccelli G et al., 2001; Ricci V et al, 2003; Chang JH et al., 2005; 
Kato T et al., 2005]. Most small deletions from 1 to 3 bp lead to frameshift and 
premature chain termination. For those mutations predicting termination of 
translation located very near to the C-terminal end, e.g. Q531X may cause a mild 
phenotype due to the normal C-terminal proteolytic processing [Bunge S et al., 
1992]. However, the premature stop codon happened at other regions may affect 
protein synthesis and/ or stability. For instance, W345X and 787delG (A263X) 
resulted in unstable truncated enzyme protein and cause clinically severe MPS II 
[Bunge S et al., 1992; Kim CH et al., 2003]. 
Genetics alterations belong to the conservative changes at sulfatase C-X-P-S-R 
motif are correlated with severe forms of MPS 11. The mutations at Cys84 residue 
have drastic effect for IDS processing and abolish the enzymatic activity. [Millat G 
et al., 1997a] IDS Arg88 residue is not essential for processing but contributes to 
normal transport of the polypeptides from the early vacuolar compartment to 
lysosomes [Villani GRD et al., 2000]. Substitution studies of Pro86 residue also 
revealed failure of lysosomal targeting and lead to severe disease [Millat G et al., 
1998]. Mutations at other residues, e.g. W267C and S117del also lead to partial 
targeting or no lysosomal targeting of the IDS polypeptides resulting in severe 
phenotypes [Rathmann M et al., 1996; Chang JH et al., 2005]. Mistargeted IDS 
polypeptides may be inactive due to the loss of lysosomal environment which 
provides optimum pH for catalytic activity. 
Some mutations, such as S333L and G336V may change the active site 
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conformation at adjacent residues Asp334 and His335 cause severe phenotypes by 
reducing the enzymatic activity [Isogai K et al., 1998; Froissart R et al” 1998; Kato 
M et al., 2005]. Mutations like K347T, N265I and 473delTcc may also have possible 
effects on enzyme conformation and catalytic function [Bonuccelli G et al., 2001]. 
For those mutations not conserved for IDS processing or lysosomal targeting or not 
structurally important for functional activity may cause mild to intermediate 
phenotypes. For instance, the amino acids alterations at Arg95 residue changed to 
lysine, leucine or threonine are responsible for intermediate phenotype [Dierks T et 
al., 1999; Goldenfum SL et al., 1996; Moreira da Silva I et al.’ 2001]. 
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1.3 In this study 
To date, there are totally 4 individuals affected by MPS II in Hong Kong. As 
mentioned in Chapter 1.1，mutations of the IDS gene are responsible for the disease. 
However, no mutation data and family pedigree for the patients was published 
before. In this study, there are three main objectives: 1) to identify the genetic 
defects lying in the IDS gene for all the MPS II patients in Hong Kong; 2) to 
examine the deleterious effects of the mutations so that possible correlations 
between the mutation data and clinical phenotypes can be estimated, and; 3) to 
investigate the mechanism of post-translational processing for IDS polypeptides 
maturation. 
1.3.1 Mutational analysis 
To my knowledge, this is the first time to study the molecular lesions for MPS 
II patients in Hong Kong. In this study, mutations of the IDS gene were identified 
comprehensively by direct sequencing the entire coding sequence. Restriction 
analysis was carried out to confirm the absence of the novel mutation in 50 normal 
individuals. The identified mutations were used for prenatal diagnosis and carrier 
detection among the patients' families. 
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1.3.2 In vitro expression of mutant IDS 
The major evidence of causality for novel mutations should preferably involve 
well-designed expression studies of the mutant enzyme [Wilson PJ et al., 1990; 
Daniele A et al” 1993; Bonuccelli G et al., 2001]. The mutant cDNA was 
synthesized by site-directed mutagenesis which was commonly used for IDS studies 
since the early 1990s [Annella T et cd., 1993]. Two different in vitro expression 
systems were used for evaluating the functional consequences of the novel missense 
mutation at codon Leu339. Besides the pathological effects, the structural 
importance of this residue was also verified by substitution studies. 
Three complementary experiments were involved in this study. Although 
human cell lines allow better processing of IDS precursors, COS-7 cells was proved 
to have identical processing steps of IDS precursors as in human fibroblasts [Millat 
G et al, 1997b]. The IDS mutants were expressed in COS-7 cells for 1) 
investigating IDS enzymatic defect by fluorometric activity measurement; 2) 
investigating IDS niRNA stability by RT-PCR study. The IDS mutants were also 
expressed in cell-free in vitro expression systems for 3) examining IDS precursors 
stability by simple protein staining. The cell-free expression systems are coupled 
with transcription and translation in a single reaction tube for recombinant protein 
production. This alternative approach becomes one of the most important tasks in 
biotechnology today. 
This is the first time to apply cell-free expression systems to synthesize IDS 
protein. The performance of microbial systems, plant systems and mammalian 
systems were compared (Table 2.4). It is believed that both the plant and mammalian 
systems provide eukaryotic environments for eukaryotic mRNA binding and 
facilitate the translation process. Simultaneously, microbial expression systems 
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continue to be wildly used because of high yields and ease of manipulations [Betton 
JM, 2003; Voloshin AM and Swartz JR，2005; Graumann K and Premstaller A, 
2006]. However, one of the largest problems is the formation of inclusion bodies in 
microbial system. When large amount of foreign proteins are synthesized quickly, 
the polypeptides will be misfolded and aggregated. The cell-free systems have the 
advantages of being open and flexible, supplements can be added to assist protein 
folding or even processing in this study. 
1.3.3 Maturation of IDS polypeptides 
Previous studies revealed that none of the potential N-glycosylation sites is 
essential for lysosomal targeting although the mature IDS polypeptides have 
molecular weight suggesting that they are glycosylated [Millat G et al., 1997a]. In 
this study, the importance of glycosylation during IDS processing was studied by 
expressing wild-type IDS in the cell-free systems which do not allow glycosylation 
takes place. And the unglycosylated proteins were introduced into COS-7 cells for 
verifying the cellular uptake mechanism of IDS. Additionally, previous studies 
suggested that IDS processing can be pre-lysosomal or completed just after the 
polypeptides entered the lysosomes [Schmidt B et al” 1995]. In this study, a 
modified IDS cDNA without the signal peptide was constructed for estimating the 
location of post-translational processing. 
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Chapter 2 Materials and Methods 
2.1 Mutation screening for MPS II patients 
2.1.1 Patients 
Four male patients were diagnosed to be MPS II by clinical observations and 
biochemical testing previously. They had significant hyper-excretion of urinary 
heparin sulfate and dermatan sulfate detected by electrophoresis. Their genetic 
defects lying in IDS gene were investigated in this study. Patient 1 was diagnosed at 
14-year-old with severe phenotypes. Patient 2 and Patient 3 are brothers preserved 
normal intelligence and affected mildly by the disease. The screening for IDS 
mutations was done at their age of 30s. Patient 4 was identified four years after birth 
and was affected severely by the disease. In this study, the female relatives of the 
patients were also subjected to carrier detection by mutational analysis. 
2.1.2 Genomic DNA extraction 
2.1.2.1 Materials 
Peripheral blood was obtained from the four MPS II male patients and six of 
their family members including five female relatives. Their genomic DNA was 
extracted from the whole blood samples using the commercial kit described below 
according to the manufacturer's instruction. 
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QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) comprises protease 
solvent, QIAGEN protease, buffer AL, 
Figure 2.1 QIAamp DNA 
buffer ATL, buffer AWl, buffer AW2, Blood Mini Kit 
Sample Pure genomic 
buffer AE, QIAamp spin columns, 2 mL 上 ORVJRAI DNA 
collection tubes and 1.5 mL centrifuge ^ 
Lyse 1| U 
tubes. QIAGEN protease is supplied W \ 7 
I 
lyophilized and required to be dissolved 
by the protease solvent before use. All Bind 11 M Eiote 
reagents are stored at room temperature ^ ^ 
(RT) except the dissolved protease which 
Wash I p l I p Wash 
is Stored at -20°C. The protocol claims to (b臺rAwii [g ^ [g (Buffer aw2| 
have a yield of up tol2 i^g DNA from 200 a一 e和 &― a u 
QIAamp DNA Blood Mini Kit 
i^L whole human blood. The purified isolates DNA from blood and 
DNA is from 200 bp up to 50 kb other body fluids. DNA is released 
from lysed samples and binds 
depending on the age and storage of blood specifically to the silica-gel 
samples, with majority of 20-30 kb. membrane in the QIAamp spin 
column during centrifligation. Salt 
她隱I 议te GR for analysis ^ ^ pH conditions are adjusted to 
(Merck KGaA, Darmstadt, Germany) allow optimal binding of DNA 
onto the membrane, while 
C2H5OH’ with MW 46.07，is stored at RT. contaminants pass through. Any 
It is highly flammable and should be residual contaminants which can 
act as PCR inhibitors, such as 
stored in fume cupboard. divalent cations and proteins are 
completely removed in two 
subsequent wash steps, leaving 
2.1.2.2 Methods pure DNA ready to be eluted. 
The process was summarized in 
Figure 2.1. A mixture of cell lysis reactions was prepared. 200 |iL whole blood 
samples and 20 i^L protease were added to 200 |iL buffer AL. The mixture was 
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vortexed for 15 sec and incubated at 56 °C in a heating block for 10 min. 200 |iL 
absolute ethanol was added and mixed by vortex for 15 sec. The mixture was then 
applied to the QIAamp Spin Column contained in 2 mL collection tube. The filtrated 
cell debris was discarded after centrifugation at 6000 x g for 1 min. 500 jiL buffer 
AWl was added, and the column was centrifuged at 6000 x g for 1 min. 500 |LIL 
buffer AW2 was added, and the column was centrifuged at 16100 x g for 3 min. The 
column was further centrifuged at 16100 x g for 1 min to remove any residual buffer 
AW2. 50 |iL buffer AE was then added to the column for 5 min incubation at RT. 
Finally, DNA was eluted by centrifugation at 6000 x g for 1 min and collected in a 
clean 1.5 mL centrifuge tube. The DNA yield and purity were determined 
spectrophotometrically with a BioPhotometer (Eppendorf AG, Hamburg, Germany) 
by measuring absorbance at 260nm and calculating the A260/A280 ratio respectively. 
2.1.3 IDS exons amplification by Polymerase Chain Reaction (PCR) 
2.1.3.1 Materials 
2.1.3.1.1 PCR 
100 mM dNTP Set (Invitrogen Corporation, Carlsbad, California, USA) is 
supplied in a concentration of 100 mM and required to be stored at -20°C. It is 
diluted to 10 mM with dHzO. 
AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City, California, 
USA) is supplied together with 10 x PCR Buffer and MgCb. The enzyme is stored 
at -20°C while the other components are stored at 4°C. AmpliTaq Gold DNA 
Polymerase is a chemically modified form of AmpliTaq DNA Polymerase, with a 
chemical moiety attached to the enzyme. When the chemical moiety is attached, the 
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enzyme is inactive. By a heat activation step, the chemical moiety is cleaved and 
active enzyme is released. Thus, during reaction set-up and the first ramp of thermal 
cycling, the enzyme is still inactive and mis-primed primers cannot be extended. 
Flanking primers (QIAGEN, Hilden, Germany) is customized from QIAGEN. 
Nine pairs of IDS primers, namely IDSexonlF to IDSexon9F and IDSexonlR to 
IDSexon9R (Table 2.1), were designed using a web-based software program, 
Primer3. PGR fragments amplified from the corresponding primer pairs include the 
particular exons and the flanking introns of the IDS gene. 
2.1.3.1.2 Agarose gel electrophoresis 
1 kb DNA ladder (Invitrogen Corporation, Carlsbad, California, USA) is 
supplied in a concentration of 1 fig/ [iL. It is diluted to 100 ng/ |iL by loading buffer 
and TE buffer. It is stored at 4°C. Detailed information is shown in Appendix 4.1. 
Ethidium Bromide (Invitrogen Corporation, Carlsbad, California, USA) is 
supplied in a concentration of 10 mg/mL. It is stored at RT. It is carcinogenic. 
Biowest agarose，regular (Gene Company Limited, Hong Kong, China) is 
manufactured in Europe. It is stored at RT. 
Tris-Acetate-EDTA (TAE) electrophoresis buffer (Invitrogen Corporation, 
Carlsbad, California, USA) is supplied in 10 x solution. It is diluted to 1 x with 
dH20. It is stored at RT. 
2% agarose gel was prepared by dissolving 2.4 g Biowest agarose in 120 mL 
1 X TAE electrophoresis buffer and heating in microwave oven. The solution was 
cooled under running tap water to 55°C. 60 |ig ethidium bromide was added. The 
molten mixture was mold in a gel cast with suitable combs inserted. It was allowed 
to stand at RT until set. 
27 
Materials & Methods a 
Table 2.1 Primers for screening IDS mutations 
Optimized 
Products size 
Primer name sequence (5, 3') annealing 
(bp) 
temperature 
IDSexonlF ccg Acg Agg Agg TcT cTg T 
o z C 3 4 5 
IDSexon 1R ggg A Ac g AA Tg A Tgg ATg AA 
IDSexon2F Agg AcT cAg gcT Tcc Tcc Tc 6 � � � 428 
IDSexon2R AAc AAg ATg Tcc cgc AcA AT 
IDSexon3F Tgg TTT gAg cTc Tgc ATg Ac 6 o � c ^ 
IDSexon3R AgA ggg cTc Tgc AAA gAc Ag 
IDSexon4F gTT ccA cTT gcc cAT TTg TT 5 6 � � 奶 
IDSexon4R AAT gAA gcc AcT gcT ccT gT 
IDSexonSF Tgc cTg gAA AAc AAg AAA cA 
56 C 469 
IDSexonSR gAT gTA gcc Acc TTc ccT gT 
IDSexon6F AAA Tgc ATc ccA ggc TTA gA �� 」，」 
60 C 464 
IDSexon6R gcA AcA cTg ccT gTg Tcc TA 
IDSexonTF gcT gTg AcT cTg Tgg gTg AA 6o °c 454 
IDSexonTR ccA ggA Tcc cAc TTT gTT Tg 
IDSexonSF ccT gAT TTT gAA TAA Age Age A 石。�c 
IDSexonSR ccc cAA Age cTA TgA TTc AA 
IDSexon9F cAT ATg gAg ccc AgA cAg gT " � � 
— — 64 C 641 
IDSexon9R cgA ccA gcT cTA AcT ccT ccT 
Table 2.1 The flanking primers are used for amplifying the IDS exons and also 
used as sequencing primers to screen mutations. 
28 
Materials & Methods ja 
2.1.3.1.3 PGR fragments purification 
MicroSpin S-400 HR columns (Amersham Biosciences, Uppsala, Sweden) 
are pre-packed with Sephacryl resin and equilibrated in TE buffer. They are stored at 
4°C. MicroSpin S-400 HR columns utilize spin-colomn chromatorgrapy to purify 
DNA for a wide range of applications, such as purification of PGR products from 
unincorporated primers and nucleotides (dNTPs). Spin-column chromatorgrapy 
enables desired product passing through the gel while retaining smaller impurities. 
The resin was resuspended by vortex and the cap was loosened one-fourth turn 
followed by snapping off the bottom closure before use. Excess TE buffer is then 
removal by centrifugation at 735 x g for 1 min. 
2.1.3.2 Methods 
2.1.3.2.1 Amplifying IDS exons by PCR 
All the 9 exons and their flanking introns of IDS gene were amplified by PCR 
using the genomic DNA extracted from peripheral blood as template. The reactions 
were carried out in a MJ PTC-200 (MJ Research, Waetham, Incorporated, 
Massachusetts, USA), with the following parameters: one cycle of Taq polymerase 
activation at 94 °C for 12 min; 40 cycles of DNA denaturation at 94 °C for 30 sec, 
annealing at 56 - 64 °C for 45 sec, and extension at 72 °C for 45 sec; one cycle of 
final extension at 72 °C for 7 min. The optimized annealing temperatures for each 
pairs of primers are summarized in Table 2.1. The reaction mixture of final volume 
25 |LIL contained 50 ng DNA template, 1 x PCR buffer, 50 nmol MgCl2, 5 pmol 
dNTPs, 12.5 pmol of forward / reverse primers, and 0.625 U AmpliTaq Gold DNA 
polymerase. For exon 1, 5% of DMSO was added and the amount of MgCl2 was 
increased to 62.5 nmol. The PCR products were then analyzed by 2% agarose gel 
electrophoresis to ensure that the specific bands were in correct sizes. 
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2.1.3.2.2 Purifying PCR fragments 
After removal of storage solution in the MicroSpin S-400 HR column, the PCR 
products were applied to the top-center of the resin. Purified PCR fragments were 
collected by centrifugation at 735 x g for 2 min. 
2.1.4 DNA sequencing for detecting IDS mutations 
2.1.4.1 Materials 
BigDye Terminator vl.l Cycle Sequencing Kit (Amersham Biosciences, 
Uppsala, Sweden) consists of BigDye Terminator vl . l cycle sequencing mix and 5 x 
BigDye v 1.1/3.1 sequencing buffer. The kit is stored at -20 °C. 
Sequencing primers (QIAGEN, Hilden, Germany) is the 25-fold dilution of the 
flanking primers. 
AutoSeq G-50 (Amersham Biosciences, Uppsala, Sweden) are MicroSpin 
columns prepacked with Sephadex G-50 DNA Grade F, equilibrated in water 
containing 0.05% Kathon CG/ICP biocide as a preservative. They are stored at RT. 
MegaBASE Loading Solution (Amersham Biosciences, Uppsala, Sweden) is 
stored at -20°C. 
2.1.4.2 Methods 
2.1.4.2.1 Sequencing reaction 
The purified PCR fragments of the 9 IDS exons were sequenced to screen for 
mutations by dideoxynucleotide method [Sanger et al, 1977]. The reaction mixture 
of 10 |uL final volume contains 2 }iL purified PCR products, 1 pmol forward primers, 
1 [iL BigDye Terminator vl . l cycle sequencing mix and 3 |iL of 2.5 x BigDye 
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vl.1/3.1 Sequencing Buffer. Cycle sequencing reaction was carried out in a 
GeneAmp PCR System 9700 Cycler (Applied Biosystems, Foster City, California, 
USA), with the following parameters: one cycle of 96 °C for 1 min; 25 cycles of 96 
°C for 10 sec, 50 °C for 5 sec, 60 °C for 4 min. The products are stored at -20 °C 
before further processing. If mutation is found, the results will be confirmed by 
means of DNA sequencing with the reverse primer. 
2.1.4.2.2 Purifying sequencing products 
Excess solution was removal by centrifugation at 2000 x g for 1 min. The 
sequencing reaction products were purified through the G-50 spin column 
centrifliged at 2000 x g for 1 min to remove the residual dye-labeled 
dideoxynucleotide terminators. 
2.1.4.2.3 Analyzing sequencing results 
The purified sequencing products were mixed with 12 jaL MegaBase loading 
solution and heated at a 95 °C heat block for 5 mins. The mixture was sequenced 
and analyzed automatically by the sequencer ABI PRISM 3100-Avant Genetic 
Analyzer (Applied Biosystems, Foster City, California, USA). The mutation site was 
identified manually and using BLAST programme online. 
2.1.5 Fragment restriction endonudease analysis 
2.1.5.1 Materials 
DNA template was extracted from 50 normal control females as described in 
Chapter 2.1.2.2. 
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PCR reagents are the same as described in Chapter 2.1.3.1.1 and Chapter 
2.1.3.1.2. 
Flanking primers (QIAGEN, Hilden, Germany) is customized from QIAGEN. 
IDS-InterF2 and IDS-InterR3 are used to amplify PCR fragment containing codon 
339. The sequences of primers are shown in Table 2.2. 
ScrFI，10,000 U/mL (New England Biolabs, Ipswich, UK) is supplied with 10 
X Buffer 4. The reagents are stored at -20 °C. The enzyme recognizes DNA sequence 
5'-CCNGG-'3 and forms sticky ends after cleavage. 
2.1.5.2 Methods 
The fragments of IDS gene containing codon 339 were amplified by PCR from 
the 50 control females. The reactions were carried out in a MJ PTC-200 (MJ 
Research, Waetham, Incorporated, Massachusetts, USA), with the following 
parameters: one cycle of Taq polymerase activation at 94 °C for 12 min; 30 cycles of 
DNA denaturation at 94 °C for 30 sec, annealing at 60 °C for 20 sec, and extension 
at 72 °C for 15 sec; one cycle of final extension at 72 °C for 7 min. The reaction 
mixture of final volume 25 |iL contained 50 ng DNA template, 1 x PCR buffer, 50 
nmol MgCb, 5 pmol dNTPs, 12.5 pmol of forward / reverse primers, and 0.625 U 
AmpliTaq Gold DNA polymerase. The PCR products were then analyzed by 2% 
agarose gel electrophoresis to ensure that the specific bands were in correct sizes. 
Then 6 \xL PCR products were digested by 5 U ScrF I with 1 x buffer 4 in 10 fiL 
final volume. The reaction was performed at 37 °C for 16 hours and terminated at 65 
°C for 20 min. The digested PCR fragments were analyzed by 3 % agarose gel 
electrophoresis. 
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Table 2.2 Primers for IDS cloning 
Primer name Purpose Sequence (5, -> 3,) Grade 
IDS-c-Fp Isolation from total cDNA cTgTgTTgcgcAgTcTTcATgg HPLC 
IDS-E-Fp Cloning WT into entry cAccATgccgccAccccggAccggcc HPLC 
vector 
IDSt-E-Fp Cloning N-truncated form cAccATgAcAgATgcTcTgAAcgT HPLC 
into entry vector T 
IDS-c-Rp Isolation from total cDNA ATggTTggcAAAAcTcAAggcA HPLC 
Cloning into entry vector 
IDS-Nde-Fp Cloning WT into pIVEXl.3 ATAATTATcATATgccgccAccccgg HPLC 
Accggccg 
IDSt-Nde-Fp Cloning N-truncated form ATAATTATcATATgAcAgATgcTc HPLC 
into pIVEXl.3 TgAAcgTTc 
IDS-Xho-Rp Cloning into pIVEXl.3 AATTATcTcgAgAggcATcAAcAA HPLC 
cTggAAAA 
IDS-339P Site-directed mutagenesis TcATgggTgggcTccAggTgAAcAT HPLC 
-sen ggAg 
IDS-339P Site-directed mutagenesis cTccATgTTcAccTggAgcccAcccA HPLC 
-anti TgA 
IDS-339R Site-directed mutagenesis TcATgggTgggcTcgAggTgAAcAT HPLC 
-sen ggAg 
IDS-339R Site-directed mutagenesis cTccATgTTcAccTcgAgcccAcccA HPLC 
-anti TgA 
IDS-InterRl Sequencing from +296 bp gTgTcAggTcTccTgccAgTgA salt-out 
IDS-InterF 1 Sequencing from +217 bp cTcTTccAgAATgccTTTgcgc salt-out 
IDS-InterR2 Sequencing from +859 bp gAccATAcggcAcAcTgATgTT salt-out 
IDS-InterF2 Sequencing from +760 bp gAggTcccTgATggccTAcccc salt-out 
IDS-InterF2b Sequencing from +1152 bp TgATTccgccTcAcAgTTgATg salt-out 
IDS-InterR3 Sequencing from +1381 bp TcAgTTcAcggggATTAccAgg salt-out 
IDS-InterF3 Sequencing from +1319 bp AgcATTTTcgATTccgTgAcTT salt-out 
Note: WT means wild-type IDS cDNA; N-truncated means IDS cDNA without the 
first 99 bp. The underlined sequences represent the restriction enzymes recognition 
sites. The altered codon sequences for site-directed mutagenesis are bolded. 
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2.2 Isolation of IDS cDNA from peripheral blood 
2.2.1 Materials 
2.2.1.1 Total RNA extraction 
Peripheral blood was obtained from a normal female individual with plasma 
IDS activity 343.1 nmol/4h/mL. The total RNA was extracted from the whole blood 
samples using the commercial kit described below according to the manufacturer's 
instruction. 
RNeasy Mini Kit (Qiagen, Hilden, Germany) comprises beta-mercaptoethanol, 
buffer RLT, buffer RWl, buffer RWl, buffer RPE, RNeasy Mini spin columns, 2 mL 
collection tubes and 1.5 mL centrifuge tubes. 1.5 mL buffer RLT is required to mix 
with 15 |iL beta-mercap before use. All the reagents are stored at RT. The kit claims 
to have a binding capacity of up to 100 |ag of total RNA with enriched mRNA longer 
than 200 bp. Most RNAs smaller than 200 bp, e.g. 5.8S rRNA, 5S rRNA and tRNAs, 
are selectively excluded. 
RNase-free DNase set (Qiagen, Hilden, Germany) comprises DNase I and 
buffer RDD. DNase I is supplied lyophilized. The set is stored at 4 °C. 
Ficoll-Paque Plus (Sigma-Aldrich, St. Louis, Missouri, USA) is supplied as 
solution of Ficoll 400 and sodium diatrizoate with a density of 1.077 士 0.001 g/ mL. 
The solution is sterile for in vitro isolation of lymphocytes and is stored at 4 °C. 
Phosphate Buffered Saline/ PBS (Sigma-Aldrich, St. Louis, Missouri, USA) 
contains NaCl (120 mmol/L), KCl (2.7 mmol/L) and phosphate buffer (10 mmol/L), 
pH 7.4. It is provided in powder form and stored at RT. To prepare PBS solution, 
the powder was dissolved to 1 L deionized water (dHzO) and autoclaved at 121 °C 
for 15 min. 
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Ethanol absolute GR for analysis (Merck KGaA, Darmstadt, Germany) 
C2H5OH, with MW 46.07，is stored at RT. It is highly flammable and should be 
stored in fume cupboard. 
2.2.1.2 Reverse-transcriptase PCR (RT-PCR) 
Total RNA was extracted from peripheral blood cells as described in Chapter 
2.2.2.1. 
Oligo(dT)2o primer (Invitrogen Corporation, Carlsbad, California, USA) is 
supplied as 50 fiM in dHsO and stored at -20 °C. It is a string of 20 deoxythymidylic 
acid residues that hybridized to the poly(A) tail of mRNA and can be used as a 
primer for first-strand cDNA synthesis with SuperScript III Reverse Transcriptase. 
dNTP Mix (Invitrogen Corporation, Carlsbad, California, USA) is supplied as 
2.5 mM in highly purified H2O and stored at -20 °C. It contains 2.5 mM each of 
dATP，dCTP, dGTP and dTTR 
superscript III Reverse Transcriptase, 200 U/fiL (Invitrogen Corporation, 
Carlsbad, California, USA) is supplied as a kit containing 0.1 M DTT and 5 x 
First-strand buffer. All the reagents are stored at -20 °C. The kit claims to have a 
yield ofcDNA from 100 bp to > 12 kb. 
Ribonuclease H/ RNase H，2U/ //丄(Invitrogen Corporation, Carlsbad, 
California, USA) is stored at -20 °C. It is used for removing mRNA during second 
strand cDNA synthesis. 
2.2.1.3 PCR for amplifying IDS cDNA 
PCR reagents are the same as described in Chapter 2.1.3.1.1 and Chapter 
2.1.3.1.2. 
Luciferase T7 control vector (Promega Corporation, Madison, USA) is 
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supplied in a concentration of 0.5 mg/ mL. The vector contains firefly luciferase 
cDNA. 
Flanking primers for IDS cDNA (QIAGEN, Hilden, Germany) is customized 
from QIAGEN. The five sets of primer pairs (Table 2.2), 1) IDS-c-Fp and IDS-c-Rp, 
2) IDS-E-Fp and IDS-c-Rp, 3) IDSt-E-Fp and IDS-c-Rp, 4) IDS-Nde-Fp and 
IDS-Xho-Rp, 5) IDSt-Nde-Fp and IDS-Xho-Rp were designed using a web-based 
software program, OligoAnalyzer. PCR fragments amplified by the first set of 
primers are the full length IDS cDNA with part of the regulatory sequences. PCR 
fragments amplified by the second set of primers are the full length wild-type IDS 
cDNA started from ATG to stop codon for TOPO cloning. PCR fragments amplified 
by the third set of primers are the N-terminally truncated form of IDS cDNA with 
the absence of 99 bp for TOPO cloning. Restriction sites were incorporated into the 
forth and fifth sets of PCR primers for standard sticky-end cloning. PCR fragments 
amplified by the forth set of primers are the full length IDS cDNA without stop 
codon for cloning into pi VEX-WG-1.3. PCR fragments amplified by the fifth set of 
primers are the N-terminally truncated form of IDS cDNA also for cloning into 
pIVEX-WG-1.3. 
Flanking primers for luciferase gene (QIAGEN, Hilden, Germany) is 
customized from QIAGEN. The primer pairs were designed using a web-based 
software program, OligoAnalyzer (Table 2.3). 
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Table 2.3 Primers for Luciferase cloning 
Primer name Purpose Sequence (5’ -> 3,) Grade 
Luci-E-Fp Cloning WT into entry cAccATggAAgAcgccAAAAA HPLC 
Vector cATA 
Luci-E-Rp Cloning WT into entry cAATTTggAcTTTccgcccTTc HPLC 
Vector 
Luci-InterRl Sequencing from +293 bp ATAAATAAcgcgcccAAcAc salt-out 
Luci-InterR2 Sequencing from +708 bp cgcAgTATccggAATgATTTg salt-out 
Luci-InterR3 Sequencing from +1131 bp ATccAgATccAcAAccTTcg salt-out 
Luci-InterF 1 Sequencing from +1043 bp cTATTcTgATTAcAcccgAgg salt-out 
Luci-InterF2 Sequencing from +1377 bp AcAAcAccccAAcATcTTcgA salt-out 
Note: WT means wild-type luciferase cDNA 
2.2.2 Methods 
2.2.2.1 Extracting total RNA by QIAamp RNeasy Mini Kit 
Peripheral blood sample was obtained from a normal individual. 6 mL whole 
blood samples were added to 6 mL Ficoll solution. The mixture was centrifuged at 
2500 rpm for 15 min. The ring of white matter containing peripheral white blood 
cells (WBC) was isolated and rinsed twice with 13 mL cold PBS. The resuspended 
WBC was centrifuged at 1500 rpm for 5 min. 600 \iL prepared buffer RLT was 
added and mixed with the pellet. The mixture was then homogenized through the 
QIAShredder Spin Column by centrifugation at 13,000 rpm for 2 min. 600)iL of 70 
% ethanol was mixed with the lysate. And the mixture was applied to the RNeasy 
mini column. The cell debris was filtered by centrifugation at >10,000 rpm for 15 
sec and discarded. 350 |LIL buffer RWl was added, and the column was centrifuged 
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at >10,000 rpm for 15 sec. A mixture of 10 |aL DNase I and 70 [iL buffer RDD was 
added and allowed to stand at RT for 15 min. 350 |aL buffer RWl was added, and 
the column was centrifuged at >10,000 rpm for 15 sec. The column was rinsed twice 
with 500 liL buffer RPE and centrifuged at >10,000 rpm for 15 sec and 2 min, 
respectively. The column was further centrifuged at 13,000 rpm for 1 min to remove 
any residual buffer RPE. 30 \xL RNase-free water was added and the column was 
centrifuged at > 10,000 rpm for 1 min. The eluted products was then re-applied to the 
column for further centrifugation at >10,000 rpm for 1 min. And finally, the total 
RNA was collected in a clean 1.5 mL centrifuge tube. The RNA yield and purity 
were determined spectrophotometrically with a BioPhotometer (Eppendorf AG, 
Hamburg, Germany) by measuring absorbance at 260nm and calculating the 
A260/A280 ratio respectively. The extracted products were stored at -70 °C before 
further processing. 
2.2.2.2 Converting IDS mRNA into cDNA by RT-PCR 
cDNA was synthesized from the total RNA by RT-PCR. The reactions were 
carried out in the GeneAmp PCR System 9700 Cycler. 11 |aL total RNA was mixed 
with 1 |iL of 50 \iM oligo dT and 1 |iL of 10 mM dNTP Mix. The mixture was 
incubated at 65 °C in a heating block for 5 min and allowed to cool on ice for 1 min. 
A mixture consists of 4 [xL first-strand buffer (5 x), 1 [iL of 0.1 M DTT and 2 |iL 
superscript III RT was added to the cooled samples. The mixture was heated at 50 
�C for 1 hour and the reaction was inactivated at 70 °C for 15 min. 1 [iL RNase H 
was added and incubated with the mixture at 37 °C for 20 min. The products were 
stored at -20 °C before further processing. 
38 
Materials & Methods J B 
2.2.2.3 Isolating IDS cDNA by PCR 
IDS cDNA was first amplified by PCR using the first set of primer pairs in 
order to prevent non-specific products of pseudo-gene. Then, the PCR products were 
used as DNA templates for further PCR amplifying by the other sets of primer pairs. 
The first reactions were carried out in the MJ PTC-200 with the following 
parameters: one cycle of Taq polymerase activation at 94 °C for 12 min; 40 cycles of 
DNA denaturation at 94 °C for 30 sec, annealing at 60 °C for 45 sec，and extension 
at 72 °C for 2.5 min; one cycle of final extension at 72 °C for 10 min. The optimized 
annealing temperatures for the second set and the third set of primer pairs are 66 °C 
and 64 °C, respectively. And the optimized annealing temperatures for the forth set 
and fifth set of primer pairs are 65 °C. The reaction mixture of final volume 25 i^L 
contained 1 |iL cDNA template, 1 x PCR buffer, 50 nmol MgCb, 5 pmol dNTPs, 
12.5 pmol of forward / reverse primers, and 0.625 U AmpliTaq Gold DNA 
polymerase. The PCR products were then analyzed by 2% agarose gel 
electrophoresis to ensure that the specific bands were in correct sizes. 
2.2.2.4 Isolating firefly luciferase gene by PCR 
Luciferase cDNA was amplified by PCR using the control vector as DNA 
templates. The reactions were carried out in the MJ PTC-200 with the following 
parameters: one cycle of Taq polymerase activation at 94 °C for 12 min; 35 cycles of 
DNA denaturation at 94 °C for 30 sec, annealing at 60 °C for 45 sec, and extension 
at 72 °C for 2 min; one cycle of final extension at 72 °C for 10 min. The reaction 
mixture of final volume 25 jiL contained 1 |iL diluted control vector, 1 x PCR buffer, 
50 nmol MgCb, 5 pmol dNTPs, 12.5 pmol of forward / reverse primers, and 0.625 U 
AmpliTaq Gold DNA polymerase. The PCR products were then analyzed by 2% 
agarose gel electrophoresis to ensure that the specific bands were in correct sizes. 
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2.3 Introducing IDS cDNA into Gateway Cloning System 
One of the most common 
Figure 2.2 Gateway technology 
applications for PCR fragments is cloning 隨,,—“_. 
:‘Rfitrictioa Er^ frnitckti 1 
Oi^ eftloR and U^ tion | 
into a plasmid vector for protein i J S k J i 纖‘一 ！ 
expression. Desired gene was cloned into 
pENTR/D-TOPO for entering into the ^ ^ ^ ^ ^ ^ 
Gateway system, which enabled . .....减 
enormous convenience in subsequent ^ m j s s ^ 
Adapted from Invitrogen, 2004 
expression experiments using different 
Gateway technology allows transferring 
system (Figure 2.2). All cloning DNA fragments into different expression 
vectors by lambda phage site-specific 
procedures for IDS cDNA are identical to 
recombination [Landy A, 1989]. 
those for luciferase gene. Here only 
described the cloning procedures of IDS cDNA as example. There were two forms 
of IDS cDNA, the full length form and the N-terminally truncated form, cloned in 
this study. 
2.3.1 Materials 
2.3.1.1 Directional cloning 
pENTR Directional TOPO Cloning Kit (Invitrogen Corporation, Carlsbad, 
California, USA) provides pENTR TOPO reagents and TOP 10 Chemically 
Competent Kcoli set for directional cloning of PCR fragment. pENTR TOPO 
reagents include pENTR/D-TOPO vector, dNTP Mix, salt solution and sterile water. 
Ml3 Forward (-20) sequencing primer and Ml3 reverse sequencing primer are 
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included for verification of the insert by sequencing. 
pENTR/D-TOPO vector is supplied in a concentration of 5-10 ng/^L. A 
detailed map is shown in Appendix 5. 
pcDNA-DEST40 vector (Invitrogen Corporation, Carlsbad, California, USA) is 
supplied lyophilized in TE, pH 8.0. The vector is resuspended to 150 ng/ jiL with 
RNase-free dH20. A detailed map is shown in Appendix 6. 
pEXPl-DEST vector (Invitrogen Corporation, Carlsbad, California, USA) is 
supplied lyophilized in TE, pH 8.0. The vector is resuspended to 150 ng/ ^L with 
RNase-free dHsO. A detailed map is shown in Appendix 7. 
QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, 
California, USA) consists of 10 x reaction buffer，QuikSolution reagent, dNTP mix, 
PfuXMvdi high fidelity DNA polymerase (2.5 U/ |xL) and Dpnl restriction enzyme (10 
U/ |iL). It is stored at -20 °C. The kit claims to have an efficiency greater than 80%. 
Mutagenic primers, containing the desired mutations of IDS, i.e. c.l016T>C 
and c . l 0 1 6 T � Q were designed by a web-based primer design software program at 
http://labtools.stratagene.com/QC. The primers were synthesized by QIAGEN 
(QIAGEN, Hilden, Germany) with HPLC purification. The primer sequences were 
described in Table 2.2. 
LR Clonase Reaction mix (Invitrogen Corporation, Carlsbad, California, USA) 
consists of Gateway LR Clonase enzyme mix, LR reaction buffer and proteinase K 
solution. Gateway LR Clonase enzyme mix contains bacteriophage lambda 
recombination proteins Integrase and Excisionase, and the E.co/7-encoded protein 
Integration Host Factor. It is stored at -70 
TOPIO Chemically Competent Kcoli set consists of SOC Medium and 
OneShot TOPIO Competent Cells. The TOPIO cells yield 1 x 10^cfu/|igDNAin a 50 
HL transformation reaction. The genotype of TOP 10 is shown in Appendix 8. 
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2.3.1.2 LB medium/ agar with antibiotics preparation 
Kanamycin sulfate (Invitrogen Corporation, California, USA) 
C18H36N4O11 •H2SO4, with MW 583, is supplied lyophilized. It is reconstituted to 10 
mg/ mL with sterile dHaO and stored at -20 It is used as 50|ig/ mL in LB 
medium or agar. 
Ampicillin (Invitrogen Corporation, Carlsbad, California, USA) 
CieHisNsCUSNa, with MW 371.4, is supplied lyophilized. It is reconstituted to 10 
mg/ mL with sterile dHaO and stored at -20 °C. It is used as 100 |ig/ mL in LB 
medium or agar. 
LB Agar/ Lennox L agar (Invitrogen Corporation, Carlsbad, California, USA) 
is supplied in powder form and stored at RT. For preparation, 32 g was added to 1 L 
distilled water and autoclaved at 121 for 15 mins. The agar was cooled in a 55 
water bath. Appropriate antibiotics were added. The agar was poured into plates and 
allowed to stand overnight. The plates were stored at 4 °C in dark. 
LB Broth Base/ Lennox L Broth Base (Invitrogen Corporation, Carlsbad, 
California, USA) is supplied in powder form and stored at RT. For preparation, 20 g 
was added to 1 L distilled water and autoclaved at 121 for 15 mins. Appropriate 
antibiotics were added just prior to using the medium. 
2.3.1.3 Plasmids purification from transformed cells 
QIAprep Miniprep Kit (QIAGEN, Hilden, Germany) consists of buffer PI, 
buffer P2, buffer N3, buffer PB, buffer PE, buffer EB, RNase A, QIAprep spin 
columns and 2 mL collection tubes. RNase A is added to Buffer PI before use. The 
ready-to-use buffer PI is stored at 4 °C. All the other reagents are stored at RT. The 
DNA binding capacity of the membrane in a QIAprep spin column is 20 |ig. 
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2.3.1.4 Validation of IDS inserted plasmids 
Internal primers were designed by Figure 2.3 Gateway-
directional TOPO cloning 
the web-based software program, ~ 
Topoisoinciase I recognition sile.s 
OligoAnalyzer, and were synthesized by IflpNv 二 翻 
^^  J^ ® ~ phosphate 
QIAGEN (QIAGEN, Hilden, Germany). • SIL,切 I 
Table 2.2 shows the sequences of the 一_im:u_gvector 
S^ ^^ BBBDI 
primers. Seven internal primers are used mum-end pcr rnnhc-, * * (designed wilh CACC ut the 5' cnU. no nmUirication al I he 3'end) 
to screen the entire ZDS cDNA: 1650 bp 5 minutes al I 1 room (cnipcniuirc 
and 1551 bp. Sequencing using primer ^ 
•B CCCTT frnWilHIiiW jM 
IDS-inter-Rl can cover the 5'-end of IDS 
I TopoiM>mcrasc I I ipjj^  丨、relased 
cxuj WU；：； rolcj^ cd 
cDNA while IDS-inter-F3 can cover the Lk’a_a>npi«c 
3'-end. Similarly, internal primers were Adapted from invitrogen, 2004 
TOPO cloning utilizes the enzyme 
designed for sequencing the entire cDNA 
topoisomerase I [Shuman S， 1994] 
of luciferase (Table 2.3). replacing DNA ligase in traditional 
cloning. Topoisomerase I is isolated 
Sequencing reagents are the same as 
from vaccinia virus. It functions as both 
described in Chapter 2.1.4.1. restriction enzyme and ligase. It 
specifically recognizes the sequence 
5'-(C/T)CCTT-3' and covalently bind to 
the phosphate group of the 3'-thymidine. 
It cleaves one DNA strand, enabling the 
2.3.2 Methods 一 DNA to unwind. The enzyme then 
religates the ends of the cleaved strand 
and releases itself from the DNA. 
2.3.2.1 TOPO cloning reaction 
The sequence 5'-CACC-3' was 
added to the IDS cDNA by specific primers either IDS-E-Fp or EDSt-E-Fp (Figure 
2.3). 2 [iL PCR products synthesized from the second and third sets of primer pairs 
were ligated with 0.5 ^L pENTR/D-TOPO vector in 0.5 \iL salt solution. The 
ligation mixtures were incubated at RT for 10 min. Then, the ligation products were 
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used for transformation immediately. 
2.3.2.2 Transformation 
The entire ligation products were added into 25 [iL OneShot TOP 10 Competent 
E.coli Cells. The mixture was incubated on ice for 30 min. This incubation allowed 
attachment of the plasmids onto the cell surface. The cells were heat shocked in a 
water bath at 42 °C for 30 seconds and immediately chilled on ice. This facilitated 
the ligation products entering into the competent cells. Then, the cells were 
recovered in 250 jiL SOC medium by shaking at 37 °C，200 rpm for 30 min. The 
transformed cells were then spread onto LB agar plates containing 50 fag/ mL 
kanamycin and incubated at 37 °C for 16 hours. A single colony was then picked and 
inoculated into 5 mL LB medium containing 50 |ag/ mL kanamycin. The inoculum 
was shaken at 37 °C, 200 rpm for 16 hours. A total of 5 colonies were picked for 
subsequent experiments. 
2.3.2.3 Small-scale plasmids preparation by QIAprep Miniprep Kit 
The plasmid was extracted from the bacteria by using QIAprep Miniprep Kit 
according to the manufacturer's instruction (Figure 2.4). 5 mL of bacterial culture 
was pelleted by centrifugation at 3500 rpm for 10 min at 4 °C. The cell pellet was 
resuspended in 250 |aL Buffer PI. And 250 \iL Buffer P2 was added. The tube was 
inverted gently 4 times and incubated at RT for not more than 5 min to prevent 
release of genomic DNA. 350 \iL Buffer N3 was then added and mixed as before. 
The mixture was centrifuged at 16100 x g for 10 min. The supernatant was applied 
to the QIAprep Spin Column and centrifuged at 16100 x g for 1 min. 500 |LIL Buffer 
PB was added and centrifuged at 16100 x g for 1 min. 750|LIL Buffer PE was added 
and centrifuged at 16100 x g for 1 min. The column was further centrifuged at 
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16100 X g for 1 min to remove any residual ethanol. The plasmids were eluted with 
50 |iL dH20. 1 min incubation at RT is prior to centrifugation at 16100 x g for 1 min. 
The DNA yield and quality were determined spectrophotometrically with a 
NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, 
Delaware, USA) by measuring A260 and calculating the A260/A280 ratio respectively. 
Figure 2.4 QIAprep Miniprep 
2.3.2.4 Sequencing the plasmids 
ry,. 1 , J , , Overnight cultures 
The cloning orientation and the 
1 
entire sequence of IDS cDNA were PURE PIASMID DNA 
verified by sequencing reaction. The ^^ 
purified plasmids were directly added as c j ^ ,工、 
template. The reaction mixture of 10 ^L g 
Bind M i Elute 
final volume contains 2 \xL purified ^ “ 
plasmids, 1 pmol IDS internal primers, 2 ^ ^ 
|jL BigDye Terminator v l . l cycle wosh 
Adapted from Qiagen, 2004 
sequencing mix and 1 ^L of 5 x BigDye 
QIAprep Miniprep Kit utilizes a modified 
V 1.1/3.1 Sequencing Buffer. The cycle alkaline lysis method of bacteria cells 
[Bimboim HC and Doly J，1979], in 
reaction, purification of products and 
which Buffer P2 contains SDS，which 
sequencing analysis were described as in solubilizes the phospholipids and protein 
components of the cell membrane and 
Chaper 2.2.3.2. If there is no mutation 
releases the cell contents. Buffer N3 was 
found in the IDS cDNA and the insert is used to neutralize the lysate and its high 
salt concentration precipitates denatured 
in desired direction in pENTR/D-TOPO 
proteins, chromosomal DNA, cellular 
vector, this entry clone will be stored at 4 debris, and SDS. The lysate is loaded into 
QIAprep coluirms with a silica-gel 
°C for subsequence experiments. 
membrane which absorbs piasmid DNA 
in high-salt buffer and elutes in low-salt 
buffer. 
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2.3.2.5 QuikChange n XL site-directed mutagenesis 
2.3.2.5.1 Synthesizing mutant strand Figure 2.5 QuikChange H XL 
with desired mutations Site-directed Mutagenesis Kit 
Mutagenesis was carried out in the ^ ^ ^ 
entry clones to create the following amino ^ ^ ^ 
acid changes: Leu339Pro and Leu399Arg • 
(Figure 2.5). 10 ng dsDNA template was ^ ^ ^ ^ 
amplified in a reaction mix of 50 |LIL final ^ ^ ^ 
• — 
volume containing 125 ng of the ^ ^ ^ 
corresponding oligonucleotide primer and 一 — — 雇 
125 ng of its anti-sense oligonucleotide QuikChange II XL Site-Directed 
Mutagenesis Kit replaces, inserts, or 
primer, 1 i^L dNTPs, 3 |LIL QuikSolution 
deletes nucleotides from a 
and Ix reaction buffer. An addition of 2.5 double-stranded vector. Two synthetic 
oligonucleotide primers containing the 
U /yi/Ultra HF DNA polymerase was then 
desired mutation, each complementary to 
added. PCR parameters were as follow: opposite strands of the vector, are 
extended to generate a mutated plasmid. 
denaturation at 95 °C for 1 min, 18 cycles 
The products are treated with Dpnl 
of denaturation at 95 °C for 50 sec, primer endonudease (target sequence: 
5'-Gm^ATC-3'), which is specific for 
annealing at 60 °C for 50 sec, extension at 
methylated and hemimethylated DNA 
68 °C for 5 min, and a final extension at [McClelland M and Nelson M, 1992]. 
The parental DNA template is dam 
68 °C for 7 min. 
methylated, thus it is digested. Only the 
mutant vector remains intact. 
2.3.2.5.2 Digesting parental strand 
The amplification products containing parental strand and mutated vector were 
digested by 10 U Dpnl restriction enzyme at 37 °C for 1 hour. 5 \iL Dpnl-tveated 
products were analyzed by 2 % agarose gel electrophoresis. A sharp band indicates 
successful mutant strand synthesis. 
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2.3.2.5.3 IVansformation 
The intact mutant strand (2 i^ L) was transformed into OneShot TOP 10 
Competent Cells for propagation as described in Chapter 2.3.2.2. The plasmids 
were then purified by QIAprep Miniprep Kit as described in Chapter 2.3.2.3. Mutant 
IDS genes were obtained. The mutant plasmids were subjected to further sequencing 
to exclude the presence of undesired mutations in the IDS cDNA as described in 
Chapter 2.3.2.4. 
2.3.2.6 Swapping IDS gene from entry done to expression vectors 
2.3.2.6.1 LR clonase reaction 
Both the wild-type and mutant | Figure 2.6 LR clonase reaction 
IDS cDNA were swapped from “mh 
f \ 、•识» 
pENTR/D-TOPO into expression f 二。“ j f ， C J 
v ^ y I" 一； viL/ 
vectors by LR clonase reaction (Figure ^ <： 
Gene Z A 
2.6). 300 ng entry clones and 300 ng of 
<，",>P Dy pro<k)ct r cfH* I 
the destination vector, pEXPl-DEST or 
Adapted from Invitrogen. 2004 
pcDNA-DEST40, were recombined in 
Gateway technology utilizes lambda phage 
a reaction mixture of 20 ^L final site-specific recombination (attL x attR 
. . . <——»• attP X attB) to insert a gene into 
volume containing 1 x LR reaction 
vector in replacement of the use of 
buffer and 4 |iL Gateway LR clonase endonuclease and ligase in traditional 
cloning. Any DNA fragment flanked by a 
enzyme mix. The mixture was 
recombination site (attL) can be transferred 
incubated in a water bath at 25 °C for into any vector that has a corresponding site 
(attR) by LR Clonase enzyme mix. 
60 min. The reaction was terminated by 
the action of 2 jiL proteinase K solution 
at 37 °C for 10 min. 
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2.3.2.6.2 Transformation 
The LR clonase reaction product (1 )LIL) was transformed into OneShot TOP 10 
Competent Cells as described in Chapter 2.3.2.2. For selecting the expression 
vectors from entry clones, the cells were cultured on LB agar plates / LB medium 
containing 100 \igl mL ampicillin. The plasmids were then purified by QIAprep 
Miniprep Kit as described in Chapter 2.3.2.3. The expression clones were sequenced 
to exclude the presence of undesired mutations in the IDS cDNA as described in 
Chapter 2.3.2.4. 
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2.4 Introducing IDS cDNA into RTS pIVEX Wheat Germ vector 
IDS cDNA was also cloned by traditional method. Restriction sites can be 
incorporated into PCR primers for standard sticky-ended cloning but this method 
introduces potential problems related to poor enzyme cleavage at DNA ends. 
Nevertheless, pIVEX一 1.3—WG is highly recommended because it is specialized for 
in vitro expression in the Roche wheat germ-based cell-free system. 
2.4.1 Materials 
2.4.1.1 Restriction digestion 
pENTR/D-TOPO vector containing IDS cDNA was cloned as described in 
Chapter 2.3.2. Only the entry vector carrying wild-type IDS cDNA was used. 
pIVEX_L3_WG vector (Roche Diagnostics GmbH, Basel, Switzerland) is 
supplied lyophilized in TE, pH 8.0. The vector is resuspended to 100 ng/|iL with 
RNase-free dHaO. A detailed map is shown in Appendix 9. 
Nde I’ 20,000 U/mL (New England Biolabs, Ipswich, UK) is supplied with 10 
X Buffer 4. The reagents are stored at -20 ®C. The reagents are stored at -20 The 
enzyme recognizes DNA sequence 5'-CATATG-'3 and forms sticky ends after 
cleavage. 
Xho I，20,000 U/mL (New England Biolabs, Ipswich, UK) is supplied with 10 
X Buffer 2 and 10 x Bovine Serum Albumin (BSA). The reagents are stored at -20 
°C. The enzyme recognizes DNA sequence 5'-CTCGAG-'3 and forms sticky ends 
after cleavage. 
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2.4.1.2 Purification of digested products 
QIAquick gel extraction kit (Qiagen, Hilden, Germany) comprises buffer QG, 
buffer PE, QIAamp spin columns, 2 mL collection tubes and 1.5 mL centrifuge 
tubes. All the reagents are stored at RT. The kit claims to yield DNA from 70 bp to 
10 kb. 
Isopropanol (Merck KGaA, Darmstadt, Germany) CsHgO, with MW 60.09，is 
supplied as colorless liquid with a pleasant odor. It is stored at RT. 
2.4.1.3 Ligation of the IDS insert into pIVEX_1.3_WG 
Ligate-IT rapid ligation kit (USB Corporation, Ohio, USA) contains Ligate-IT 
T4 DNA Ligase, 5 x Ligate-IT reaction buffer. The kit is stored at -20�C. 
Polyethylenglycol 1500 for synthesis/ PEG (Merck KGaA, Darmstadt, 
Germany) H0(C2H40)nH, with MW 1500，is stored at RT. 
2.4.2 Methods 
2.4.2.1 Restriction digestion to create sticky ends 
IDS cDNA was amplified by the forth set of primer pairs as described in 
Chapter 2.2.2.3. Then, 7 ^L IDS insert was digested by 10 U oiNde /and l O U ^ o 
/in a reaction mixture of 10 }iL final volume containing 1 x Buffer 4 and 1 x BSA. 
14.4 laL pIVEX_1.3_WG was digested bylO U of Nde I and 10 U oi Xho / in a 
reaction mixture of 20 fiL final volume containing 1 x Buffer 4 and 1 x BSA. The 
mixture was incubated at 37 °C for 2 hours. The digested products were analyzed by 
2% agarose gel electrophoresis to ensure that the specific bands were in correct 
sizes. 
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2.4.2.2 Purifying the digested products 
The digested products were purified from the agarose gel by QIAquick gel 
extraction kit. Both the specific bands of IDS and the vector were cut from 
appropriate positions on the agarose gel. 3 volume of buffer QG was added to 1 
volume of gel slice (100 mg ~ 100|LIL). The gel was allowed to melt in 50 °C for 10 
min. 1 volume of absolute isopropanol was added to the melted solution. Then the 
mixture was applied to the QIAprep Spin Column and centrifuged at 16100 x g for 1 
min. 500 pL Buffer GC was added and centrifuged at 16100 x g for 1 min. 750|j,L 
Buffer PE was added and centrifuged at 16100 x g for 1 min. The column was 
further centrifuged at 16100 x g for 1 min to remove any residual ethanol. The DNA 
were eluted with 30 fiL dH20. 1 min incubation at RT is prior to centrifugation at 
16100 X g for 1 min. The DNA yield and quality were determined 
spectrophotometrically with a NanoDrop ND-1000 Spectrophotometer (NanoDrop 
Technologies, Wilmington, Delaware, USA) by measuring A260 and calculating the 
A260/A280 ratio respectively. 
2.4.2.3 Ligating the IDS insert into pIVEX_1.3_WG 
The ligation reaction had 10 [iL final volume containing 3 U of T4 DNA ligase, 
1 X UBS buffer, 15 % PEG and insert to vector ratio = 3:1. The reaction was carried 
out in Gene Amp PGR System 9700 Cycler at 25 °C for 2 hours and 12 °C for 16 
hours. 
2.4.2.4 Transformation 
The ligated product (5 [iL) was transformed into OneShot TOPIO Competent 
Cells as described in Chapter 2.3.2.2. For selecting the expression vectors from entry 
clones, the cells were cultured on LB agar plates / LB medium containing 100 fig/ 
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mL ampicillin. The plasmids were then purified by QIAprep Miniprep Kit as 
described in Chapter 2.3.2.3. Only the normal full length form of IDS was succefully 
cloned into the expression vector. The expression clones were sequenced to exclude 
the presence of undesired mutations in the IDS cDNA as described in Chapter 
2.3.2.4. 
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2.5 Transient expression study of IDS constructs 
2.5.1 Materials 
Dulbecco Modified Eagle Medium/ DMEM, powder (high glucose) 
(Invitrogen Corporation, Carlsbad, California, USA) is in standard formulation, 
containing 4500 mg/L D-glucose, and L-glutamine, but no sodium pyruvate or 
sodium bicarbonate. To prepare 1 x liquid medium, the powdered medium was 
dissolved in 1 L autoclaved dHaO with 3.7 g NaHCOa. The medium was adjusted to 
pH 7.1-7.2 with 1 N HCl or 1 N NaOH. Desired final working pH units will be 
achieved after filtration, usually pH will rise 0.1-0.3. In the biological safety cabinet, 
the medium was steriled by filtration with a 4.5 nm filter. 
Fetal Bovine Serum, Certified (US)/ FBS (Invitrogen Corporation, Carlsbad, 
California, USA) is stored at -20 °C. It is tested to have endotoxin level lower than 
10 EU/mL and hemoglobin level lower than 15 mg/dL. It is heat-inactivated at 55°C 
for 30 mins. 
Phosphate Buffered Saline/ PBS (Sigma-Aldrich，St. Louis, Missouri, USA): 
as described in Chapter 2.2.1.1. 
Hanks' Balanced Salt Solution/HBSS (10 x liquid) (Invitrogen Corporation, 
Carlsbad, California, USA) is in standard formulation containing no calcium 
chloride, magnesium chloride, magnesium sulfate, or sodium bicarbonate. It is 
stored at 4 °C. 
Trypsin-EDTA/ 0.5% Trypsin, EDTA*4Na (10 x liquid) (Invitrogen 
Corporation, Carlsbad, California, USA) contains 5.0 g /L trypsin (1:250), 2.0 g/L 
EDTA*4Na and 8.5 g/L NaCl. It was porcine parvovirus tested and mycoplasma 
tested. It was provided in 10 x solution and stored at -20 °C. To prepare 1 x 
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Trypsin-EDTA, 10 mL Trypsin-EDTA was added to 90 mL HBSS. 
Cell dissociation buffer，enzyme-free’ PBS-based (Invitrogen Corporation, 
Carlsbad, California, USA) is stored at 4 °C. 
Complete protease inhibitor cocktail tablets (Roche Diagnostics GmbH, Basel, 
Switzerland) is supplied as tablets and stored at 4 °C. To prepare working solution, 
one tablet is dissolved in 50 mL dH20. 
Opti'MEMI Reduced Serum Medium (Invitrogen Corporation, Carlsbad, 
California, USA) contains HEPES buffer, 2400 mg/L sodium bicarbonate, 
hypoxanthine, thymidine, sodium pyruvate, L-glutamine, trace elements, growth 
factors, and 1. Img/L phenol red. It is stored at 4 °C. 
COS-7 cells (American Type Culture Collection, Manassas, Virginia, USA) are 
African Green Monkey, Cercopithecus aethiops, kidney cells in fibroblast 
morphology. It is supplied frozen on dry ice. Upon receipt, the cells were thawed 
quickly in a water bath at 37 °C. 10 mL DMEM medium with 10 % FBS was added 
dropwise. The cells were then centrifuged at 1000 rpm for 5 mins to remove the 
cryopreservative. The cells were resuspended in 9 mL DMEM medium with 10 % 
FBS and plated. 
Lipofectamine 2000 (Invitrogen Corporation, Carlsbad, California, USA) is 
stored at 4 °C. The cationic lipid transfectant was mixed by gently flicking before 
use. 
pcDNA-DEST40 vector containing IDS cDNA was cloned as described in 
Chapter 2.3.2. Transcription of IDS is under the control of a strong cytomegalovirus 
(CMV) promoter. The vector also consists of polyhistidine (6 x His) region at the 3 ‘ 
end of IDS insert. However, the IDS cDNA was cloned with stop codon. Therefore, 
the IDS protein synthesized would not be His-tagged fusion protein. 
pcDNA-DEST40 vector containing luciferase cDNA was cloned as IDS cDNA 
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described in Chapter 2.3.2. 
RNeasy Mini Kit (Qiagen, Hilden, Germany) is the same as described in 
Chapter 2.2.1.1. 
RT-PCR and PCR reagents are the same as described in Chapter 2.2.1.2, 
Chapter 2.1.3.1.1 and Chapter 2.1.3.1.2. 
Figure 2.7 Lipofectamine 2000 
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2.5.2.1 Cell culturing [ 场 J - f W ^ Q 
maaiintlitn ctil 
COS-7 cells were grown in DMEM 
Adapted from Invitrogen, 2004 
medium, supplemented with 10% Cationic lipid reagent-mediated 
transfection [Feigner PL et al., 1987] 
heat-inactivated FBS at 37 °C in 5% 
involves the formation of small 
COi/air atmosphere. unilamellar liposomes, which are 
positively charged and are attracted 
electrostatically to the negative phosphate 
2.5.2.2 IVansfecting IDS backbone of DNA, forming DNA-cationic 
liposome complexes. The complexes are 
constructs by lipofection procedures 
then attracted to the negatively charged 
All transfections were performed in surface of the cell membrane [Gershon H 
et al” 1993] and enter the cells through 
triplicate. One day before transfection, 
endosomes and lysosomes into the 
0.48 X 10)6 COS-7 cells were seeded onto cytoplasm [CoonrodAe/ al., 1997]. 
one of the wells of the 6-well culturing 
plate for each samples. Introduction of the vector pcDNA-DEST40 containing IDS 
cDNA into the COS-7 cells was performed by using Lipofectamine 2000 (Figure 
2.7). The vector pcDNA-DEST40 containing luciferase cDNA was co-transfected 
with either the wild-type IDS or the mutant IDS as control for transfectioin 
efficiency and expression efficiency. 0.96 \ig of plasmid containing IDS cDNA and 55 
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0.64 }ig of plasmid containing luciferase cDNA were diluted in 100 |LIL Opti-MEMI 
Reduced Serum Medium. 4 ^L Lipofectamine 2000 was diluted with 100 \xL 
Opti-MEMI Reduced Serum Medium and the mixture was incubated at RT for 5 min. 
Diluted Lipofectamine 2000 and the plasmids were combined together and 
incubated at RT for 20 min. In the meantime, the overnight cultures of COS-7 cells 
were rinsed with PBS twice to remove any FBS which may interference with 
transfection. Then the cells were supplied with 400 \iL plain DMEM medium and 
200 |iL Opti-MEMI Reduced Serum Medium. The DNA-cationic liposome 
complexes were added to the cells dropwise. The mixture was incubated at 37 °C 
with 5% CO2 for 6 hours. Then the medium was replaced by 2 mL DMEM medium 
supplemented with 10 % FBS. The transfected cells were incubated at 37 °C with 
5% CO2 for further 42 hours. 
2.5.2.3 Harvesting COS-7 cells 
The transfected COS-7 cells were harvested after incubation for 48 hours in 
total. The culturing medium was collected and stored at -20 °C. 0.5 mL cell 
dissociation buffer was added to the transfected cells and incubated 37 °C with 5% 
CO2 for 15 min. 1 mL PBS was added to rinse and detach the cells from the plate. 
The cells were collected and centrifuged at 2,500 rpm at 4 °C for 5 min. Then the 
cell pellets were rinse with 1 mL PBS and subjected to further centrifugation at 
2,500 rpm at 4 °C for 5 min. The cell pellets were resuspended with 50 |iL dHaO 
with addition of protease inhibitor. The COS-7 cells were then stored at -70 °C for 1 
hour before sonication. Since thermal denaturation of IDS revealed that a significant 
loss of enzyme activity above 50 °C, the whole process of sonication was performed 
on ice to prevent over-heating [Parkinson-Lawrence E et al,, 2005]. There were four 
rounds of sonication with each of them lasted for 5 sec. Each rounds were performed 
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every 30 sec. The lysate of transfected COS-7 cells were centrifuged at 13,000 x g at 
4 °C for 5 min. The supernatants were stored at -20 °C for subsequence experiments. 
2.5.2.4 Total RNA extraction from transfected COS-7 cells 
IDS tranfected COS-7 cells were prepared as described in Chapter 2.5.2.2. The 
cells were harvested 4 hours after transfection. 0.2 mL PBS with 10 % 
Trypsin-EDTA was added to the cells and incubated at 37 °C for 3 min. 0.4 mL PBS 
was added to rinse and detach all the cells. The cells were centrifuged at 300 x g for 
5 min at 4 °C. Total RNA was isolated from the cell pellet as described in Chapter 
2.2.2.1 with some modifications. The cell pellet was loosened from the bottom by 
flicking prior to resuspension with 350 juL buffer RLT. The transfected COS-7 cells 
were homogenized through the QIAShredder Spin Column by centrifugation at 
13,000 rpm for 2 min. 350 |aL of 70 % ethanol was mixed with the lysate. And the 
mixture was applied to the RNeasy mini column. The cell debris was filtered by 
centrifugation at >10,000 rpm for 15 sec and discarded. 700 |LIL buffer RWl was 
added, and the column was centrifuged at >10,000 rpm for 15 sec. The column was 
rinsed twice with 500 |iL buffer RPE and centrifuged at >10,000 rpm for 15 sec and 
1 min, respectively. The column was further centrifuged at 13,000 rpm for 1 min to 
remove any residual buffer RPE. 30 \LL RNase-free water was added and the column 
was centrifuged at >10,000 rpm for 1 min. The eluted products was then re-applied 
to the column for further centrifugation at >10,000 rpm for 1 min. And finally, the 
total RNA was collected in a clean 1.5 mL centrifuge tube. The RNA yield and 
purity were determined spectrophotometrically with NanoDrop ND-1000 
Spectrophotometer (NanoDrop Technologies, Wilmington, Delaware, USA) by 
measuring absorbance at 260nm and calculating the A260/A280 ratio respectively. The 
extracted products were stored at -70 °C before further processing. 
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2.5.2.5 RT-PCR showing IDS mRNA stability 
RT-PCR was performed as described in Chapter 2.2.2.2. Luciferase cDNA was 
also amplified for normalization by PCR as described in Chapter 2.2.2.3. The 
flanking primer pairs used were Luci-E-Fp and Luci-InterR2. The optimized 
annealing temperature was 60 °C. The appropriate cycling number was found to be 
24 cycles. Then fragments of IDS cDNA were amplified by PCR as described in 
Chapter 2.2.2.3 but using 24 cycles only. There were two sets of primer pairs, i.e. 1) 
IDS-E-Fp and IDS-InterR3，2) IDS-InterF2 and IDS-InterR3, used for amplifying 
different regions of IDS cDNA. The optimized annealing temperature for both 
primer pairs was 64 °C. The PCR products were then analyzed by 2% agarose gel 
electrophoresis to ensure that the specific bands were in correct sizes. The density of 
each DNA bands were compared by using BIO RAD Quantity One 4.2.1 Model 
GS-700 Imaging Densitometer (Bio-Rad Laboratories, Hercules, California, USA). 
2.5.2.6 Endocytosis of expressed IDS products into COS-7 cells 
One day before endocytosis, 0.48 x 10^  COS-7 cells were seeded onto one of 
the wells of the 6-well culturing plate for each samples. The culturing medium was 
replaced by 1.5 mL fresh DMEM medium supplemented with 10 % FBS. 500 |aL 
expression products of IDS were added dropwise. For the IDS synthesized by 
transfected COS-7 cells, 500 pL cell-free medium was used as sample. The medium 
of untransfected cells was used as negative control. For the IDS synthesized by 
cell-free expression systems, 15 [iL expression products were diluted with 485 |iL 
DMEM medium before added to the cells. The cell-free expression reagents without 
DNA template were used as negative control. COS-7 cells immersed with IDS 
products were incubated at 37 °C with 5% CO2. Then the cells were harvested 
immediately or after 48-hour incubation as described in Chapter 2.5.2.3. 
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2.6 Synthesizing IDS by cell-free in vitro expression systems 
2.6.1 Materials 
2.6.1.1 DNA templates for expression 
pEXPl-DEST vector containing IDS cDNA (Invitrogen Corporation, Carlsbad, 
California, USA) was cloned as described in Chapter 2.3.2. Transcription of IDS is 
under the control of T7 promoter. The expression vector also consists of 
polyhistidine (6 x His) region at the 5 ‘ end of IDS insert. As the cell-free systems do 
not support signal peptide cleavage, the IDS protein synthesized would be 
His-tagged fusion protein at the N-terminal end. 
pIVEX_L3_WG vector containing IDS cDNA (Roche Diagnostics GmbH, 
Basel, Switzerland) was cloned as described in Chapter 2.4.2. Transcription of IDS 
is under the control of T7 promoter. The expression vector also consists of 
polyhistidine (6 x His) region at the 5 ‘ end of IDS insert. As the cell-free systems do 
not support signal peptide cleavage, the IDS protein synthesized would be 
His-tagged fusion protein at the N-terminal end. 
pEXPl-DEST vector containing luciferase cDNA (Invitrogen Corporation, 
Carlsbad, California, USA) was cloned as described in Chapter 2.3.2. It served as 
positive control and has the advantage to be detected quantitatively by activity assay. 
Control vector GFP (Roche Diagnostics GmbH, Basel, Switzerland) is 
supplied as lyophilized in TE，pH 8.0. The vector is resuspended to 1 fig/ |iL with 
RNase-free dH20. The coding sequence of green fluorescent protein (GFP) is 
inserted in the pIVEX expression vector under the control of T7 promoter. It serves 
as positive control in bacterial-based expression systems and has the advantage to be 
detected easily by visualizing under fluorescence light. 
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GUS Control vector (Roche Diagnostics GmbH, Basel, Switzerland) is 
supplied as lyophilized in TE, pH 8.0. The vector is resuspended to 1 i^g/ ^L with 
RNase-free cfflbO. The coding sequence of glucuronidase (GUS) is inserted in the 
pIVEX expression vector under the control of T7 promoter. It served as positive 
control in wheat germ-based expression system. 
2.6.1.2 Commercial cell-free expression kits (Table 2.4) 
Expressway Plus Expression System (Invitrogen Corporation, Carlsbad, 
California, USA) consists of I VPS plus E. coli extract, 2.5 x IVPS Plus E. coli 
reaction buffer, T7 enzyme mix, 75 mM methionine, DNase/RNase-free distilled 
H2O, RNase A (Img/ mL in DNase/RNase-free H2O) and 2 mL screw-cap tubes. All 
the reagents are stored at -80 °C. The kit claims to have a production of up to 50 ^g 
protein in 50 ^L reaction. 
RTS 100 Kcoli HY Kit (Roche Diagnostics GmbH, Basel, Switzerland) 
consists of Kcoli lysate, reaction mix, amino acids, methionine and reconstitution 
buffer. Most reagents are Figure 2.8 Microplate specialized for CECF 
supplied as lyophilized expression 
HfmpbtM Ro Action Prolain 
p�wder a n d n e e d t � b e ^ ^ ^ 謝 譽 通 
reconstituted by the K ； • 
reconstitution buffer before m �工“ v V 
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use. All the reagents are ^ 一 一 
Adapted from Roche, 2004 
Stored at -20 The kit Continuous exchange cell-free (CECF) expression: the 
claims to have a presence of the semi-permeable membrane allows 
separation of the lower feeding chamber and the upper 
production of up to 20 ng reaction chamber which facilitates supply of substrates 
protein in 50 ^L reaction. and removal of inhibitors continuously. 
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RTS 100 Wheat Germ CECF Kit (Roche Diagnostics GmbH, Basel, 
Switzerland) consists of wheat germ lysate, reaction mix, feeding mix, amino acids, 
methionine, reconstitution buffer and microplate with adhesive film (Figure 2.8). 
Most reagents are supplied as lyophilized powder and need to be reconstituted by 
the reconstitution buffer before use. All reagents are stored at -20 except the 
reconstituted lysate which is stored at -80 °C. The microplate is keep at RT. The kit 
claims to have a production of over 20 |ig protein in 50 |LIL reaction. 
TNT Coupled Wheat Germ Extract Systems (Promega Corporation, Madison, 
USA) consists of TNT wheat germ extract, TNT reaction buffer, TNT T7 RNA 
polymerase and three types of ImM amino acid mixture (minus methionine, leucine 
or cysteine). All the reagents are stored at -80 
The kit claims to have a production of up to 500 ng protein in 50|xL reaction. 
TNT Coupled Reticulocyte Lysate Systems (Promega Corporation, Madison, 
USA) consists of TNT rabbit reticulocyte lysate, TNT reaction buffer, TNT T7 RNA 
polymerase and three types of ImM amino acid mixture (minus methionine or 
leucine or cysteine). All the reagents are stored at -80 The kit claims to have a 
production of up to 500 ng protein in 50|LIL reaction. 
2.6.1.3 Supplements 
Rapid Translation System RTS GroE Supplement (Roche Diagnostics GmbH, 
Basel, Switzerland) is stored at -20 It consists of GroEL and GroES which are 
called molecular chaperones. The chaperones accomplish protein folding by directly 
interaction with the polypeptide. However, > 30 % synthesized polypeptides cannot 
fold correctly to form functional proteins even having the chaperone machinery. 
Canine Pancreatic Microsomal Membranes (Promega Corporation, Madison, 
USA) is stored at -80 ®C. It consists of microsomal vesicles which are isolated free 
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from contaminating membrane fractions and Figure 2.9 Rapid translation 
system RTS GroE supplement 
stripped of endogenous membrane-bound 
10A 
ribosomes and mRNA. Addition of the / ^ j g s " SSos^SS 
/ ^ _ GroEL with 
I 1 substrate bound 
microsomes helps post-translational 
processing of proteins such as signal peptide “ GTOEL 
cleavage and glycosylation but diminishes 
° �� J Adapted from Roche, 2004 
1 0 - 5 0 % translation efficiency. Rapid Translation System RTS GroE 
Supplement contains GroEL and GroES. 
RNasin Ribonuclease inhibitor 
GroEL is arranged in 2 heptameric rings 
(Promega Corporation, Madison, USA) is which form a cylindric complex. GroES 
, forms dome-shaped hepatiiieric rings 
supplied as 40U/ [IL and is stored at -20 °C. 
which cap the GroEL cylinder on one or 
both ends. The size of the cylinder allows 
proteins with a molecular mass up to 
60kDa to be substrates for the GroE 
system. 
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Table 2.4 Differences between the commercial cell-free expression systems 
Expressway RTS 100 RTS 100 TnT coupled TnT coupled 
Plus system E.coli HY WGCECF WG Recticulocyte 
Supplier Invitrogen Roche Roche Promega Promega 
Translation prokaryotic prokaryotic eukaryotic eukaryotic eukaryotic 
machinery 
Cell extracts E. coli E. coli wheat germ wheat germ Rabbit 
reticulocyte 
RNA T7 T7 T7 T7 T7 
polymerase 
Glycosylation/ N/A N/A N/A N/A N/A 
signal peptides 
removal 
Supplements GroE - Microsomal 
vesicles 
Functions of Refolding the - - Assist the 




Reaction 3 0 � C 3 0 � C 2 4 � C 30 °C 30 °C 
conditions 4 hours 6 hours 24 hours 1.5 hours 1.5 hours 
Max. protein 50 fig per 20 |ig per > 20 \xg 500 ng per 500 ng per 
products 50 i^L 50 i^L per 50 [iL 50 \iL 50 fiL 
Table 2.4 Summary of the similarities and the differences between the five 
cell-free in vitro expression systems. From our experience, the addition of GroE 
supplements inhibited overall expression in the Roche E. co/z-based system; and the 
addition of microsomal vesicles inhibited overall expression in the Roche wheat 
germ-based system. N/A means not available. means not applicable. 
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2.6.2 Methods 
2.6.2.1 Cell-free expression by ExpressWay plus expression system 
The cell-free system is coupled with transcription and translation in a single 
reaction tube (Figure 2.10). 1 |ag plasmid DNA was expressed in a reaction mixture 
of 56 [iL final volume containing 20 |j.L IVPS plus E.coli extract, 20 \xL 2.5x IVPS 
plus E.coli reaction buffer, 1 |iL T7 enzyme mix, 1 \xL 75mM methionine, 1 [xL 
RNasin Ribonuclease inhibitor and 6 |_iL RTS GroE Supplement. The mixture was 
shaken in RTS ProteoMaster Instrument (Roche Diagnostics GmbH, Basel, 
Switzerland) at 300 rpm, 30 °C for 4 hours. 5 i^L RNase A was added and the 
mixture was shaken for further 15 min at 37 °C. GFP or luciferase was expressed 
simultaneously as positive controls. Expressed GFP requires 24 hours incubation at 
4 °C for maturation prior to fluorescent detection. 
2.6.2.2 Cell-free expression by RTS 100 E.coli HY Kit 
The cell-free system applied similar expression machinery as described in 
Figure 2.10. It was found that addition of RTS GroE Supplement inhibited the 
overall protein expression in this system. 1 fig plasmid DNA was expressed in a 
reaction mixture of 50 juL final volume containing 12 \xL E.coli extract, 10 i^L 
reaction buffer, 12 amino acids, 1 |iL methionine, 1 \xL RNasin Ribonuclease 
inhibitor and 5 fiL reconstitution buffer. The mixture was incubated at 30 °C for 6 
hours. GFP or luciferase was expressed simultaneously as positive controls. 
2.6.2.3 Cell-free expression by RTS 100 Wheat Germ CECF Kit 
Protein expression is in a two-chamber reaction format. Feeding solution and 
reaction solution were prepared independently. 1 mL feeding solution containing 
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900 \iL feeding mix, 80 jiL amino acids, 20 i^L methionine and 0.5 i^L RNasin 
Ribonuclease inhibitor was filled into the Figure 2.10 ExpressWay plus 
feeding chamber. 2 ^g plasmid DNA was expression system 
expressed in a reaction mixture of 50 |iL A ® - __ 
final volume containing 15 |iL wheat ^ ^ T ^ ^ J 
, T . , T “ J J 丨“丨 M _ 
germ lysate, 15 ^L reaction mix, 4 |iL 、吁―， ttrna ® RHK»om« 
I , — Polym«r»$e 
w 
amino acids, 1 ^L methionine, 0.5 |iL 
Adapted from Invitrogen. 2004 
RNasin Ribonuclease inhibitor and 5 i^L Expressway Plus Expression System 
reconstitution buffer. The mixture was utilizes extract from an S30 Kcoli strain 
for expression of target DNA to protein 
shaken in RTS ProteoMaster Instrument jzubay Q 1973]. The cell extract provides 
(Roche Diagnostics GmbH, Basel, cellular machinery which is coupled with 
in vitro transcription and translation. The 
Switzerland) at 900 rpm, 2 4 � C for 24 j^ PS reaction buffer contains an AIP 
hours. GUS was expressed regenerating system for energy and all tlie 
required amino acids except methionine 
simultaneously as positive control. [Lesley SA, Brow MA and Burgess RR, 
1991]. The bacterial systems have 
advantage of fast protein expression. The 
2.6.2.4 Cell-free expression by 5' end of the transcribed mRNA is bound 
TNT Coupled Wheat Germ Extract ribosomes and undergoes translation, 
while the 3' end of the template is still 
Systems being transcribed. 
Similar to Kcoli-bsLsed system, the 
wheat germ extract contains cellular machinery for in vitro transcription and 
translation in a single reaction tube. 1 ^g plasmid DNA was expressed in a reaction 
mixture of 50 jiL final volume containing 25 |iL TNT wheat germ extract, 2 |iL TNT 
reaction buffer, 1 jiL T7 RNA polymerase, 0.5 ^L amino acids mixture (minus 
methionine), 0.5 )iL amino acids mixture (minus leucine) and 1 jiL RNasin 
Ribonuclease inhibitor. The mixture was incubated at 30 °C for 90 min. Luciferase 
was expressed simultaneously as positive control. 
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2.6.2.5 Cell-free expression by TNT Coupled Reticulocyte Lysate 
Systems 
The use of reticulocyte lysate was increased to 55 % of total reaction volume. 1 
fig plasmid DNA was expressed in a reaction mixture of 50 i^L final volume 
containing 27.5 \xL TNT wheat germ extract, 2 fiL TNT reaction buffer, 1 i^L T7 RNA 
polymerase, 0.5 \iL amino acids mixture (minus methionine), 0.5 |iL amino acids 
mixture (minus leucine) and 1 \iL RNasin Ribonuclease inhibitor. The mixture was 
incubated at 30 °C for 90 min. Luciferase was expressed simultaneously as positive 
control. 
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2.7 Investigations of IDS protein expression 
The presence of expressed IDS was examined by simple protein staining after 
SDS-PAGE. For those IDS synthesized from the cell-free systems, the results were 
further confirmed by staining His-tagged proteins in the expression products. To 
determine the catalytic activity of the expressed IDS, a fluorometric enzyme assay 
was used. 
2.7.1 Materials 
2.7.1.1 Isolation of Histidine-tagged proteins 
Dynabeads TALON solution (Dynal Biotech ASA, Oslo, Norway) is stored at 4 
TALON binding buffer and washing buffer (Dynal Biotech ASA, Oslo, 
Norway) is stored at 4 
TALON elation buffer (Dynal Biotech ASA, Oslo, Norway) is stored at 4 "C. 
Magnetic stand (Dynal Biotech ASA, Oslo, Norway) is suitable for 1.5 mL 
centrifugation tubes. 
2.7.1.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis/ 
SDS-PAGE 
Sodium Dodecyl Sulfate/ SDS (Sigma-Aldrich Co., St. Louis, Missouri, USA) 
is supplied in powder form. 10% SDS is prepared by dissolving 10 g SDS with 100 
mL dH20. It is stored at RT. 
30% Acrylamide/Bis solution (Bio-rad Laboratories, Hercules, California, 
USA) is stored at 4 in dark. 
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Ammonium persulphate/APS (Sigma-Aldrich Co., St. Louis, Missouri, USA) 
is supplied in powder form. 10 % APS solution is prepared by dissolving 0.5 g APS 
with 5 mL dHsO. Dissolved APS is stored at -20 °C. 
N，N，N，，N’-tetramethylenediamine/ TEMED (Sigma-Aldrich Co., St. Louis, 
Missouri, USA) is stored at 4 °C in dark. 
Tris Base (Sigma-Aldrich Co., St. Louis, Missouri, USA) is supplied in powder 
form. Tris-HCl buffer was prepared by dissolving Tris-base with dH20 to a desired 
concentration and adjusting the pH with HCl. Tris-HCl buffer was stored at 4 
10 % running gel was prepared by mixing 4 mL water, 3.33 mL 30 % 
acrylamide/Bis solution, 2.5 mL of 1.5 M Tris-HCl (pH 8.8), 50 i^L 10 % SDS, 150 
[xL 10 % APS and 2.5 i^L TEMED. 
4,5 % stacking gel was prepared by mixing 3.4 mL water, 0.9 mL 30 % 
acrylamide/Bis solution solution, 1.5 mL 0.5 M Tris-HCl (pH 6.8)，60 |iL 10 % SDS, 
80 [iL 10 % APS and 6 ^L TEMED. 
lOx Tns-Glycine-SDS Electrophoresis Buffer is prepared by dissolving 0.25 
M Tris-HCl (pH 7.5)，1.92 M glycine and 1 % SDS. It is stored at 4 °C. It is diluted 
to 1 X working solution with dHaO. 
Sample buffer is prepared by mixing 25 mL Tris-HCl (pH 6.8), 15.83 mL 
glycerol, 10 g SDS, 0.005 % bromophenol blue, 5 mL 20 mM EDTA and adjusting 
the pH to 7.5. 9 volumes of sample buffer are diluted to working solution with 1 
volume of beta-mercaptoethanol. 
Kaleidoscope Prestained Standards (Bio-Rad Laboratories, Hercules, 
California, USA) contains approximately 1.6 mg total proteins and acts at protein 
size marker. It is stored at -20 Before use, it is heated at 40 °C for 10 min to 
separate any aggregated proteins. A detailed description is shown in Appendix 4.2. 
Acetic acid, glacial 100 % GR (Merck KGaA, Darmstadt, Germany) 
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CH3COOH, has a MW 60.05. It is corrosive and should be stored in fume cupboard. 
Methanol, >99.8 % GR (Merck KGaA, Darmstadt, Germany) CH3OH, has a 
MW 32.04. It is highly flammable and toxic and should be stored in fume cupboard. 
Fixing solution/ destaining solution is prepared by mixing acetic acid, 
methanol and dHsO in ratio of 1:3:10. It is stored at RT 
Coomassie Brilliant Blue R-250 staining solution，IL (Bio-Rad Laboratories, 
Hercules, California, USA) is stored at 4 °C. 
Staining solution is prepared by adding 0.05 % Coomassie Blue in fixing 
solution. It is stored at RT. 
In Vision His-tag In-gel Staining Kit (Invitrogen Corporation, Carlsbad, 
California, USA) consists of In Vision His-tag In-gel Stain. BenchMark His-tagged 
Protein Standard is included as the marker and positive control of the kit. The kit 
claims to detect 0.5 pmol of a 6 x His-tagged fusion protein. The stain is stored at 
RT but BenchMark His-tagged Protein Standard is stored at -20 °C. A detailed 
description of BenchMark His-tagged Protein Standard is shown in Appendix 4.3. 
Potassium phosphate (Dibasic) (Sigma-Aldrich, St. Louis, Missouri, USA) 
K2HPO4 has a MW 174.2, anhydrous (98 %). It is in powder form and stored at RT. 
Potassium phosphate (Monobasic) (Sigma-Aldrich, St. Louis, Missouri, USA) 
KH2PO4 has a MW 136，anhydrous (99+ %). It is in powder form and stored at RT. 
2.7.1.3 Fluorometric activity assay for IDS 
Sodium acetate，99 % (Sigma-Aldrich, St. Louis, Missouri, USA) CaHsC^Na’ 
with MW 82.03, is supplied in powder form. To prepare 0.1 M solution, 8.2 g of 
powder is dissolved in 1 L dHaO. It is stored at RT. 
Acetic acid, glacial 100 % GR (Merck KGaA, Darmstadt, Germany) 
CH3COOH, with MW 60.05, is stored in fume cupboard at RT. To prepare 0.1 M 
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solution, 5.775 mL of 100% acetic acid is diluted to 1 L with dH20 inside the fume 
cupboard. 
Leadll acetate trihydrate GR ACS ISO 99.5+ % (International Laboratory 
Limited, Nevada, USA) C4H604Pb.3H20, with MW 379.33，is supplied in powder 
form. It is stored at RT. 
Substrate buffer, pH 5.0 is prepared by adding 3.79 mg lead acetate into the 
100 mL solution mixture containing 35.2 mL of 0.1 M sodium acetate and 14.8 mL 
of 0.1 M acetic acid. It is stored at RT. 
4-methylumbelliferyl-a-L-iduronide-2-sulphate.Na2/ 4-Mu-aIdu-2S (Dept. 
Clinical Genetics, Netherlands) is supplied as lyophilized powder. To prepare 1.25 
mM substrate solution, 0.6 mg powder is dissolved in 1 mL substrate buffer. The 
substrate solution is stored at -80 
7-Hydroxy-4-methylcoumarin/ 4-Methylumbelliferone/ 4-Mu (International 
Laboratory Limited, Nevada, USA) CioHgOs, with FW 176.17, is supplied as 
powder form and stored at 4 It is dissolved in substrate buffer to produce a series 
concentration of standard 4-Mu from 0.2 |LIM to 1 M. 
Citric acid, mono hydrate (Sigma-Aldrich, St. Louis, Missouri, USA) 
CcHgOv-HzO, with FW 210.1 is supplied in powder form. To prepare 0.2 M solution, 
38.42 g powder is dissolved in 1 L dHsO. It is stored at RT. 
Sodium phosphate, dibasic anhydrous, reagent grade (Sigma-Aldrich, St. 
Louis, Missouri, USA) NasHPCU，with FW 142 is supplied in powder form. To 
prepare 0.4 M solution, 56.78 g powder is dissolved in 1 L dHzO. It is stored at RT. 
Sodium azide/Na-azide (Sigma-Aldrich, St. Louis, Missouri, USA) NaNs, with 
MW 65.01 is supplied in powder form and stored in RT. It is very toxic. 
Pi/Ci-buffer，pH 4.5 (double concentrated Mcllvains phosphate/ citric-acid 
buffer) is prepared by adding 0.02 % Na-azide into the 100 mL solution mixture 
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containing 26.7 mL of 0.2 M citric acid and 23.3 mL of 0.4 M NasHPO^ It is stored 
atRT. 
Sodium hydrogen bicarbonate (May & Bayer Ltd, Dagenham, UK) NaHCOa, 
with MW 84.01，is supplied in powder form. To prepare 0.5 M solution, 53 g of 
powder is dissolved in 1 L dHsO. It is stored at RT. 
Sodium carbonate (Sigma-Aldrich, St. Louis, Missouri, USA) NasCO;, with 
MW 106, is supplied in powder form. To prepare 0.5 M solution, 42 g of powder is 
dissolved in 1 L dH20. It is stored at RT. 
Triton X-100 (BDH Chemicals Ltd, Poole, UK) C34H62O11 with MW 647, is 
stored at RT. 
Stop buffer, pH 10.7 is prepared by adding 0.025 % Triton X-100 into the 100 
mL solution mixture containing 87.9 mL of 0.5 M NaHCOs and 12.1 mL of 0.5 M 
Na2C03. It is stored at RT. 
Bovine Serum Albumin/ BSA (Sigma-Aldrich, St. Louis, Missouri, USA) with 
MW 66,000 is stored at -20 °C. It is pH and heat denatured as follows: 5 g BSA 
powder is dissolved slowly in 40 mL dHsO to form a 10 % solution. Then the pH 
value of dissolved BSA was adjusted to pH 10.0 with 6 M sodium hydroxide. It is 
heated at 50 °C for 4 hours. The pH value of cooled solution was then adjusted to pH 
7.0 with 1 M HCl. Final volume of the neutral BSA was adjusted to 50 mL with 
dH20. Precipitates were removed by centrifugation at 3000 rpm for 10 min. 0.02 % 
of Na-azide was added to the supernatant. Inactivated BSA solution is diluted 
50-fold to 0.2 % and stored at -20 
Lysosomal enzymes/ LEBT (Dept. Clinical Genetics, Netherlands) is supplied 
as lyophilized powder. The enzymes mix is purified form bovine testis. To prepare 
working solution of LEBT, one vial of powder is reconstituted with 2.2 mL dHsO 
and stored in aliquots at -80 °C. 
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2.7.1.4 Luciferase activity assay 
Figure 2.11 Dynabeads 
Luciferase assay reagent (Promega TALON 
Corporation, Madison, USA) consists of T A L O N ™ c h e l a t o r c o b a l t i o n H . s . t a g g e d p r o t e . „ 
Luciferase Assay Substrate dissolved in ^ ^ ^ 丄、〜^；^? 
Luciferase Assay Buffer. It is stored in ‘* ( r： '^ 
aliquots at -80 °C. ” V � 
广 — 、 
Q e Equil ibrat ion 
2.7.2 Methods �� , 
Add sample contalnmg 
CKpressed h l s t id lne -
• Idssed proteins 
2.7.2.1 Isolating His-tagged IDS p 
丨 I n c u b a t e for aff ini ty 
from cell-free expression products ，二;：：：^，^  
It is magnetic bead-based protein I . 
• Magne t i c s e p a r a t i o n a n d 
isolation. 50 |iL Dynabeads TALON jC^ —“叩一“丨 
solution (2 mg) was equilibrated in 700 
\iL binding and washing buffer. The beads ^ /^X t^—n 
were pelleted by using a magnet and the O + 迷 
Recombinant protein Purified racombinanl 
lmmoblU2ed on bead protein 
supernatant was discarded. 700 nL Ada一一 D y 一 c 隨肩 
binding and washing buffer containing 20 PuriTicalion is based on the melal 
coordination of the histidine-tag to the 
uL cell-free expression products were 
^ cobalt ion held in tlie TALON chelator, 
added. The mixture was incubated on a 
roller for 10 min at RT. By using the magnet, the beads were rinsed with 700 ^L 
binding and washing buffer for 4 times. Then, 100 |iL elution buffer was added and 
incubated for 5 min at RT. The supernatant was collected. 
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2.7.2.2 Protein staining of expression products 
2.7,2.2.1 Preparation of protein separating gel 
Bio-Rad Mini-Protein II was set up by clamping two clean glass plates which 
were held apart by plastic spacers on the two sides. 10 % separating gel solution was 
pipetted into the space between the two glass plates until the liquid level reached a 
height of 1 cm below the lowest portion of the well-forming comb. Isopropanol was 
added to cover the meniscus in order to keep atmospheric oxygen away from the gel 
solution. Upon setting of the separating gel, isopropanol was drained and washed 
away with deionized water. 4.5 % stacking gel solution was filled into the remaining 
space. Well-forming comb was put into the space between the glass plates. The gel 
was allowed to stand at RT until set. 
2.7.2,2.2 Preparation of proteins for SDS-PAGE 
The expression products were separated into insoluble fraction and soluble 
fraction of protein by centrifuging 5 |iL samples at 10000 x g for 8 min. The 
samples were resuspended in 20 i^L 1 x SDS sample buffer. And the mixtures were 
heated at 98 °C for 3 min. The protein products synthesized by the two E.coli-based 
cell-free expression systems required additional purification step before adding SDS 
sample buffer. 20 fiL of ice-cool acetone was added to the supernatant and protein 
pellet. The mixtures were incubated on ice for 5 min for protein precipitation. Then 
the proteins were air-dried after centrifugation at 12000 rpm for 5 min. 
2.7.2.2.3 SDS-PAGE analysis 
The proteins were separated by SDS-PAGE. 6 |aL insoluble samples and 3 |aL 
soluble samples were loaded per lane. 3 \iL Kaleidoscope Prestained Standards was 
loaded as marker. After electrophoresis, the gel was immersed in 15 mL staining 
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solution and shaken at 100 rpm for 1 hour. Then the gel was destained by immersing 
in 15 mL staining solution and shaking at 100 rpm for 1 hour. 
Fixed proteins can be stained by InVision his-tag In-gel stain (Figure 2.11). 5 
|iL BenchMark His-tagged Protein Standard was loaded as marker and positive 
control. After electrophoresis, the gel was immersed in 15 mL fixing solution for 1 
hour. Fixed proteins were rinsed with 100 Figure 2.12 InVision His-tag 
In-gel Stain 
mL dH20 twice for 10 minutes to remove “ 
j. His-tag Ni-NTA 
_ _ Nil 
the fixative. The gel was then immersed \ � 
O C=0 (J 
in 15 mL InVision His-tag In-gel Stain for 广 况力… J ；⑶爹 
\ Jf ~ h " i / � � / � . 
2 hours. The gel was rinsed with 15 mL L “ � 
R 
20 mM Phosphate Buffer (pH 7.8) for 10 
^ / Adapted from Qiagen, 2003 
minutes. Stained proteins were visualized The InVision His-tag In-gel Stain is a 
. stain capable of visualizing His-tagged 
using a 302 nm UV transillummator 
fusion proteins in a polyacrylamide gel 
equipped with an ethidium bromide filter after electrophoresis directly. It consists of 
a fluorescent dye conjugated to NP": 
and the fluorescent image was captured 
nitrilotriacetic acid (NTA) complex. The 
with a CCD camera. The exposure time Ni^ "^  binds specifically to the 
oligohisitidine domain of the His-tagged 
was 30 seconds. 
fusion protein, allowing specific detection 
of His-tagged fusion proteins. 
BenchMark His-tagged Protein Standard 
2.7.2.3 Fluorometric enzyme 
acts as a positive control and a protein 
assay for IDS proteins size marker. 
IDS activity was assayed by the 
fluorometric method developed in 2001 [Voznyi YV’ Keulemans JLM and van 
Diggelen OP, 2001]. The IDS enzyme assay is composed of two parts: 1) the 
catalytic reaction of IDS on the substrate desulphation, and 2) the hydrolysis 
reaction of IDUA on the intermediate to release fluorescent 4-methylumbelliferone 
(4-Mu). In this study, the IDS activities of three different samples were evaluated: 1) 
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the lysate of IDS transfected COS-7 cells, 2) the total expression products of 
cell-free systems, and 3) 5-fold diluted plasma samples. For negative control, 0.2 % 
of pH and heat inactivated BSA was used as testing sample. 10 JLIL of the testing 
samples was added to 20 \XL substrate (1.25 mM 4-Mu-aIdu-2S). The enzymatic 
reaction was carried out at 37 °C for 4 hours. Then a mixture containing 40 \iL 
Pi/Ci-bufFer and 10 |LIL LEBT was added to the reaction. After 24-hour incubation at 
37 the reaction was terminated with 200 fiL stop buffer. Released 4-Mu emits 
fluorescence at 460 nm upon excitation at 355 nm. The fluorescence of 4-Mu was 
measured in PerkinElmer 1420 Multilabel Counter VICTOR^ under the control of 
Wallac 1420 workstation (PerkinElmer, Inc., Wellesley, USA). Then, the 
concentration of expression protein products were assayed using Braford method for 
IDS activity calculations. 
2.7.2.4 Luciferase activity assay 
The activity of expressed luciferase was assayed by adding 2.5 jiL expression 
products in 50 fiL luciferase assay reagent. The luminescence was measured for 10 
sec immediately by PerkinElmer 1420 Multilabel Counter VICTOR] under the 
control of Wallac 1420 workstation (PerkinElmer, Inc., Wellesley, USA). 
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Chapter 3 Results 
3.1 Mutational analysis of MPS II and carrier detection 
Mutational analysis confirmed that the four MPS II patients have their genetic 
defects lying in the IDS gene. All the fragments containing IDS exons were 
amplified from the patients and sequenced. Two of the families and their female 
relatives were also screened for mutations. As summarized in Table 3.1, a total of 3 
different nucleotide changes were detected in exon 8. These included two nonsense 
mutations and one missense mutation. One of the two nonsense mutations was 
previously reported while the other two mutations described here are novel [Jonsson 
JJ et al., 1995]. 
A simplified method was used to verify the novel missense mutation. The 
nucleotide changed by p.L339P (c.l016T>C) created an additional Serf I restriction 
site within the PCR fragment amplified by IDS internal primers F2 and R3 (Figure 
3.1). Figure 3.2 shows the partial results of fragment restriction endonuclease 
analysis. The mutation was not found on screening 100 X-chromosomes in 50 
control females. Patient 4 is confirmed to carry a novel mutation in the IDS gene. 
For the novel nonsense mutation, it is unusual to occur as polymorphism in normal 
individuals. There is no need to perform fragment restriction endonuclease analysis. 
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Table 3.1 IDS mutations identified in this study 
Mutation Nucleotide Amino acid alteration Phenotype Remarks 
alteration analysis 
P.L339P C T A � C C A Leucine to Proline Severe Novel 
P.S369X TCA > TGA Serine to terminal codon Mild Novel 
P.Q389X CAG > TAG Glutamine to terminal codon Severe 
Table 3.1 All the mutations described above are located in exon 8 of IDS gene. 
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Figure 3.1 Potential restriction sites on PCR fragment containing codon 339 
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Figure 3.1 Fragment restriction endonudease analysis for c.l016T>C: ScrF I 
digestion of the PCR fragment amplified from IDS internal primers F2 and R3. 
Codon 339 is boxed and the recognition base pairs (CCAGG) of ScrF I is underlined. 
(A) normal PCR fragment do not have ScrF I at codon 339; and (B) c . l016T�C 
mutant PCR fragment created an additional aSCT-F/ restriction site. 
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Figure 3.2 Fragment restriction endonuclease analysis for c.l016T>C: Serf I 
digestion of the PCR fragment amplified from IDS internal primers F2 and R3. 
Un-cut fragment: 622 bp. Normal allele: 293 bp, 183 bp, 87 bp, 39 bp and 20 bp. 
c . l016T�C mutant allele: 218 bp, 183 bp, 87 bp, 75 bp, 39 bp and 20 bp. It is easier 
to compare the 293 bp fragment from normal allele with the 218 bp fragment from 
mutant allele in 3 % agarose gel. Homozygous normal female: 293 bp only. Female 




In Family A (Figure 3.3)，Patient 1 has the reported mutation identified in the 
IDS exon 8. The codon Gln389 is substituted by a termination codon, i.e., CAG > 
TAG or P.Q389X. The patient is inherited this mutation from his carrier 
asymptomatic mother. The screening for his sister and maternal aunt revealed that 
they are not carriers. The sequencing results are shown in Figure 3.4. 
Figure 3.3 Pedigree of Family A 
I ^ p i i A 
” - 6 
Patient 1 
Figure 3.3 Patient 1 inherited the nonsense mutation p.Q389X from his mother. 
Shaded square represents affected male; dotted circle represents female carrier; and 
open circle / square means the person is carrying normal IDS gene. 
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Figure 3.4 A reported nonsense mutation, p.Q389X, identified in Family A 
A Normal B Patient 1 
370 380 320 330 
' C C G C C T C A C A G T T G A T G G； CCGCCTCATAGTTGATGGi i 
C Mother D Sister 
3 3.0 320 310 32 0 CCGC CTCANAGT T G A T G G CCGCCTCACAGXXGAXG G. 
frtiMfi M^iJ 
E Maternal Aunt 
320 3 30 CCTGC CTCJWCAGTXGiWTOG 
Figure 3.4 Partial sequence electropherograms of IDS exon 8 from Family A. The 
sequence is shown in sense direction. The affected nucleotide is arrowed and the 
corresponding codon is underlined. Heterozygous base pair is denoted by "N". (A) 
Normal female; (B) Patient 1 with p.Q389X, i.e., CAG > TAG; (C) the mother; (D) 
the sister; and (E) the maternal aunt. 
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In Family B (Figure 3.5)，Patient 2 and Patient 3 carry the same novel nonsense 
mutation in the IDS exon 8. The codon Ser369 changed to termination codon, i.e., 
TCA > TGA or p.S369X. Their sister also inherited the mutation from the carrier 
asymptomatic mother. Fortunately, the amniocyte screening for her baby revealed 
that it is not affected. The patients have another brother without any genetic defect in 
IDS gene. The sequencing results are shown in Figure 3.6. 
Figure 3.5 Pedigree of Family B 
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Patient 2 Patient 3 
"I <6 
Figure 3.5 Patient 2 and Patient 3 inherited the nonsense mutation p.S369X from 
their mother. Shaded square represents affected males; dotted circle represents 
female carriers; and open area means the person is carrying normal IDS gene. 
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Figure 3.6 A novel nonsense mutation, p.S369X, identified in Family B 
A Normal B Patient 2 
260 270 260 270 
G A C G G C T T C A C T T C C G G A G A C G G C T T G A C T T C C G G A 
C Patient 3 D Mother 
270 260 2 7 0 G A C G G C T T GJWCXXCCGG A • GACGGCTXNACXTCCGGAC 
M M Itoitfri 
E Sister F Brother 
2 e O 2 7 O 2 6 O 270 
GACGGCTTNJWCXXCCGGA. ； GA.CGGCXTCACTXCCGGA. 
itoMM kwM 
G Amniocytes from the sister 
2SO 2 so ；G A C G GC 丁 TCAC 丁 T C C O G A 
k k y 
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Figure 3.6 Partial sequence electropherograms of IDS exon 8 from Family B. The 
sequence is shown in sense direction. The affected nucleotide is arrowed and the 
corresponding codon is underlined. Heterozygous base pair is denoted by "N". (A) 
Normal female; (B) Patient 2 with p.S369X, i.e., TCA> TGA; (C) Patient 3 with the 
same mutation; (D) the mother; and (E) the sister; (F) the brother; and (G) prenatal 
diagnosis for the sister.. 
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Patient 4 has a novel missense mutation identified in the IDS exon 8, p.L339P. 
The single nucleotide changed leucine residue to proline, i.e., CTA > CCA or 
c.l016T> C (Figure 3.7). Since the two premature stop codons described above 
probably predict protein instability, only the novel missense mutation p.L339P was 
subjected to further investigations. 
Figure 3.7 A novel missense mutation, p.L339P, identified in Patient 4 
A Normal B Patient 4 
230 240 170 180 
G G T G G G C T C T A G G T G A A C G G T G G G C T C C A G G T G A A C 
Figure 3.7 Partial sequence electropherograms of IDS exon 8 from Patient 4. The 
sequence is shown in sense direction. The nucleotide changed is arrowed and the 
corresponding codon is underlined. (A) Normal female; and (B) Patient 4 with 
P.L339P (c.l016T>C). 
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3.2 Investigating IDS mutants by transient expression 
3.2.1 Fluorometric enzyme assay for measuring IDS activity 
The fluorometric enzyme assay was established in 2001 [Voznyi YV et al., 
2001]. It involves two steps of enzymatic actions for 1) desulphation of the 
4-methylumbelliferone-derived substrates (4-Mu-aIdoA-2S), and 2) hydrolysis of 
the intermediate to form 4-methylumbelliferone (4-Mu). The first step depends on 
the IDS activity. In this part, the testing samples were IDS generated from transient 
expression in COS-7 cells. The second enzymatic reaction depends on the 
a-iduronidase (IDUA) provided together with the substrate. The fluorescence 
response from blank-substrate was lowered to 28 % as suggested by the protocol. 
Around 14 pmol 4-Mu was released from the blank-substrate. 
The relationship of absorbance at 460 nm on different number of mole of pure 
4-Mu was used as standard curve for subsequence calculations (Figure 3.8 and 
Figure 3.9). Before the experiment, the assay was validated by measuring plasma 
IDS activity for 10 normal individuals. The mean plasma IDS activity is 269.44 士 
86.76 nmol/4h/ml. The results lay within the normal range of 167 — 475 nmol/4h/ml 
IDS activity as suggested by the protocol [Voznyi YV et al., 2001]. 
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Figure 3.8 The linear relationship of fluorometric reaction in IDS enzyme 
assay 
Absorbance Standard curve of 4-Mu concentration for 
IDS activity fluorometric assay 
9 0 0 0 0 0 • 
800000 
7 0 0 0 0 0 
6 0 0 0 0 0 y 2 = 3208X 
500000 ^ ^ R = 0.98^ 
4 0 0 0 0 0 • 
3 0 0 0 0 0 
200000 ^ ^ 
100000 
^^ 1 I 1 1 1 1 
0 5 0 100 150 2 0 0 2 5 0 3 0 0 
No. of moles of 4-Mu (pmol) 
Figure 3.8 The absorbance at 460nm of the enzyme assay shows a linear 
relationship from 0 - 250 pmol of 4-methylumliferone (4-Mu). 1 pmol of 4-Mu 
emits 3208 fluorescence response at A460nm. 
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Figure 3.9 Calculations for IDS activity assay 
IDS activity is measured as the amount of 4-methylumliferone (4-Mu) produced 
during the fluorometric enzyme assay. 
No of moles of 4-Mu (nmol)^  
Activity of IDS (in 4 hour)= “ 
Volume of sample (ml)'' or protein content (mg)� 
a number of moles of 4-Mu = A460iim 丨 slope of standard curve * dilution factor 
b for plasma samples or media of transfected COS-7 cells 
c for cell extracts either from COS-7 cells or cell-free systems 
For the transient expression products, IDS activity was adjusted with the expression 
level of co-transfected positive control ~ luciferase. 
Figure 3.9 IDS activity is expressed as the amount of 4-Mu produced. Only the 
first step involves IDS enzymatic reaction, so the IDS activity is calculated 
depending on the first incubation, i.e. 4 hours. The IDS activity is expressed as 




3.2.2 Source of IDS gene for transient expression in COS-7 cells 
IDS gene was successfully isolated from the normal blood sample with plasma 
IDS activity 343.1 nmol/4h/ml. Direct DNA sequencing showed that the IDS 
pseudogene was not amplified in the PCR. The wild-type IDS cDNA was cloned 
into the Gateway Entry vector pENTR/D-TOPO and swapped into the mammalian 
expression vector pcDNA-DEST40. The cDNA sequence is showed in Appendix 3. 
Both vectors containing wild-type IDS cDNA were confirmed by sequencing (Figure 
3.10 and Figure 3.11). 
The effects of both the mutations at codon 339，p.L339P identified in Patient 4 
and P.L339R previously reported in 1998, were investigated [Froissart R et al” 
1998]. The two mutant IDS cDNAs were produced by site-directed mutagenesis 
before swapping into the mammalian expression vector. Desired mutations were 
confirmed by sequencing (Figure 3.10 and Figure 3.11). A modified IDS cDNA 
without 99 base pair at the N-terminal end including the signal sequence was also 
constructed. This N-terminally truncated IDS cDNA was cloned as the same way as 
the wild-type IDS cDNA and confirmed by sequencing (Appendix 3). 
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Figure 3.10 pENTR/D-IDS with desired mutations generated 
A Wild-type B Leu339Pro (CTA > CCA) 
230 2 4 O 220 230 2 GGGXGGGCTCXAGGXGAACA GGGTG GGCXCCAGOTGAACA 
C Leu339Arg (CJA > CGA) 
230 240 GGGTGGGC TCOAG GTGXACA 
Figure 3.10 Partial sequence electropherograms of the vector pENTR/D-TOPO 
containing IDS cDNA. The plasmids were sequenced by IDS-InterF2 primer and the 
results are shown in sense direction. The nucleotide changes (arrowed) in the 
designated codons (underlined), indicated successful site-directed mutagenesis. The 
whole gene was further sequenced to ensure the absence of undesired mutations. (A) 
Wild-type IDS; (B) Leu339Pro and; (C) Leu339Arg. 
90 
R e s u t e J ^ l 
Figure 3.11 pcDNA-DEST40-IDS with desired mutations generated 
A Wild-type B Leu339Pro (CTA > CCA) 
230 2 4 O 230 24 O GGGT GGGCTCTAG GTGAACA GGGXGGGCXCCAGGXGAACA 
N f ^ toiWl 
C Leu339Arg (CIA^CGA) 
230 24 O GGGTGGGCTCGAGCTOAACA 
NNkWl 
Figure 3.11 Partial sequence electropherograms of the vector pcDNA-DEST40 
containing IDS cDNA. The plasmids were sequenced by IDS-InterF2 primer and the 
results are shown in sense direction. The nucleotide changes (arrowed) in the 
designated codons (underlined), indicated successful swapping of IDS gene between 
Gateway cloning vectors. The whole gene was further sequenced to ensure the 
absence of undesired mutations. (A) Wild-type IDS; (B) Leu339Pro and; (C) 
Leu339Arg. 
91 
Results J B 
3.2.3 In vitro expression of IDS and its mutants in COS-7 cells 
3.2.3.1 Analysis of transient expression in terms of IDS activity 
IDS activity was measured in the transfected COS-7 cell lysate and in the 
cell-free growth medium. COS-7 cells transfected by the wild-type IDS cDNA 
showed a striking increase in IDS activity compared with the basal IDS activity of 
COS-7 cells both in the cell lysate and in the medium. The over-expressed wild-type 
had IDS activity 218.38 nmol/4h/mg in cell lysate (Table 3.2) and 136.68 
nmol/4h/ml in the cell-free growth medium (Table 3.3). Active wild-type IDS was 
successfully expressed in COS-7 cells. 
The mutant IDS cDNAs carrying the two mutations p丄339P (c.l016T�C) and 
P.L339R (c.l016T�G) were then expressed in COS-7 cells to evaluate their 
functional consequence on IDS activity. Both the mutants only remained residual 
IDS activity less than 2.5 % of the wild-type (Table 3.2). The mutation L339P 
decreased the IDS activity to 17.86 ninol/4h/mg and the mutation p.L339R had only 
20.26 nmol/4h/mg of IDS activity in the cell lysate. The transient expression study 
demonstrated that both the mutations at IDS codon 339, p.L339P and p.L339R, 
cause significant reduction on IDS activity. The two mutations can reduce the 
enzymatic activity by introducting protein instability or mRNA instability. 
There was no active form of the N-terminally truncated IDS detected in the cell 
lysate. However, a residual IDS activity more than 50 % of the wild-type was 
measured in the cell-free medium of transfected COS-7 cells (Table 3.3). Together 
with the evidence of co-transfected positive control luciferase (data not shown), it 
can be concluded that all the IDS cDNAs were successfully transfected and 
expressed in the cell-based in vitro expression system. 
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Table 3.2 Expression of IDS in transfected COS-7 cells. 
Transfected IDS cDNA IDS activity Total 
(nmol/4h/mg) (percentage of wild-type) 
Empty vector (Blank) 15.53 0% 
wild-type IDS 218.38 100% 
P.L339P 17.86 1.15% 
p 丄339R 20.26 2.33% 
N-terminally truncated IDS 9.00 0% 
Table 3.2 IDS activity was measured in the cell extracts of transfected COS-7 
cells. The activities shown here are the means of three independent experiments. The 
endogenous IDS activity in COS-7 cells was subtracted before the percentage of 
wild-type was calculated. IDS mutants carrying the mutations p.L339P or p.L339R 
remained < 2.5 % of wild-type activity. No active form of the N-terminally truncated 
IDS without the first 33 N-terminal amino acids was detected from the cell lysate. 
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Table 3.3 Secretion of IDS from transfected COS-7 cells 
Transfected IDS cDNA IDS activity Total 
(nmol/4h/ml) (percentage of wild-type) 
Empty vector (Blank) 39.27 0% 
wild-type IDS 136.68 100% 
P.L339P 20.59 0% 
p 丄339R 53.14 14.24% 
N-terminally truncated IDS 98.47 60.77% 
Table 3.3 IDS activity was measured in the growth medium of transfected COS-7 
cells. The secreted IDS activity in COS-7 cells was subtracted before the percentage 
of wild-type was calculated. No active form of the mutant IDS carrying the mutation 
P.L339P was detected in the cell-free media. The N-terminally truncated IDS 
without signal peptide and the subsequence 8 amino acids conserved > 50 % of 
wild-type IDS activity. 
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3.2.3.2 Analysis of IDS mRNA stability in COS-7 cells 
Secondary structures of partial IDS mRNA were predicted by computer 
programmes (data not shown). The mutation p丄339P created an additional hairpin 
structure with decreased AG -1.04 kcal/mol. Such hairpin structure have the codon 
339 CCA forming double-strand mRNA which may induce its degradation. However, 
this evidence is not strong enough to prove that the mutation p丄339P declined the 
mRNA stability. 
Presence of IDS mRNA was confirmed by RT-PCR. The expression level of 
IDS mRNA was normalized by the mRNA of co-transfected luciferase. At the same 
expression level of luciferase mRNA, the expression levels of IDS mRNA 
transcripted from different IDS constructs were similar (Figure 3.12). This illustrated 
that the two mutants, p.L339P and p.L339R, have relatively stable mRNA as the 
wild-type IDS. The missense mutations debilitated the IDS enzyme function but not 
declined the mRNA stability. 
3.2.3.3 Analysis of IDS protein stability in COS-7 cells 
Normal IDS processing removes parts of the N-terminal sequences and parts of 
the C-terminal sequences. Fusion protein of IDS carrying GFP or His-tag is not 
practical. As there are no commercial anti-IDS antibodies for western blotting, only 
simple protein staining was applied in this study. SDS-PAGE analysis does not show 
any difference between the COS-7 cells transfected either by wild-type IDS or its 
mutants, or by empty vector (Figure 3.13). The active wild-type IDS was 
over-expressed without any evidence shown by SDS-PAGE analysis. Luciferase was 
co-transfected as positive control, similarly, no additional protein band or thickened 
band were observed. SDS-PAGE analysis is not feasible for detecting IDS protein 
expression in COS-7 cells. 
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Figure 3.12 RT-PCR of IDS mRNA in transfected COS-7 cells 
A L 
Figure 3.12 RT-PCR of IDS cDNA fragments isolated from transfected COS-7 
cells. The IDS mRNA expression levels are similar between the wild-type IDS and 
its mutants. Panel A: normalization with co-transfected luciferase cDNA, 712 bp. 
Panel B: amplified IDS cDNA containing exon 1 to half of exon 9, 1385bp. Panel C: 
amplified IDS cDNA containing only exon 6 to half of exon 9, 621 bp. Lane 1: 
COS-7 cells transfected by empty vector. Lane 2: COS-7 cells transfected by 
wild-type IDS. Lane 3: COS-7 cells transfected by the N-terminally truncated IDS 
without signal sequence and subsequence 24 bp. Lane 4: COS-7 cells transfected by 
mutant IDS carrying the mutation p.L339P. Lane 5: COS-7 cells transfected by 
mutant IDS carrying the mutation p.L339R. 
96 
R e s u t e J H 
Figure 3.13 SDS-PAGE analysis for transient expression of IDS and its mutants 
1 2 3 4 5 6 7 8 9 10 11 12 
-60 
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Figure 3.13 IDS protein expression in COS-7 cells was shown by SDS-PAGE 
analysis. Luciferase was co-transfected with wild-type IDS or its mutants as the 
positive control of the expression. Although both wild-type IDS and luciferase were 
expressed with activities, no additional band or thickened band can be 
distinguishable between the lanes (expected sizes for IDS and luciferase were 55 
kDa and 62 kDa respectively). Lanes 1 - 4: the first independent experiment for the 
expression of wild-type IDS and its mutants. Lanes 5 - 8 : the second independent 
experiment. Lanes 9 - 12: the third independent experiment. Lanes 4’ 8 and 12: total 
cells extracts from COS-7 cells transfected by empty vector. Lanes 3，7 and 11: total 
cells extracts from COS-7 cells transfected by wild-type IDS. Lanes 2, 6 and 10: 
total cells extracts from COS-7 cells transfected by mutant IDS carrying the 
mutation p.L339P. Lanes 1, 5 and 9: total cells extracts from COS-7 cells transfected 
by mutant IDS carrying the mutation p.L339R. 
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3.3 Cell-free in vitro expression for investigating the IDS mutants 
3.3.1 The five cell-free systems involved 
Both prokaryotic and eukaryotic systems were tested for in vitro expression of 
wild-type IDS. There were three different cell-free expression methods based on 
microbial system, plant system and mammalian system. They included two 
E.coli-hsLSQd systems from Invitrogen and Roche, two wheat germ-based systems 
from Roche and Promega and a rabbit reticulocytes-based system from Promega. 
These cell-free expression systems are coupled with transcription and translation in 
the same reaction tube. The features of each system are summarized in Table 2.4. 
Successful cell-free expression was confirmed by positive controls: green 
fluorescence protein (GFP), glucuronidase (GUS) and luciferase. 
3.3.2 Source of IDS gene for cell-free in vitro expression 
To express IDS in the cell-free systems, two different TT-driven vectors were 
used. The wild-type IDS and the mutant IDS carrying the mutation p.L339P were 
swapped into another expression vector pEXPl-DEST by Gateway Cloning System. 
The wild type IDS was also cloned into pIVEX-1.3-WG by traditional cloning 
methods. Successful cloning was confirmed by sequencing (Figure 3.14). These 
vectors produce N-terminal and C-terminal His-tagged protein respectively for easy 
detection of the recombinant IDS. 
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Figure 3.14 pEXPl-DEST-IDS with desired mutations generated 
A Wild-type B Leu339Pro (CTA > CCA) 
220 230 220 230 
G G G T G G G C T C T A G G T G A A C A G G O T G G G C T C C A G G T G A A C A 
tfftki f^Mft 
C Leu339Arg (CIA今CgA) 
24 Q 250 
G G G T G G G C T C G A G G T G A A C A 
Figure 3.14 Partial sequence electropherograms of the vector pEXPl-DEST 
containing IDS cDNA. The plasmids were sequenced by IDS-InterF2 primer and the 
results were shown in sense direction. The nucleotide changes (arrowed) in the 
designated codons (underlined), indicated successful swapping of IDS gene between 
Gateway cloning vectors. The whole gene was further sequenced to ensure the 




3.3.3 SDS-PAGE analysis of IDS protein stability in cell-free systems 
SDS-PAGE analyses demonstrate that IDS was successfully expressed by three 
of the cell-free expression systems including both E.coli-hasQd systems and the 
wheat germ-based system from Roche. The expression products were separated into 
the insoluble pellet and supernatant fraction. Active proteins should be present in the 
soluble fraction of proteins. Specific band of IDS was observed in both the soluble 
fraction as well as the insoluble pellet in contrast to the negative control without 
DNA added. 
3.3.3.1 Wheat germ-based cell-free expression system (Roche) 
The wild-type IDS was successfully expressed as soluble form in the plant 
system (Figure 3.15). GUS was expressed as positive control and revealed a 
thickened band with an apparent molecular weight of � 7 0 kDa. However, it was 
up-shifted to be ~ 85 kDa indicated by the marker. Therefore, the marker 
Kaleidoscope Prestained Standards may have some deviations in the estimation of 
protein size. The specific band for wild-type IDS has an over-estimated protein size 
which must be smaller than 70 kDa. When repeating the SDS-PAGE analysis using 
another marker BenchMark His-tagged Standard (data not shown), it reveals that 
specific band of wild-type IDS has molecular weight of 60 kDa. 
Although Canine Pancreatic Microsomal Membranes may initiate 
post-translational processing of proteins, it was recommended not to add into the 
open system of Promega wheat germ-based cell-free expression system. In this study, 
it proofed that the microsomal vesicles are also not suitable for adding into Roche 
wheat germ-based cell-free expression system. The membrane inhibited the overall 
expression efficiency, no specific band of IDS can be observed (Figure 3.15). 
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Figure 3.15 SDS-PAGE analysis of wheat germ-based cell-free expression 
(Roche) 
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Figure 3.15 Successful synthesis of wild-type IDS was shown by SDS-PAGE 
analysis. The cell-free expression products were separated into the insoluble pellet 
and the soluble fraction of proteins. Specific band of wild-type IDS was observed in 
the supernatant as well as in the pellet when compared with the control. Specific 
bands of both the wild-type IDS and the positive control GUS were boxed in pink 
and brown respectively. Only the soluble fraction of proteins was shown. The 
positive control GUS should be � 7 0 kDa which indicated that the molecular weight 
was over-estimated by the marker Kaleidoscope Prestained Standards. Lane 1: 
expression of positive control GUS. Lane 2: expression of wild-type IDS. Lane 3: 
expression with the presence of canine pancreatic membrane which inhibited the 
reaction. Lane 4: first washed fluent of purified wild-type IDS in Lane 2. The 
purification of His-tagged IDS was failed. 
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3.3.3.2 £".c0//-based cell-free expression system (Invitrogen) 
The wild-type IDS was successfully expressed as insoluble protein in the 
五.co//-based system (Figure 3.16). The absence of the additional band in the 
supernatant fraction illustrated that the wild-type IDS was likely to be trapped in the 
inclusion bodies and probably not active. As indicated by the marker, the insoluble 
IDS had molecular weight similar to the soluble IDS expressed in the plant system, 
i.e. 60 kDa. 
A thickened specific band of the N-terminally truncated IDS was observed in 
the pellet fraction. Such modified IDS without 33 amino acids was a bit smaller than 
the wild-type IDS as expected (Figure 3.16). Since there is no proteolytic cleavage 
of signal peptide by the cell-free system, the N-terminally truncated IDS was 
expected to fold into active form spontaneously in the presence of RTS GroE 
Supplement. However, the results illustrated that there was no further processing of 
C-terminal proteolysis. E.co/z-based system can only synthesize insoluble IDS either 
with or without signal peptide. 
3.3.3.3 E.coli-hsised cell-free expression system (Roche) 
Both the wild-type IDS and the mutant IDS carrying p.L339P were successfully 
expressed as insoluble proteins in the E.coli-hased system (Figure 3.17). The 
absence of the specific band in the supernatant fraction indicated that all the proteins 
were likely to be trapped in the inclusion bodies and probably not active. 
Nonetheless, the protein expression level can be compared between the wild-type 
and the mutant. The precursor protein of mutant IDS with intact signal peptide was 
relatively stable as the wild-type. The missense mutation p.L339P debilitated the 
enzyme function but not declined the protein stability of precursor IDS. 
RTS GroE Supplement may assist in proper folding of the proteins. However, it 
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did not work in Roche E.coli-hasQd systems. The addition of GroE into the open 
system of Roche £.co//-based system even inhibited the expression of IDS (data not 
shown). No more specific band of wild-type IDS was observed in any size. 
Therefore, the GroE supplement and the Canine Microsomal Membranes are not 
suitable for Roche cell-free expression systems. 
3.3.4 InVision His-tag In-gel stain for wild-type IDS and its mutant 
The expression of wild-type IDS and its mutant carrying the mutation p.L339P 
was further confirmed by specific staining His-tagged proteins (Figure 3.18). The 
recombinant IDS proteins synthesized by the cell-free system were N-terminally 
His-tagged. Both the specific bands for the wild-type IDS and its mutant were 
visualized in the total protein fraction with similar intensity. The pellet fraction 
revealed more apparent results of insoluble wild-type IDS and mutant protein. The 
two protein bands had similar expression level indicating that both wild-type and 
mutant protein were relatively stable. Additionally, the absence of specific band of 
IDS in the soluble fraction is consistent with simple protein staining (Figure 3.17). 
Figure 3.18 also shows some other His-tagged proteins presented in the Roche E.coli 
extracts both in the supernatant fraction and the total protein fraction. These proteins 
may be synthesized by Roche for transcription and translation reactions. 
For both cell-free expression systems from Promega, no detectable IDS was 
visualized even by specific staining the His-tagged proteins (data not shown). The 
expression level in both the Promega systems may be too low. 
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Figure 3.16 SDS-PAGE analysis of E.coli-bnsed cell-free expression (Invitrogen) 
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Figure 3.16 Successful synthesis of wild-type IDS was shown by SDS-PAGE 
analysis. Specific band of the wild-type IDS and the N-terminally truncated IDS was 
observed in the pellet and the total expression products when compared with the 
negative control. Wild-type IDS was boxed in pink while the shortened IDS was 
boxed in brown. Both the IDS proteins have their molecular weight over-estimated. 
They should be 60 kDa only. Lanes 1 - 3 : expression of without DNA template. 
Lanes 4 - 6 : expression of wild-type IDS. Lanes 7 - 9 : expression of the 
N-terminally truncated IDS without 99 bp. Lanes 1, 4 and 7: total expression 
products. Lanes 2, 5 and 8: insoluble pellet fraction. Lanes 3, 6 and 9: soluble 
fraction of proteins. The marker was Kaleidoscope Prestained Standards. 
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Figure 3.17 SDS-PAGE analysis of E.coli-hsLsed cell-free expression (Roche) 
1 2 3 4 5 6 
^^ HL -vnrn-i fitVu A^ a^ sfl^  
r 一 
Figure 3.17 Successful synthesis of wild-type IDS and its mutant was shown by 
SDS-PAGE analysis. Only the samples of wild-type EDS and its mutant were shown. 
Specific band of the wild-type IDS and the mutant carrying p.L339P was observed 
in the pellet and the total expression products when compared with the negative 
control (narrowed). The absence of specific band in the soluble fraction indicated 
that the cell-free system synthesized insoluble IDS proteins only. The wild-type IDS 
and its mutant have similar expression level which implied that both the proteins 
were relatively stable. Lanes 1 - 3 : expression of wild-type IDS. Lanes 4 - 6 : 
expression of mutant IDS carrying the mutation p.L339P. Lanes 1 and 4: total 




Figure 3.18 His-tagged protein staining of E.coli-bsLsed cell-free expression 
(Roche) 
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Figure 3.18 Successful synthesis of wild-type IDS and its mutant was further 
confirmed by His-tag In-gel staining. Specific band of the wild-type IDS and its 
mutant carrying the mutation p.L339P was observed in the pellet and the total 
expression products when compared with the negative control. IDS proteins were 
boxed in pink while the positive control GFP was boxed in green. The absence of 
specific band in the soluble fraction indicated that the cell-free system synthesized 
insoluble IDS proteins only. The wild-type IDS and its mutant have similar 
expression level which implied that both the proteins were relatively stable. Lanes 1 
-4: total expression products. Lanes 5 - 8 : soluble fraction of proteins. Lanes 10 and 
12: insoluble pellet. Lanes 1 and 5: expression without DNA template. Lanes 2, 6 
and 10: expression of wild-type IDS. Lanes 3, 7 and 12: expression of mutant IDS 
carrying p.L339P. Lanes 4 and 8: expression of positive control GFP. Lanes 9 and 11: 
no sample loaded. The marker was BenchMark His-tagged Protein Standard. 
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3.3.5 Analysis of IDS activity in cell-free expression systems 
The overall performance of each cell-free expression systems was summarized 
in Table 3.4. The IDS activity assay was tested on the total expression products. All 
the IDS protein synthesized in either of the cell-free systems was inactive when 
compared with the negative control (Figure 3.19). Although SDS-PAGE analysis 
indicated successful protein expression by the cell-free systems, most of the 
recombinant IDS was insoluble. The wild-type IDS expressed by Roche wheat 
germ-based system was not active even in soluble form. Additionally, the assay 
results confirmed that no active IDS was synthesized by the two Promega cell-free 
expression systems. For the mammalian system, negative results were reproduced by 
using the expression vector pcDNA-DEST40 containing IDS cDNA (data not 
shown). Since the cell-free systems failed to produce active wild-type IDS, the 
mutant was not subjected to further activity assay. 
As shown by SDS-PAGE analysis (Figure 3.15), purification of His-tagged 
protein was failed. The His-tagged wild-type IDS synthesized by the Roche wheat 
germ-based system was tried to isolate from the total expression products. However, 
there was a striking amount of wild-type IDS rinsed away in the first wash (Figure 
3.15). The purified products and the fluent from the washing steps were not 
subjected to further activity assay. 
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Table 3.4 Summary of IDS expression in COS-7 cells and in cell-free systems 
COS-7 E.Coli E.Coli Wheat germ Wheat germ Reticulocyte 
(Invitrogen) (Roche) (Roche) (Promega) (Promega) 
Expression + Luci + Luci + Luci + GUS + Luci + Luci 
of positive + GFP + GFP 
control 
IDS protein + Insoluble Insoluble soluble & not not 
expression precursor precursor insoluble visualized visualized 
precursors 
IDS catalytic + not not not not not 
activity detectable detectable detectable detectable detectable 
Table 3.4 The overall performance of all the expression systems. Only the 
cell-based method using COS-7 cells produce active IDS protein. None of the 
cell-free system expressed active wild-type IDS although some of the systems 
showed good protein expression of IDS. “+，，means positive results; "+ Luci" means 
successful expression of active luciferase; “+ GFP" means successful expression of 
GFP showing fluorescence under UV light; “+ GUS" means successful expression 
of GUS with evidence shown by SDS-PAGE. 
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Figure 3.19 Analysis of cell-free expression in terms of IDS activity 
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Figure 3.19 Wild-type IDS synthesized by any of the cell-free systems was not 
active. Each expression was repeated at least three times. All the absorbance in the 
activity assay lay in the linear range, indicating that the activity assay was not yet 
saturated and the results were reliable. Successful protein expression of the different 
cell-free systems was also confirmed by active luciferase co-expressed as positive 
control. Blank: expression reagents without DNA template. Wild-type: expression of 
wild-type IDS. Inv-E.coli: £.co//-based expression system Invitrogen. RTS-E.coli: 
£.co//-based expression system from Roche. RTS-WG: wheat germ-based 
expression system from Roche. TNT-WG: wheat germ-based expression system 
from Promega. TNT-RR: rabbit reticulocytes-based expression system from 
Promega. 
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3.3.6 Analysis of the cellular uptake of IDS 
The IDS protein was allowed to enter the COS-7 cells by endocytosis. 
Successful endocytosis of IDS was demonstrated by active IDS expressed in COS-7 
cells previously (Table 3.5). After 48-hour incubation, the N-terminally truncated 
IDS entered into the COS-7 cells and showed more than 50 % of wild-type IDS 
activity. It is consistant with the results obtained from transfected COS-7 cells. In 
contrast, the soluble IDS synthesized by the wheat germ-based Roche system 
remained inactive after endocytosis (Table 3.6). It is believed that precursor may be 
processed and resume its activity after entering the cells. The results of the soluble 
IDS were similar to the results of expression reagents without DNA template. It 
indicated that the soluble IDS precursor did not enter the COS-7 cells after 48-hour 
incubation. Thus, the insoluble IDS synthesized by the other cell-free systems was 
not subjected to further endocytosis study in COS-7 cells. 
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Table 3.5 Endocytosis study of active IDS into un-transfected COS-7 cells 
Incubation IDS activity 
Donor Medium of wild-type IDS 136.68'' 
transfected COS-7 cells 
Recipient Un-transfected COS-7 cells 0 hour 0.98^ 
Un-transfected COS-7 cells 48 hours 126^ 
Donor Medium of N-terminally truncated 98.47^ 
IDS transfected COS-7 cells 
Recipient Un-transfected COS-7 cells 0 hour 0.54^ 
Un-transfected COS-7 cells 48 hours 0.98^ 
a IDS activity expressed in nmol/4h/ml; ^ IDS activity expressed in nmol/41Vmg 
Table 3.5 Cellular uptake of active IDS into un-transfected COS-7 cells was 
successful. The N-terminally truncated IDS remained > 50 % of wild-type activity 
after endocytosis. The result was consistent with transient expression. The activity 
differences before and after endocytosis were similar for both the two types of IDS. 
I l l 
Results j a 
Table 3.6 Endocytosis study of the total expression products from cell-free 
system 
Incubation IDS activity 
(nmol/4h/mg) 
Donor Negative control from wheat 5.91 
germ-based system (Roche) 
Recipent Un-transfected COS-7 cells 0 hour 3.90 
Un-transfected COS-7 cells 48 hours 0.65 
Donor Wild-type IDS from wheat 5.12 
germ-based system (Roche) 
Recipent Un-transfected COS-7 cells 0 hour 5.19 
Un-transfected COS-7 cells 48 hours 0.58 
Table 3.6 Endocytosis of the total expression products containing soluble IDS 
synthesized by the Roche wheat germ-based system. The activity of wild-type IDS 
was lower than the negative control after endocytosis. No active form of the soluble 
IDS was generated after endocytosis. Insoluble IDS expressed by the other cell-free 
expression systems was not subjected to further endocytosis study. 
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Chapter 4 Discussions 
4.1 Mutational analysis 
4.1.1 Heterogeneity of IDS mutations 
MPS II is a rare genetic disease. With the two novel mutations described in this 
study, a total of 321 mutations have already been identified in the IDS locus. It 
indicates a high allelic heterogeneity in the IDS gene and which is responsible for 
the broad spectrum of clinical severity observed in MPS II patients [Hopwood JJ et 
al., 1993]. As mentioned in Chapter 1.2.3.2, exons 3, 5, 8 and 9 are the hot spots of 
point mutation. Of which, 12.3 % of reported point mutations, predicting amino acid 
substitution and translational termination, were identified in exon 8. In this study, all 
the three mutations are also located in exon 8. It further demonstrates that IDS exon 
8 is the hot spot of point mutations in Chinese population [Liu S et al., 2002]. 
4.1.2 Role of molecular diagnosis for MPS II 
Mucopolysaccharidoses are suspected when elevated GAG is detected in the 
urine samples. However, MPS I and MPS II share the same biochemical markers in 
this preliminary test. Since IDUA and IDS are involved to complete the first step of 
GAG degradations (Figure 1.1)，both types of patient excrete the common substrates 
in massive amount. In order to distinguish between MPS I and MPS II when 
elevated heparin sulfate and dermatan sulfate are detected, further investigations 
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must be done. MPS II can be confirmed by demonstrating the IDS deficiency in the 
patients plasma or cultured fibroblasts. However, it may take days to weeks to 
confirm the results. A more efficient method is necessary, especially for prenatal 
diagnosis. 
Majority of LSDs only require low enzymatic activity to maintain normal 
phenotypes although the minimum requirement of IDS is unknown for MPS II 
patients [Thomas GH, 1994]. It is also difficult to differentiate the clinical severity 
of MPS II based on residual IDS activity [Parkinson EJ et al, 2004; Kato T et al., 
2005]. On the other hand, recent studies established some genotype-phenotype 
correlations by mutational analysis as described in Chapter 1.2.3.3 [Millat G et al., 
1998; Dierks T et al” 1999; Moreira da Silva I et al, 2001; Kato T et al., 2005]. 
Therefore, direct DNA sequencing on IDS gene serves as a better diagnostic method 
for MPS II. It provides definitive results with high specificity and the automated 
procedures speed up the screening process within one-day. Having the mutation 
identified in Patient 2 and Patient 3，prenatal diagnosis for their sister was performed 
efficiently in this study. 
In addition, mutational analysis can replace enzyme assay for accurate carrier 
detection [Froissart R et al” 1998; Keulemans JLM et al., 2002]. Skewed 
X-chromosome inactivation may occur in some carriers and lead to lower enzymatic 
activity as in the patients [Lyon MF, 1961; Cudry S et al., 2000]. On the other hand, 
the identified mutations found in the patients help effective screening for the female 
carriers as in this study. Three MPS II female carriers including the patients' mothers 
were confirmed by direct DNA sequencing. The results showed that the two 
nonsense mutations are not de novo but inherited from the patients' mothers. 
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4.1.3 Two novel mutations and one reported mutation were identified 
4.1.3.1 A novel nonsense mutation: Ser369term 
Patient 2 and Patient 3 are carrying the same mutation p.S369X in the IDS gene 
which is responsible for mild form of MPS II. Since the two patients are brothers, 
the frequency of p.S369X only counts once as in Table 1.2. The nonsense mutation 
predicts termination of translation from Ser369 residue and leads to C-terminally 
truncated protein without 181 amino acids. It is believed that Ser369 residue is not 
the second proteolytic cleavage site for normal C-terminal processing otherwise the 
nonsense mutation would not lead to MPS II [Wilson PJ et cd” 1990; Millat G et al., 
1997a]. Kato's group predicted that the last putative active site is located at Lys347 
residue [Kato T et al., 2005]. Therefore, the mutant protein carrying p.S369X should 
have all the catalytic domain and subdomains preserved for residual enzymatic 
activity. IDS deficiency may be due to protein instability. Including this novel 
mutation, there are 33 different nonsense mutations reported. And they account for 
nearly 10 % of total mutations identified in the IDS locus. 
4.1.3.2 A reported nonsense mutation: Gln389terin 
Patient 1 carried the mutation p.Q389X in the IDS gene which is responsible 
for clinically severe MPS II. This nonsense mutation was first reported in America 
[Jonsson JJ et al” 1995]. The translation is likely to terminate at Gln389 residue 
leading to the loss of 161 amino acids at the C-terminal end. The un-translated 
sequence does not contain any putative active site [Kato T et cd., 2005]. p.Q389X 
should result in shortened polypeptides with residual enzymatic activity similar to 
P.S369X described above. Interestingly, with the addition of 20 amino acids 
following residue 369, the disease becomes a severe form. Together with the mild 
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forms having nonsense mutations in exon 1, such as W12X, it indicates that 
structural analysis is not enough to explain the pathological lesion of nonsense 
mutation in IDS gene [Filocamo M et cd., 2001; Kato T et al., 2005]. 
4.1.3.3 A novel missense mutation: Leu339Pro 
In the severely affected Patient 4，a novel missense mutation p.L339P was 
identified. The point mutation predicts substitution of Leu339 residue by proline. 
The restriction analysis revealed the absence of c.l016T>C in at least 50 normal 
control individuals. However, it is a non-conservative change when comparing at 
least ten human sulfatases (Appendix 1). And Leu339 residue does not belong to the 
active C-X-P-S-R motif and it is not a potential N-glycosylation site [Millat G et al, 
1997a]. Indeed, it is not enough to support the view that single base pair change is 
the pathological lesion for clinically severe MPS II. Previous transient expression 
studies provided major evidence for the causality of most missense mutations 
[Bonuccelli G et al.’ 2001; Chang JH et al., 2005]. Therefore, in vitro expression of 
the mutant gene was involved in this study for verifying the enzyme defect. 
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4.2 Expression studies of the IDS mutants 
Besides the novel mutation p.L339P, there is another missense mutation 
reported at the same codon 339, i.e. p.L339R [Froissart R et al., 1998]. Although the 
deleterious effect of p.L339R was not verified by expression study previously, it was 
reported to be responsible for clinically severe MPS II. Therefore, it is worth to 
investigate both the missense mutations at codon 339 for their effects of amino acids 
alterations and the functional importance of Leu339 residue. p.L339P and p.L339R 
were studied through site-directed mutagenesis and in vitro expression. Transient 
expression in COS-7 cells demonstrated that both of the missense mutations caused 
significant consequences on IDS catalytic activity but did not affect the mRNA 
stability. And the in vitro expression using cell-free systems demonstrated the mutant 
proteins carrying p.L339P were relatively stable as wild-type IDS. 
4.2.1 Analysis of transient expression in COS-7 cells 
To evaluate the functional consequence on enzyme activity of IDS mutants, it is 
common to carry out expression studies in COS-7 cells [Villani GR et al., 2000; 
Bonuccelli G et al., 2001; Ricci V et al” 2003; Chang JH et al., 2005]. The 
mammalian cells serve as a good tool for which provide all the necessary 
post-translational modifications including FGly formation, glycosylation and 
proteolytic processing. Additionally, human IDS maturation steps in COS-7 cells are 
identical in human fibroblasts and lymphoblastoid cell lines [Wilson PJ et al., 1990; 
Millat G et al” 1997a, 1997b, 1998; Cudry S et al” 2000]. In COS-7 cells, the two 
precursor forms of IDS, 76 kDa and 90 kDa are processed through a series of 
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intermediates to two mature polypeptides, 55 kDa and 45 kDa. The 
immunoprecipitation of ^^S-labeled IDS revealed that all the precursors were 
processed 48-hour after transfection leaving mature forms in the cells [Millat G et 
al., 1997b]. Therefore, all the harvested IDS were fully processed in this study. 
A positive control vector containing firefly luciferase was synthesized for 
co-transfection with IDS constructs. Similar to IDS, luciferase polypeptides also 
consist of 550 amino acids but no modification required. With the use of CMV 
promoter and the use of lipofection procedures, it is believed that both luciferase 
proteins and IDS proteins have the same transfection efficiency and expression 
efficiency. Luciferase and wild-type IDS were successfully expressed with positive 
activities in the COS-7 cells. However, no specific band of either luciferase or IDS 
was observed by simple protein staining. The expression level of both the products 
may be very low. Therefore, simple protein staining is not feasible for direct 
visualization of IDS in transfected COS-7 cell lysate as in normal human fibroblast 
lysate [Millat G et al., 1997b]. 
There are some other limitations when using COS-7 cells. One of which is the 
basal IDS activity in the mammalian cells. Other studies have used enzyme-deficient 
fibroblasts for transient expression study [Sukegawa K et al., 1995; Tomanin R et al., 
2002]. Nevertheless, the wild-type IDS was successfully over-expressed resulted in 
a 13-fold increase in catalytic activity and only the relative activities were required 
for comparison in this study. The other drawbacks are the low transfection efficiency 
and low expression efficiency of the mammalian cells. In this study, the use of 
cationic lipid transfectants provides higher transfection efficiency for the COS-7 
cells [Ciccarone et al., 1999; Chang JH et al, 2005]. And the expression efficiency 
was maximized by using expression vectors containing CMV promoter. Additionally, 
both the wild-type and mutant constructs were subjected to the same expression 
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conditions. Therefore, neither transfection efficiency nor expression efficiency is a 
major problem for investigating the causality of the two missense mutations. 
4.2.1.1 Stability of mutant mRNA 
The expression constructs contained the cDNA of either wild-type IDS or the 
mutants IDS. So there is no mRNA splicing required after transcription in COS-7 
cells. The total mRNA level of IDS was estimated by RT-PCR. The N-terminally 
truncated IDS without the 33 amino acids at the N-terminal end served as a second 
negative control. This construct also resulted in no specific band for the amplicon of 
IDS from exon 1 to exon 9 indicating that the basal IDS mRNA expression in COS-7 
cells is negligible (Figure 3.13B). When compared with the wild-type IDS mRNA, 
both the mutants have similar mRNA expression level and their mRNA is relatively 
stable in the COS-7 cells (Figure 3.13B & C). Therefore, both the single base pair 
changes, CTA > CCA and CTA > CGA, at IDS codon 339 did not decline the mRNA 
stability in general. 
4.2.1.2 IDS catalytic activity 
IDS activity is routinely assayed using radiolabeled disaccharides substrate 
derived from heparin [Guglielmo RD et al., 2000; Bonuccelli G et al., 2001; Hong 
YT et al., 2003]. Obviously, 4-methylumbelliferyl derived substrates used in the 
fluorometric method is more convenient and less cumbersome than the conventional 
assay [Voznyi YV, Keulemans JLM and van Diggelen OP, 2001]. After the 
development of the fluorometric assay for IDS in 2001, prenatal diagnosis for MPS 
II began to apply this method to screen the cultured CV-cells [Keulemans JLM et al., 
2002]. Due to its sensitivity and specificity, the fluorometric assay is also used in 
various expression studies as well as in the present study [Tomanin R et al, 2002; 
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Ricci V et al, 2003; Chang JH et al” 2005]. Nowadays, fluorogenic substrates are 
widely used for most other MPS diagnosis, e.g. MPS III A/C，MPS IV A, and for 
other enzymes like a-L-flicosidase and p-galactosidase [Cuer M et al., 2000; 
McGuire JBJ et al, 2002]. 
The transient expression study demonstrated the functional consequence of 
both missense mutations p.L339P (novel) and p.L339R. Both the amino acids 
alterations at Leu339 residue cause significant reduction on IDS activity, only less 
than 2.5 % of normal level, which illustrated the deleterious nature of both the 
mutations (Table 3.2). The results confirmed that p.L339P identified in Patient 4 is a 
novel disease-causing missense mutation. As mentioned in Chapter 1.1.4.1, the 
clinical severity does not depend on the deficient IDS enzyme activity, ranging from 
no detectable activity to residual activity [Li P, Bellows AB and Thompson JN 1999; 
Parkinson EJ et al., 2004; Kato T et al., 2005]. And the minimum active IDS level 
for normal phenotypes remains unknown [Thomas GH, 1994]. Nevertheless, both 
P.L339P and p.L339R were identified in severely affected patients. The results 
confirmed that both the point mutations at codon 339 are correlated with clinically 
severe MPS II. 
4.2.2 Analysis of mutant stability by cell-free expression systems 
To date, there are no commercial anti-IDS antibodies available for Western 
blotting [Cudry S et al., 2000]. And Figure 3.12 shows that IDS synthesized in 
COS-7 cells was not visualized by simple protein staining. Alternative methods were 
used to synthesize His-tagged recombinant IDS for specific staining. If the 
substitution of proline at Leu339 residue really changes the conformation of IDS 
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polypeptide and affects its stability, the precursor would be easily degraded due to 
improper folding [Tikkanen R et al., 1995]. In the study, detectable amount of IDS 
precursors were successfully synthesized by the cell-free expression systems. 
SDS-PAGE analysis, using simple protein staining and His-tagged protein staining, 
revealed that both the wild-type IDS and mutant precursors were quite stable. 
Therefore, the novel missense mutation p.L339P does not decline the protein 
stability. 
4.2.3 Structural analysis of amino acids alterations 
Structural characteristics of IDS mutations were investigated in several groups 
although there is no official 3D structure of mature IDS published to date [Kim CH 
et al., 2003; Parkinson-Lawrence E et al, 2005; Kato T et al” 2005]. A 3D structure 
of the enzyme is useful for analysis of genotype/phenotype correlations in some 
diseases such as MPS IVA [Sukegawa K et al.’ 2000; Kato T et al., 2005]. It could 
clearly indicate molecular effects of the mutations. Generally, great structural 
change in the mutant IDS is responsible for clincially severe MPS II 
[Parkinson-Lawrence E et al” 2005]. Missense mutations found in the severe MPS 
II patients would have direct interactions with the active site residues [Kato T et cd., 
2005]. And for those mutations found in the mild form of MPS II were located in the 
peripheral region of IDS. 
In a non-conservative residue, which does not conserved in other human 
sulfatase and does not belong to the sulfatases C-X-P-S-R motif, different amino 
acids alterations at the particular residue may lead to different clinical consequence. 
For instance, patients inherited the missense mutation p.R95T were mildly affected 
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with normal intelligence while patients inherited p.R95G were classified as 
intermediate with a little mental retardation [Goldenfum SL et al., 1996; Dierks T et 
cd., 1999; Moreira da Silva I et al., 2001]. In addition, IDS deficiency caused by 
cyclic proline substitution at different leucine residues also resulted in different 
clinical severity. For instance, p.L182P leaded to intermediate form of MPS II with 
subnormal intelligence but p.L259P leaded to severe phenotypes with mental 
retardation [Isogai K et al., 1998; Kim CH et al.’ 2003]. 
4.2.3.1 P.L339P causes conformational change 
In this study, the novel mutation p.L339P have the hydrophobic Leu339 residue 
replaced by the equally non-polar but ambivalent cyclic proline. Leucine belongs to 
the aliphatic R groups which generally buried inside the folded protein molecules. 
However, proline can exist as trans- or cis- isomers and is responsible for protein 
folding. The low residual activity of the IDS mutant suggested that the single base 
pair change probably affects the proper folding of the polypeptides. In this study, 
IDS enzymatic activity was also measured in the medium of transfected COS-7 cells 
because IDS proteins were released into the cell-free medium spontaneously from 
the senescent cells. Interestingly, there was no detectable IDS activity of the mutants 
carrying p.L339P. It implied that conformational changes caused by p.L339P may 
also affect the protein leaving the cells. 
4.2.3.2 P.L339R changes overall charge balance 
For the reported mutation identified at the same codon, i.e. p.L339R, the 
non-polar and hydrophobic Leu339 residue was substituted by polar and very 
hydrophilic arginine. As a cation, arginine may alter the overall charge of the IDS 
polypeptides. The deleterious effect of p丄339R may due to the disturbance of 
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overall charge balance of the mutant protein and cause deficient IDS. Therefore, the 
substitutions of different amino acids at Leu339 residue may result in different 
degree of deleterious effects. In fact, both the conformational change (p.L339P) and 
the overall charge change (p丄339R) of the polypeptides cause clinical severe 
phenotypes simultaneously. Leu339 residue should have some function importance 
for IDS activity. 
4.2.3.3 Mutations at Leu339 residue affect substrate binding 
The nine putative active site residues: Asp45, Asn46, Cys84，Arg88, Lysl35, 
Hisl38，Asp334, His335, and Lys347, were proposed to form a loop-like region in 
an open area of the folded IDS polypeptide (Appendix 10). According to the same 
3D structure, Leu339 residue is located in a supercoiled structure adjacent to the 
active sites region. It seems that the cavity between the active sites region and the 
supercoiled structure is responsible for substrate binding. Therefore, Leu339 residue 
is close to a potential substrate binding site. Previous studies suggested that Ser333 
to Gly336 may form a region of functional significance located near Leu339 residue 
[Wilson PJ et al” 1990; Sukegawa K et al., 1995; Isogai K et al., 1998; Froissart R 
et al” 1998; Li P et al.’ 1999; Kato T et al, 2005]. This tetrapeptide may be 
functionally important for substrate binding. Thus, amino acid alterations at Leu339 
residue may significantly reduce the substrate binding ability due to conformational 
change or charge imbalance of this potential substrate binding site. 
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4.3 Analysis of IDS maturation processing 
4.3.1 Active IDS modifications are not completed in lysosomes 
The complex processing steps for IDS were studied indirectly. However, not 
every step was monitored. The location of post-translational processing steps was 
determined by investigating the activity of the N-terminally truncated IDS in 
transfected COS-7 cells. The results also showed the significance of the first 33 
amino acids at the N-terminal end for IDS localization and functional consequence. 
This N-terminally truncated IDS was successfully expressed in COS-7 cells and in 
the cell-free systems. In the absence of signal sequence and the subsequence 24 base 
pairs, mRNA of this modified IDS was relatively stable as the wild-type (Figure 
3.13 C). In the absence of the signal peptide and the subsequence 8 amino acids, the 
precursors of this modified IDS were quite stable (Figure 3.16). Therefore, the first 
99 bp mRNA sequences of IDS are not significant for mRNA stability. And the first 
33 amino acids are not essential for maintaining protein stability during processing. 
In vitro measurement of IDS activity for the N-terminally truncated proteins 
revealed that no detectable active IDS was found in the transfected cell lysate. All 
the IDS proteins without signal peptides should be mistargeted and secreted by 
exocytosis after translation. Interestingly, these proteins without entering the 
lysosomes were found active in the cell-free medium. Therefore, lacking the 33 
amino acids at the N-terminal end does not affect maturation of the polypeptides. 
The processing steps do not depend on the presence of the first 33 amino acids. The 
results also indicated that the maturation steps for active IDS were completed before 
the polypeptides entered the lysosomes. These 33 amino acids containing the signal 
peptide may only serve for lysosomal targeting. The N-terminal proteolytic 
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processing should be the final step completed inside the lysosomes. 
The results showed that all the processing steps necessary for active IDS are 
pre-lysosomal. These modifications include the conversion of Cys84 residue in the 
catalytic domain [Villani GRD et al., 2000; Landgrebe J et al., 2003]. Since the 
secreted IDS of the N-terminally truncated form was active, the conversion of Cys84 
into Ca-formylglycine should be completed. This modification probably started as 
an early post-translational processing or as a co-translational event in the 
endoplasmic reticulum [Schmidt B et al； 1995; Dierks T et al, 1997, 1998; 
Marquordt C et al., 2003; Preusser-Kunze A et al.’ 2005]. In addition, the results of 
endocytosis study confirmed that glycosylation was preformed. The secreted IDS 
was successfully imported into the imtransfected COS-7 cells probably by 
mannose-6-phosphate receptor-mediated cellular uptaking [Millat G et al., 1997b]. It 
suggested that IDS have already been glycosylated and the oligosaccharide chains 
were modified in the endoplasmic reticulum [Parkinson-Lawrence E et al, 2005]. 
4.3.2 C-terminal proteolysis is essential for active IDS 
The results also suggested that the C-terminal proteolytsis is partially 
pre-lysosomal [Schmidt B et al., 1995]. The N-terminally truncated IDS synthesized 
by the cell-free systems were in precursor form without C-terminal processing. 
These precursors were inactive which indicated that C-terminal proteolysis 
determine the catalytic activity of IDS. As mentioned in Chapter 4.2.3.3，there is an 
open cavity for substrate binding above the loop-like region of active sites residues. 
Uncleaved C-terminal end may occupy this cavity and bury the active domains 
inside the folded polypeptides. The results of transient expression showed that IDS 
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without entering the lysosomes remained only 60 % of wild-type activity. Therefore, 
incomplete C-terminal cleavages may occur. Probably, the internal cleavage step of 
the 55 kDa mature form to create the 45-44 kDa second mature form is completed 
inside the lysosomes. In the absence of the 45-44 kDa mature form, the overall IDS 
activity may be reduced. 
Further investigations of the C-terminal processing will be useful. The second 
proteolytic cleavage site can be determined for comparing the catalytic activity 
between the two mature forms of IDS. Since mature IDS have parts of N-terminal 
and C-terminal sequences removed during processing, fusion proteins of IDS cannot 
be produced for easy detection. In order to monitor the entire process, specific 
immunoblot analysis may serve as better visualizing method for transient expression 
in COS-7 cells. The anti-IDS polyclonal antibodies can specifically stain the IDS 
proteins for accurate detection in the cell extracts [Parkinson EJ et al., 2004; 
Parkinson-Lawrence E et al.’ 2005; Pena O et al. 2005]. And the experiments should 
be performed at different time points within the first 48-hour upon transfection 
because IDS will be completely processed thereafter [Millat G et al., 1997b]. 
4.3.3 Functional role of giycosylation during IDS processing 
As a lysosomal enzyme, the destination of IDS should be the lysosomes which 
provide suitable pH for IDS activity. However, previous study proved that it is not 
the potential N-glycosylation sites responsible for lysosomal targeting of IDS [Millat 
G et al., 1997a]. Tunicamycin was used to produce unglycosylated IDS precursor to 
examine its functional consequence [Millat G et 1997b]. In this study, the 
functional role of giycosylation was determined by synthesizing unglycosylated IDS 
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in the cell-free expression systems. Both the methods could allow us to investigate 
the cumulative effects of lacking glycosylation on processing and enzyme activity. 
It is suggested that the N-oligosaccharide chains formed by glycosylation is 
responsible for quality control process that ensures correct protein folding 
[Parkinson-Lawrence E et al., 2005]. Misfolded precursors are degraded in the 
endoplasmic reticulum [Tikkanen R et al., 1995]. In this study, the cell-free 
expression systems showed stable protein production of IDS precursors but all the 
proteins were inactive. These IDS polypeptides had the C-terminal end uncleaved. 
Therefore, unglycosylated IDS precursors were not able to process C-terminal 
proteolysis. As mentioned in Chapter 4.3.2, IDS without C-terminal cleavages 
resulted in enzyme deficiency. The results confirmed that glycosylation of IDS is 
crucial for IDS folding, processing and catalytic activity. 
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4.4 Analysis of cell-free expression systems 
To date, cell-free in vitro expression experiments are rarely applied. It is 
because the strategies of protein maturations are vary in different enzymes. This is 
the first study using cell-free systems to synthesize IDS proteins. In the study, 
different extracts from three different cell types were tried to compare their 
performance on producing active IDS. However, the results revealed that 
catalytically active IDS was difficult to be synthesized by any of the cell-free 
systems. In fact, both the bacterial-based and wheat germ-based systems have good 
protein expression. It indicated that the sulfatase activity probably depends on 
normal secondary modifications including formylglycine generation, glycosylation 
and C-terminal proteolysis. The overall performance of the difference systems is 
summarized in Table 3.4. 
4.4.1 Microbial systems using Kcoli cell extracts: insoluble IDS precursors 
Among the three different types of cell-free expression systems, the bacterial 
systems were constantly expressing the human proteins. Both E.co/i-based systems 
from different manufacturers successfully expressed the IDS precursors. E.coli has 
alternative FGly-generating system to modify cysteine residues for their sulfatases. 
However, all the precursors were inactive and likely to be trapped in the inclusion 
bodies. IDS precursors are long polypeptides which have the potential to form 
partially folded intermediates and aggregated in the bacterial system. The presence 
of GroE supplements did not assist the systems to form soluble IDS proteins. Indeed, 
the prokaryotic system is greatly different from eukaryotic system by lacking other 
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post-translational modifications such as glycosylation [Landgrebe J et al., 2003]. 
Therefore, the other eukaryotic systems used in this study were expected to improve 
the situations. 
4.4.2 Plant system using wheat germ extracts: soluble IDS precursors 
For the wheat germ-based system from Roche, soluble IDS precursors were 
successfully expressed. The longer incubation time lasted for 24 hours may allow 
slow folding of the polypeptides. However, the IDS proteins were inactive probably 
due to the un-modified Cys84 residue and lack of glycosylation. From the 
SDS-PAGE analysis, the precursor IDS was expressed as one single band with 
approximately 60 kDa instead of 76 or 90 kDa. The molecular weight revealed that 
the precursors were unglycosylated without further processing [Millat G et al” 
1997b]. This also explained why the soluble IDS failed in entering the COS-7 cells 
during the endocytosis study. Cellular uptake of IDS is either by cell-cell interaction 
or M6P receptor-mediated endocytosis [Millat G et al.’ 1997b]. 
4.4.3 Mammalian system using rabbit reticulocytes extracts: undetectable 
The mammalian system has been successfully used for cell-free expression of 
active human IDUA and P53 [Keeling KM and Bedwell DM. 2002]. As an open 
system, microsomal vesicles were added into the rabbit reticulocytes-based 
expression system to aid post-translational modifications. Only the positive control 
luciferase was successfully synthesized with activity. The system did not yield any 
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catalytically active IDS and no detectable IDS protein was visualized even by 
staining His-tagged proteins. The maturation processing steps of human IDS is much 
more complex than in human IDUA, human P53 and firefly luciferase. Both the 
proteolytic cleavages and glycosylation of IDS may be completed with the aid of 
microsomal vesicles. However, modification of Cys84 residue probably becomes the 
limiting factor for active IDS synthesis in the mammalian cell-free system. 
The FGly generating enzyme (FGE) is a soluble enzyme located in the 
endoplasmic reticulum for modifying cysteine residues of sulfatases. For 
microsomal vesicles, all the surface mRNA was stripped. It indicated that the 
uselessness of adding microsomal vesicles to produce active sulfatases. In addition, 
protein transfection of the IDS products back into mammalian cells is not practical. 
It is because FGE only acts on newly synthesized and unfolded sulfatase 
polypeptides co- or post-translationally [Baenziger JU, 2003; Preusser-Kunze A et 
al., 2005]. Therefore, future application of the cell-free system should better 
co-express the IDS or other sulfatases with wild-type FGE. Previous study revealed 
that co-expression of the FGE gene and sulfatases cDNA can increase up-to 50-fold 
of sulfatase activities in cultured cells [Baenziger JU, 2003]. 
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4.5 Role of transfecting IDS constructs 
Bone marrow transplantation may be suitable in mildly affected Hunter disease 
patients only. For severe patients, recent researches attempt to use enzyme 
replacement therapy as alternative treatment [Muenzer J et al” 2002]. However, 
these MPS II patients are also suffered from mental retardation. One of the 
difficulties for enzyme replacement therapy is that the enzyme cannot enter the 
nervous system easily. Millat's group suggested that IDS enzymes can be imported 
into human cells efficiently by cell-to-cell contact [Millat G et al., 1997b]. As some 
macrophagic cells can enter the central nervous system, long-term transfection of 
these cells may express normal IDS enzyme and transfer to the nerve cells ultimately. 
Previous study suggested that the transfection can be performed in the hematopoietic 
stem cells which will then differentiate into the macrophagic cells [Krivit W et al., 
1995]. More recently, muscle electro-gene transfer showed a tenfold increase in IDS 
activity in a knockout mouse model [Tomanin R et al., 2002]. These approaches 
may serve as promising gene therapy for MPS II. 
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4.6 Conclusion 
Molecular investigations of a particular mutation could contribute to a better 
understanding of the disease causing mechanisms. In this study, transient expression 
confirmed that it is the novel missense mutation p.L339P responsible for clinically 
severe MPS II. The amino acids alteration cause deficient enzyme activity but its 
deleterious effect does not affect mRNA stability or protein stability. The hypothetic 
causality of the mutation may be due to conformational changes. And it is suggested 
that Leu339 residue may be functionally important for substrate binding. The results 
also suggested that active IDS is processed pre-lysosomally and glycosylation is 
essential for IDS processing and catalytic activity. Finally, with the identified 
mutations, carrier detection and prenatal diagnosis were performed efficiently 
among the patients' families. 
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SUL2 一 HUMAN —MGPPSLVLCLLSATV—FSLLGGSSAFLSHHRLKGRFQRDRRNIRPNIILVLTDDQ-
GLeS.HUMAN -MRLLPLAPGRLRRGSPRHLPSCSPALLLLVLGGCLGVFGVAAGTRRPNVVLLLTDDQ— 
SUL1_HUMAN -—MKYSCCALVLAVLG—TELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLTDDQ— 
* * * * 
IDS.HUMAN PSLGCYGDKLVRSPNIDQLASHSLLFQNAFAQQAV CAPSF VSFLTGRRPDTTRLYDFNS-
ARSE_HUMAN GDIGCYGNNTMRTPNIDRLAEDGVKLTQHISAASLCTPSFAAFLTGRYPVRSGMVSSIGY 
ARSF_HUMAN GDLGCYGNDTMRTPHIDRLAREGVRLTQHISAASLCSPSFSAFLTGRYPIRSGMVSSGNR 
ARSD—HUMAN GDLGCYGNNTLRTPNIDQLAEEGVRLTQHLAAAPL CTPSF AAFLTGRHSFRSGMDASNGY 
GA6S_HUMAN GDLGVYGEPSRETPNLDRMAAEGLLFPNFYSANPL CSPSF AALLTGRLPIRNGFYTTNAH 
STS_HUMAN GDPGCYGNKTIRTPNIDRLASGGVKLTQHLAASPLCTPSFAAFMTGRYPVRSGMASWSRT 
ARSA_HUMAN GDLGCYGHPSSTTPNLDQLAAGGLRFTDFYVPVSL CTPSF AALLTGRLPVRMGMYPGVLV 
ARSB_HUMAN NDVGFHGSRIR-TPHLDALAAGGVLLDN-YYTQPL CTPSF SQLLTGRYQIRTGLQHQIIW 
SUL2_HUMAN -D-VELGSMQVMNKTRRIMEQGGAHFINAFVTTPVCCPSRSSILTGKY-VHNHNTYTNN-
GL6S_HUMAN -D-EVLGGMTPLKKTKALIGEMGMTFSSAYVPSALCCPSFASILTGKYPHNHHVVNNTLE 
SULl—HUMAN -D-VELGSLQVMNKTRKIMEHGGATFINAFVTTP 冗 CPSRSSMLTGKY-VHNHNVYTNN-
* * 
IDS-HUMAN YWR-VHAGNFSTIPQYFKEN-GYVTMSVGK VFH 
ARSE_HUMAN RV—LQWTGASGGLPTNE-TTFAKILKEK-GYATGLIGK WH 
ARSF_HUMAN RV~IQNLAVPAGLPLNE-TTLAALLKKQ-GYSTGLIGK WH 
ARSD_HUMAN RA~LQWNAGSGGLPENE-TTFARILQQH-GYATGLIGK WH 
GA6S_HLJMAN ARNAYTPQEIVGGIPDSE-QLLPELLKKA-GYVSKIVGK WH 
STS_HUMAN GV-FLFTASSGGLPTDE-ITFAKLLKDQ-GYSTALIGK WH 
ARSA_HUMAN P SSRGGLPLEE-VTVAEVLAAR-GYLTGMAGK WH 
ARSB_HUMAN P CQPSCVPLDE-KLLPQLLKEA-GYTTHMVGK WH 
SUL2_HUMAN ENCSSPSWQAQHESRTFAVYLNST-GYRTAFFGKYLNEY NGSYVPPGWK 
GL6S_HUMAN G NCSSKSWQKIQEPNTFPAILRSMCGYQTFFAGKYLNEYGAPDAGGLEHVPLGWS 
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SULl 一 HUMAN ENCSSPSWQAMHEPRTFAVYLNNT-GYRTAFFGKYLNEY NGSYIPPGWR 
* * * 
IDS_HUMAN PGISSNHTDDSP—YSWS-FPPYHPSSE KYEN 
ARSE.HUMAN LGLNCE—SASDHCHH—PLHHGFEH F YGM-PFSL 
ARSF_HUMAN QGLNCD—SRSDQCHH—PYNYGFDY Y YGM-PFTL 
ARSD_HUMAN QGVNCA—SRGD-—HCHH—PLNHGFDY F YGM-PFTL 
GA6S_HUMAN LGHRPQ~FH PLKHGFDE 
STS_HUMAN LGMSCH—SKTD―-FCHH~PLHHGFNY F YGI-SLTN 
ARSA_HUMAN LGVGPE—GAFL PPHQGFHR 










STS 一 HUMAN LRDCKPGEGSVFTTGFKRLVFLPLQIVGVTLLTLAALNCLGLLH-VPLGVFFSLLFLAAL 
ARSA_HUMAN FLG-IPYSHDQGPCQNLTC 










ARSA 一 HUMAN FPPATPCDGGCDQGLVPIPLLANLSVEAQPPWLPGLEARYMAFAHDLMADAQRQDR-PFF 
ARSB_HUMAN RCT~LIDALNVTRC—ALDFRDGEEVATGYKNMYSTNIFTKRAIALITNHPPEKP—LF 









STS 一 HUMAN LVLSYLH——VH——TALFSSKDFAGKSQHGVYG-DAVEEMDWS-VGQILN——LLD 





IDS-HUMAN DLQLANSTIIA—-FTSDHG WA|G E 
ARSE_HUMAN VEGLSNSTLIY—-FTSDHG GSLENQLG NTQ 
ARSF_HL1MAN DFGLRNNTLVY—FTSDHG GHLEARRG HAQ 
ARSD 一 HUMAN DNGLKNSTFTY—-FTSDHG GHLEARDG HSQ 
GA6S_HUMAN DLHVADNTFVF——FTSDNG AALISAP EQ 
STS_HUMAN ELRLANDTLIY-—FTSDQG AHVEEVSSK GEI 
ARSA_HUMAN DLGLLEETLVI—FTADNG PETMRMS R 
ARSB_HUMAN SSGLWNNTVFI—FSTDNG GQTLAG 
SUL2 一 HUMAN RFHLKKKMRVWRDSFLVERGKLLHKRDNDKVDAQEENFLPKYQRVKDLCQRAEYQTACEQ 
GL6S_HUMAN G ASNLTWRSDVLVEYQ 
SULl 一 HUMAN RFRTNKKAKIWRDTFLVERGKFLRKKEESSKNIQQSNHLPKYERVKELCQQARYQTACEQ 
氺 * 
IDS.HUMAN HG EWAKYSN—FDVATH VPLIFY VPGRTA 
ARSE—HUMAN YG-GW NGIYKGGKGMG-GWEGGIR VPGIFR WPGVLP 
ARSF.HUMAN LG-GW NGIYKGGKGMG-GWEGGIR VPGIVR WPGKVP 
ARSD_HUMAN LG-GW NGIYKGGKGMG-GWEGGIR VPGIFH WPGVLP 
GA6S_HUMAN GG SNGPFLCGKQTT—FEGGMR EPALAW WPGHVT 
STS_HUMAN HG-GS NGIYKGGK-AN-NWEGGIR VPGILR WPRVIQ 
ARSA.HUMAN GG CSGLLRCGKGTT—YEGGVR EPALAF WPGHIA 






I DS_HUMAN SLP——EAG EKLFPYLD—PFDSASQLME PGRQ—SMD 
ARSE_HUMAN AGR VIG EPTSLMD—VFPTVVRLAG G EVPQ---DR 
ARSF_HUMAN AGR——LIK EPTSLMD—ILPTVASVSG G SLPQ—DR 
ARSD_HUMAN AGR VIG EPTSLMD—VFPTVVQLVG G EVPQ—DR 
GA6S_HUMAN AGQ—VS HQLGSIMD—LFTTSLALAG LTPP—SDR 
STS_HUMAN AGQ——KID EPTSNMD—IFPTVAKLAG A PLPE-—DR 
ARSA_HUMAN PGVT HELASSLD—LLPTLAALAG APLPN V 
ARSB—HUMAN KGVK——NR ELIHISD—WLPTLVKLAR GHTN—GTK 
SUL2_HUMAN GRR-KKLFKK KYKASYVRSRSIRSVAIEVDGRVYHVGLG DAAQPRNLTKR 
GL6S_HUMAN G 
SUL1_HUMAN QRKSQRQFLRNQGTPKYKPRFVHTRQTRSLSVEFEGEIYDINLEEEEELQVLQPRNIAKR 
IDS_HUMAN LVEL——VSLFPTLAG LAGLQVP PRCPVPSFHVELCREG—K 
ARSE_HUMAN VIDG——QDLLPLLLG TAQHSDHE——FLMHYCERFLHAARWHQRD—R 
ARSF 一 HUMAN VIDG——RDLMPLLQG NVRHSEHE——FLFHYCGSYLHAVRWIPKDD—S 
ARSD_HUMAN VIDG——HSLVPLLQG AEARSAHE——FLFHYCGQHLHAARWHQKD——S 
GA6S—HUMAN AIDG——LNLLPTLLQ GRLMDRP IFYYRGDTLMAATLGQHK—AH 
STS—HUMAN I IDG——RDLMPLLEG KSQRSDHE——FLFHYCNAYLNAVRWHPQN—S 
ARSA—HUMAN TLDG——FDLSPLLLG TGKSPRQ SLFFYPSYPDEVRGVFAV——R 
ARSB_HUMAN PLDG——FDVWKTISE GSPSPRI——ELLHNIDPNFVDSSPCPRN---S 
SUL2_HUMAN HWPG—APEDQDDKDGGDFSGTGGLPDYSAANP—IKVTHRCYILENDTVQCDLDLYKS 
GL6S_HUMAN —EG——RNVTDPTCP SLSPGVSQ—-CFPDCVCEDAYNNTYACVRT-一M 
SUL1_HUMAN HDEGHKGPRDLQASSGG-NRGRMLADSSNAVGPPTTVRVTHKCFILPNDSIHCERELYQS 
IDS.HUMAN NLLK—HFR FR DLEEDPYLPGNPRELIAYS-QYPRPSDIPQWNSDKP 
ARSE 一 HUMAN GTMWKVHFV TPVFQ PEGAGACYGRKVCPCFGE-KVVHHDP-PLLFDLSR 
ARSF_HUMAN GSVWKAHYV TPVFQ PPASGGCYVTSLCRCFGE-QVTYHNP-PLLFDLSR 
ARSD_HUMAN GSVWKVHYT TPQFH PEERGLLTAEASAHAEWG-GVTHHRP-PLLFDLSR 
GA6S_HUMAN FWTW—TNS WENFR QGIDFCPGQNVSGVTTH-NLEDHTKLPLIFHLGR 
STS_HUMAN TSIWKAFFF TPNFN PVGSNGCFATHVCFCFGS-YVTHHDP-PLLFDISK 
ARSA_HUMAN TGKYKAHFF TQGSAHSDTTADPACHASSSLTAHEP-PLLYDLSK 
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ARSB_HUMAN MAPAKDDSS LPEYSAFNTSVHAIIRHGNWKLLTGYP-GCGYWFPP 
SUL2_HUMAN LQAWKDHKLHIDHEIETLQNKIKNLREVRGHLKKKRPEECDCH-KISYHTQ-HKGRLKHR 
GL6S_HUMAN SALWNLQYC EFDD QEVFVEVYNLTA.DPDQIT-NIAKTID-PELLGKMN 
SUL1_HUMAN ARAWKDHKAYIDKEIEALQDKIKNLREVRGHLKRRKPEECSCS-KQSYYNK-EKGVKKQE 
IDS—HUMAN S-LKDIKIMGYSIRT—-IDYRYTVWVGFNPDEFLANTFSDIH AGELYFVDSDPL 
ARSE—HUMAN D-PSETHILTPASEP VFYQVMERVQQAVWEHQRTLS PVPLQLDRLGNI 
ARSF—HUMAN D-PSESTPLTPATEP LYDFVIKKVANALKEHQETIV PVTYQLSELN-Q 
ARSD_HUMAN D-PSEARPLTPDSEP LYHAVIARVGAAVSEHRQTLS PVPQQFSMSNIL 
GA6S_HUMAN D-PGERFPLSFASAE YQEALSRITSVVQQHQEALV PAQPQLNVCNWA 
STS_HUMAN D-PRERNPLTPASEP RFYEILKVMQEAADRHTQTLP EVPDQFSWNNFL 
ARSA—HUMAN D-PGENYNLLGGVAG ATPEVLQALKQLQLLKAQLDA AVTFGPSQVARG 
ARSB_HUMAN PSQYNVSEIPSSDPP---TKTLWLFDIDRDPEERHDLSREYP HIVTKLLSRLQFY 
SUL2_HUMAN —GSSLHPFRKGLQEKD-KVWLLREQ-KRKKKLRKLLKRLQNNDTCSMPGLTCFTHDNQH 




































Appendix 1 The multiple alignments of human sulfatases' amino acid sequences 
were done by Clustal W. IDS has strong sequence homology with other human 
sulfatases. Highly conserved residues are shared in yellow. The conserved 
pentapeptide for sulfatase activity is boxed. Amino acids identical in at least ten 
sulfatases are starred on the bottom line. The Leu339 residue of IDS is shared in pink. 
IDS: iduronate-2-sulfatase; ARSE: arylsulfatase E; ARSF: arylsulfatase F; ARSD: 
arylsulfatase D; GA6S: N-acetylgalactosamine-6-sulfatase; STS: steroid sulfatase or 
arylsulfatase C; ARSA: galactose 3-sufatase or arylsulfatase A; ARSB: 
N-acetylgalactosamine 4-sulfatase or arylsulfatase B; SUL2: extracellular sulfatase 
Sulf-2; GL6S: N-acetylglucosamine-6-sulfatase and; SULl: extracellular sulfatase 
Sulf-1. 
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Appendix 2 Gene tree of human sulfatases 
p I D S . H U M A N 
I—ARSD.HUMAN 
r— SUL2 .HUMAN 
~ ^ S U L l , H U M A N 
——GL6S.HUMAN 
- ——ARSE.HUMAN 
~ r - ARSA.HUMAN 




Appendix 2 It is suggested that the human sulfatases comprise an evolutionarily 
related family of genes that arose by gene duplication and divergent evolution. IDS: 
iduronate-2-sulfatase; ARSD: arylsulfatase D; SUL2: extracellular sulfatase Sulf-2; 
SULl: extracellular sulfatase Siilf-1; GL6S: N-acetylglucosamine-6-sulfatase; ARSE: 
arylsulfatase E; ARSA: galactose 3-sufatase or arylsulfatase A; ARSB: 
N-acetylgalactosamine 4-sulfatase or arylsulfatase B; ARSF: arylsulfatase F; GA6S: 
N-acetylgalactosamine-6-sulfatase and; STS: steroid sulfatase or arylsulfatase C. 
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Appendix 3 cDNA sequence of IDS gene 
1 atgccgcca ccccggaccg gccgaggcct tctctggctg ggtctggttc tgagctccgt 
61 ctgcgtcgcc ctcggatccg aaacgcaggc caactcgacc acagatgctc tgaacgttct 
121 tctcatcatc gtggatgacc tgcgcccctc cctgggctgt tatggggata agctggtgag 
181 gtccccaaat attgaccaac tggcatccca cagcctcctc ttccagaatg cctttgcgca 
241 gcaagcagtg tgcgccccga gccgcgtttc tttcctcact ggcaggagac ctgacaccac 
301 ccgcctgtac gacttcaact cctactggag ggtgcacgct ggaaacttct ccaccatccc 
361 ccagtacttc aaggagaatg gctatgtgac catgtcggtg ggaaaagtct ttcaccctgg 
421 gatatcttct aaccataccg atgattctcc gtatagctgg tcttttccac cttatcatcc 
481 ttcctctgag aagtatgaaa acactaagac atgtcgaggg ccagatggag aactccatgc 
541 caacctgctt tgccctgtgg atgtgctgga tgttcccgag ggcaccttgc ctgacaaaca 
601 gagcactgag caagccatac agttgttgga aaagatgaaa acgtcagcca gtcctttctt 
661 cctggccgtt gggtatcata agccacacat ccccttcaga taccccaagg aatttcagaa 
721 gttgtatccc ttggagaaca tcaccctggc ccccgatccc gaggtccctg atggcctacc 
781 ccctgtggcc tacaacccct ggatggacat caggcaacgg gaagacgtcc aagccttaaa 
841 catcagtgtg ccgtatggtc caattcctgt ggactttcag cggaaaatcc gccagagcta 
901 ctttgcctct gtgtcatatt tggatacaca ggtcggccgc ctcttgagtg ctttggacga 
961 tcttcagctg gccaacagca ccatcattgc atttacctcg gatcatgggt gggct|cta|gg 
1021 tgaacatgga gaatgggcca aatacagcaa ttttgatgtt gctacccatg ttcccctgat 
1081 attctatgtt cctggaagga cggcttcact tccggaggca ggcgagaagc ttttccctta 
1141 cctcgaccct tttgattccg cctcacagtt gatggagcca ggcaggcaat ccatggacct 
1201 tgtggaactt gtgtctcttt ttcccacgct ggctggactt gcaggactgc aggttccacc 
1261 tcgctgcccc gttccttcat ttcacgttga gctgtgcaga gaaggcaaga accttctgaa 
1321 gcattttcga ttccgtgact tggaagagga tccgtacctc cctggtaatc cccgtgaact 
1381 gattgcctat agccagtatc cccggccttc agacatccct cagtggaatt ctgacaagcc 
1441 gagtttaaaa gatataaaga tcatgggcta ttccatacgc accatagact ataggtatac 
1501 tgtgtgggtt ggcttcaatc ctgatgaatt tctagctaac ttttctgaca tccatgcagg 
1561 ggaactgtat tttgtggatt ctgacccatt gcaggatcac aatatgtata atgattccca 
1621 aggtggagat cttttccagt tgttgatgcc ttga 
Appendix 3 The cDNA sequence of wild-type IDS gene was adapted from 
NM_000202 (NCBI). The N-terminally truncated IDS constructs containing all the 
coding sequence except the first 99 base pairs (underlined). Codon 339，i.e. CTA, 
was bolded and boxed. 
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Appendix 4 Details of markers 
Appendix 4.1 Ikb DNA Ladder 








Appendix 4.2 Kaleidoscope Prestained Standards 
kDa 
Myosin 208 
3 -galactosidase 127 
Bovine serum albumin ‘、. 85 
Carbonic anhydrase ^^ 
Soybean trypsin inhibitor 32 
Lysozyme • 18 
Aprotinin 7.4 
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Appendix 4.3 BenchMark His-tagged Standards 
H B 1 6 0 
120 
H H j j j V l (io ^ I f Um 1: S1丨I of ceW lysmt、 
_ 秘 with exj3it?sstHl His-
雄 _ f^t u w d sixiucnce 
i ^ H 似 _ 仙 、 
^ ^ I j f l • u _ ；0 Line 2 :5 (tl of ihe 
l l ^ H 罐 BenchMark" 
_ 20 lljs^iaggtNl Slandard 
• a IS -
H Q 10 _ ^ 10 
A. Siained with D. Blotted onto nitrocellulose, followed 
InVisioir llb-idg by dciccuon w"h the Aaii-llls{C'ierm) 
In.队I Suiin Antibody and visiuilixecl using 
VVcsicrnBrcczc"' Chemiluminesceni Kit 
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Appendix 5 Vector information of pENTR/D-TOPO 
Appendix 5.1 Map 
二 RRflBn lt«9939 o 
m pENTR/D-TOPO® ‘ 
1 2580 bp j 
Elements: mB T2 transcription termination sequence: bases 268-295 
rniB T1 transcription termination sequence: bases 427-470 
M13 forward (-20) priming site: bases 537-552 
attLl: bases 569-668 (complementary strand) 
TOPO recognition site 1: bases 680-684 
Overhang: bases 685-688 
TOPO recognition site 2: bases 689-693 
attL2: bases 705-804 
M13 reverse priming site: bases 845-861 
Kanamycin resistance gene: bases 974-1783 
pUC origin: bases 1904-2577 
Appendix 5 pENTR/D-TOPO vector is linearized with topoisomerase I covalently 
bound to each 3-phosphate at both ends. Then, a GTGG overhanging on the 5'-end 
and a blunt end on the 3-end are generated. The four-nucleotide overhang anneals to 
the 5'CACC sequence of the PCR products so that the insert is in a desired 5'->3' 
orientation. The vector contains the attL recombination regions for efficient 
swapping of the insert with other Gateway destination vectors; kanamycin resistance 
gene for selection in E.coli. 
143 
Appendix 6 Vector information of pcDNA-DEST40 
Appendix 6.1 Multiple cloning site 
i5l ATTAATADSA CTCACTATJW TAj�.?XTATCJ\ 
CCJ^ThC^TT TAATTATCTT CCTCTC.<^r ATTCC^iWjViT 
•14 2M1 
I ... Pro Ma Leu Tyr D/K Val V3I 
911 ArAA':,1TIj3T ACAAAAAAGC AOXTO—^^^ >H\C CCA OCT TIL tTC. TAC <JT<3 CtTT 
T^ nrCAMCA TVJTimTCG TOCGA>J—MTG GGT <Xl»\ XJVG i\i\C ATG TIT CHC CM 
I I •• 11 III .iMi.iiii.i_ II.J “ *"''• I >i«iiiww»iiiii 111 II iiiuI iiin_inniTi^jii^rii^nii?。nrrimm_iniii_nm丨丨山i_ iiaiiiiiiniijiiiiii-jiu声 
am 
Asp Leu O.lu <il y Pro Aix; P1;e <311: <51y Lys Pro lit; Pro A«r. Pro L«tu Letu CUy 
2617 J^AT CTA CMI <WC COS <XM TTC CAA (?<JT ANS OCT i\TC OCT H\C OCT CTC CK ^F 
CTA CAT CTC OCG C<5C <50C CTT CCA TTC 05A TAG m <5GA <JiY5 縱、CCi�. 
<i»><ta aq 
L«c iVp 5«r TlirArx; Tl.r <ily Kis Kis His His His Kl» 
2671 CTC CAT XCT HCG COT NX 05T CAT CAT CAC m CAC CAT TOi�OrmiUC 
CTA ATA TrtC fiCA OCA fflPA OTA <fKi Oth <iTCi hTt CAAMTm 
Appendix 6.2 Map 
|LpcDNA-DEST40 气 
I 7.1 kb I 
Comments for pcDNA«OEST40 
7143 nuclootidos j ^ Q r 
CMV promotor: basos 232-819 ^ S S E B B ^ ^ 
T7 promoter, bases 863 882 
owni fooombinatlon sito: bases 911-1035 
Chloramphenicol resistance gone: basos 1144-1803 
ccdB Qono: bases 2145-2450 
recombination sito: basos 2491-2615 
V5 epitope: basos 2641-26S2 
6xHis tog: basos 2692-2709 
BGH polyadonylation region: bases 2735-2962 
f 1 origin: basos 3008-3436 
SV40 oarJy promoter and origin: basos 3463-3771 
Noomycin rosistanco ORF: basos 3846-4640 
SV40 oariy pofyadonylatJon region: txisos 4816-4946 
pUC origin: txisos 5329-6002 
Ampcaun [bio) rosistanco ORR basos 61A7-7Q07 (conplomontary strand) 
bbj promoter: basos 7008-7106 (canplomontary strand) 
Appendix 6 The human CMV promoter: for high-level expression in mammalian 
cells; bovine growth hormone (BGH) polyadenylation sequence: for proper 
termination of the transcript; the attR recombination regions for efficient swapping of 
insert with pENTR/D-TOPO. 
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Appendix 7 Vector information of pEXPl-DEST 
Appendix 7.1 Recombination region 
^Trpntmytr [ 
1 T^v-TTCGATC CCGCGAAATT A;iTAC<?ACTC ACTATAGGGA GACCACAAC<? aTTTCCCTCT AC5A7J^TAATT TTGTTTAACT 
HfeGyagpq 
BBS 胁， j, r ^ S T ~ ~ ~ 1 ‘.T I 1 I K^ t hi q <51y Ser Kift HiB Hi^  lUn^  Hi it Hin <Uy Mtst AU S^r mt 7hi <Uy 8X TTAAC;AA0GA <;ATATACAT ATO coo 03T TCT CAT CAT CAT CAT CAT CAT <5GT ATC <3CT hQC ATO ACT 
Xprw*** •知《 
I D<»oognt5on<itc "H 21� 
<?ly Gitx Nttt <51 y Ar脅 tttu Tyr Anp A ftp A»p Lyft Aitp Kiss Th i： Sfer It^ mi Ty r T.ys 
151 CAr； CAA AT<3 GCT CGC； CTG TAC GAC 这AT GAC <;AT AAa.Cy^ T CAT CM ACA AGT TAC AAA A OTT t<;T TCA AAC AT^? TTT 
I 的 2 D< dtji^ tsa^ fl 、、一、一 一一一 
hi A Giy ] . 
AAA GCA GGC TON --- MACCCAGCTT TCTTC5TACAA TCOAAGCTTa ATCCTtGCTGC： TATiCMAISCC 
TTT CGT CCG ANN --- NTGOGTCCM TCACCM<3CT AGCTTCSAAC 
1 I 1 
— L a 成 T7 prifrho t«c 
T Jtmafmntron ^antiojcofi ffg^km j-- .•• .二：善“^二：‘：：“^‘：圓二：‘：：：了'""*"**.，*""*"""、**】 
194X CTSAOTTCKSC TSCTGCCACC GCT<3A<^CAAT AACTAGCATJ"! AOCCCTTr.ISa OCCTCTAAAC GGGTCTTCiAi? 




» 4622 bp / 
Comments for pEXPI-DEST Nv 
4622 nucleoUdes 
T7 promoler: bases 20-36 
T7 promoler priming site: bases 20-39 
Ribosomo binding site: bases 8&-92 
InjIiMtion ATGc basos 100-102 
PolyhiRlUintt (6xHi&) region; baaos 112-129 
Xpress"" epilupo: basott 169*192 
Entirokinaso (EK) rocogiitian sito: 17S-1d2 
a浙 1 site: bases 202-326 
Chloramphenicol resistance gane (Cm**): bases435-1094 
ccdB gene: bases 1436-1741 
QttR2 site: bases 1782-1906 
T7 rever&e priming site: basos 1966-1985 
T7 tranBCfiption loriTination regton; ba&os 1927-2056 
ft origki: bases2127-2582 
bla promolor: bases 2669^2767 
Ampic^ lin resistance gone: bases 2768-3628 
pUC origin: 3773-4446 
Appendix 7 The vector contains transcription / translation regulatory elements, 
including bacteriophage T7 RNA polymerase promoter，prokaryotic Shine-Dalgamo 
ribosome binding site (RBS) and T7 terminator. 6xHis sequence enables rapid 
detection and purification of the fusion protein. It contains the attR recombination 
regions for efficient swapping of insert with pENTR/D-TOPO, 
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Appendix 8 Genotype of bacterial cells 
Competent cells Genotype 
TOP 10 ¥'mcrAAimrr-hsdRMS-mcrBC)0SOlacZAM 15 
AlacX14deoRrecA 1 araD U9A{am-leu) 
7697galUgal¥irpsL{Str^)endAlnupG 
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Appendix 9 Vector information of pIVEX_1.3_WG 
Appendix 9.1 Multiple cloning site 
T 7 - P r o m o t o r H i n d i I I 
7 0 1 TTACGCCAAG CTCATTAATA CGACTCACTA TAGGCCTAAG CTTACAAATA 
AATGCGGTTC GAGTAATTAT GCTGAGTGAT ATCCGGATTC GAATGTTTAT 
5 、 - B n h a n c t t r 
7 5 1 C T C C C C C A C A ACAGCTTACA ATACTCCCCC ACACAGCTTA CAAATACTCC 
GAGGGGGTGT TGTCGAATGT TATGAGGGGG TGTGTCGAAT GTTTATGAGG 
S t a r t 
N c o l NdoX N o t I S a l X 
ftOl CCCACAACAG CTTGTCGAAC CATGGCACAT ATGAGCGGCC GCGTCGACTC 
GGGTGTTGTC GAACAGCTTG GTACCGTGTA TACTCGCCGG CGCAGCTGAG 
X h o l S a d S m a l L l nko r- i-H l s «- t ag i S t o p 
8 51GAGCGAGCTC CCGGGGGGGG TTCTCATCAT CATCATCATC ATTAATAAGG 
CTCGCTCGAG GGCCCCCCCC AAGAGTAGTA GTAGTAGTAG TAATTATTCC 
3 ‘ - E n h a n o « r 
9 0 1 TACCCAGCTC TTCTGGTTTG GTTTGGACCT CTGGTCCTGC AACTTGAGGT 
ATGGGTCGAG AAGACCAAAC CAAACCTGGA GACCAGGACG TTGAACTCCA 
Appendix 9.2 Map 
I V U II ( 5 3 0 � 
, ^ ^ Z T7-Promotor 
(f l / Hill dill (739) 
备 \ Enhancer (748-803) 
I P - - . 3 W , 
； 3 2 3 6 bp 爾 二 二 
A i i i p i _ J % M m s a / i (84々 ） 
\ \ \s/na 1(863) 
^ t ： ^ ： — \ \ \ \ '^inker+Hivtag (866-895) 
\ \ \ \ s t o p 
\\ \ 3'-Enhancet (906-nA8) 
I \ \ \ 
PMyl0284) EcoRIOlGl) 
Appendix 9 The vector contains transcription / translation regulatory elements, 
including bacteriophage T7 RNA polymerase promoter, 5' and 3' enhancers. 6xHis 
sequence enables rapid detection and purification of the fusion protein. 
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Appendix 10 Predicted 3D structure of BOS polypeptide 
Appendix 10 The predicted 3D structure of IDS polypeptides was adapted from 
Kato T et a/.，2005. The orange spheres represent the putative active sites. The 
numbered spheres were used to indicate the altered residues in Kato's study. Red 
sphere no.2 is Ser336 residue. It is believed that Leu339 residue is located in a 
supercoiled structure near to a substrate binding site(arrowed). 
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Electronic-database and computing system 
URLs for data presented are as follows: 
http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=3099Q0 [for MPS 11 in OMIM 
Database] 
http ://www. ncbi. nlm.nih. gov/entrez/viewer. fcgi?db=nucleotide&val=5360215 [for 
IDS cDNA sequence in NCBI] 
http://www.hgmd• cf.ac.uk/hgmdO.html [for IDS in Human Gene Mutation Database] 
http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi [for primer design using 
Primer3] 
http://dove.embl-heidelberg.de/Blast2e/ [for multiple aligment of human sulfatases 
using CLUSTALW] 
http://www.idtdna.com/analyzer/Applications/01igoAnalvzer/Default.aspx [for 
hairpin prediction using OligoAnalyzer 3.0] 
http://tools.neb.com/NEBcutter2/index.php [for restriction site prediction using 
NEBcutter V2.0] 
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